Target Information

General Information of This Target

Target ID	PATR0CXRBX
Target Name	Microtubule (MT)
Function	Microtubules are polymers of tubulin that form part of the cytoskeleton and provide structure and shape to eukaryotic cells. Microtubules play an important role in a number of cellular processes. They are involved in maintaining the structure of the cell and, together with microfilaments and intermediate filaments, they form the cytoskeleton. They also make up the internal structure of cilia and flagella. They provide platforms for intracellular transport and are involved in a variety of cellular processes, including the movement of secretory vesicles, organelles, and intracellular macromolecular assemblies. Click to Show/Hide

Full List of The ADC Related to This Target

Approved

Click To Hide/Show 8 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Disitamab vedotin	Hertuzumab	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[1]
ADC Info	Tisotumab vedotin-tftv	Tisotumab	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[2]
ADC Info	Belantamab mafodotin	Belantamab	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[3]
ADC Info	Enfortumab vedotin	Enfortumab	NECTIN4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[4]
ADC Info	Mirvetuximab soravtansine	Mirvetuximab	FOLR1	Mertansine DM4	Sulfo-SPDB	[5]
ADC Info	Polatuzumab vedotin	Polatuzumab	CD79B	Monomethyl auristatin E	Mc-Val-Cit-PABC	[6]
ADC Info	Brentuximab vedotin	Brentuximab	TNFRSF8	Monomethyl auristatin E	Mc-Val-Cit-PABC	[7]
ADC Info	Trastuzumab emtansine	Trastuzumab	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[8]

Phase 3

Click To Hide/Show 10 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Tusamitamab ravtansine	Tusamitamab	CEACAM5	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[9]
ADC Info	MRG-003	JMT101	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[10]
ADC Info	Telisotuzumab vedotin	Telisotuzumab	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[11]
ADC Info	Depatuxizumab mafodotin	Depatuxizumab	EGFR	Monomethyl auristatin F	Maleimido-caproyl	[12]
ADC Info	ARX-788	Modified pAcPhe trastuzumab	ERBB2	Monomethyl auristatin F	Hydroxylamine-PEG4	[13]
ADC Info	LCB14-0110	Trastuzumab	ERBB2	Monomethyl auristatin F	Geranyl ketone pyrophosphate oxime ligation	[14]
ADC Info	MRG-002	MAB802	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[15]
ADC Info	Zilovertamab vedotin	Cirmtuzumab	ROR1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[16]
ADC Info	DP-303c	DP001	ERBB2	Monomethyl auristatin E	PEG2-Val-Cit-PABC	[17]
ADC Info	Upifitamab rilsodotin	XMT-1535	SLC34A2	Auristatin F hydroxypropylamide (AF-HPA)	Dolaflexin polymer	[18]

Phase 1/2

Click To Hide/Show 37 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	BB-1701	Undisclosed	ERBB2 exon 20	Eribulin	Undisclosed	[19]
ADC Info	Mecbotamab vedotin	Mecbotamab	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[20]
ADC Info	Ozuriftamab vedotin	Ozuriftamab	ROR2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[21]
ADC Info	OBI-999	OBI-888	Undisclosed	Monomethyl auristatin E	ThioBridge-PEG24-Val-Ala-PAB	[22]
ADC Info	STRO-001	Undisclosed	CD74	Maytansinoid derivative	Cys-12 ADC linker	[23]
ADC Info	Indatuximab ravtansine	Indatuximab	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[24]
ADC Info	Enapotamab vedotin	AXL-107	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[25]
ADC Info	Praluzatamab ravtansine	Praluzatamab	ALCAM	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[26]
ADC Info	Naratuximab emtansine	Naratuximab	CD37	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[27]
ADC Info	Ladiratuzumab vedotin	Ladiratuzumab	SLC39A6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[28]
ADC Info	Lorvotuzumab mertansine	Lorvotuzumab	NCAM1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[29]
ADC Info	Coltuximab ravtansine	Coltuximab	CD19	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[30]
ADC Info	Glembatumumab vedotin	CR-011	GPNMB	Monomethyl auristatin E	Mc-Val-Cit-PABC	[31]
ADC Info	B-003	Trastuzumab	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[32]
ADC Info	AVID-100	MAB100	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[33]
ADC Info	BMS-986148	BMS-986021	MSLN	Tubulysin	Mal-EBE-Mal	[34]
ADC Info	CX-2029	Anti-CD71 CX-151 probody	TFRC	Monomethyl auristatin E	Mc-Val-Cit-PABC	[35]
ADC Info	Farletuzumab ecteribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG2Val-Cit-PAB-OH	[36]
ADC Info	Lonigutamab ugodotin	Lonigutamab	IGF1R	F554443	Maleimido-caproyl	[37]
ADC Info	RC-108	Undisclosed	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[38]
ADC Info	GQ-1001	Trastuzumab	ERBB2	Mertansine DM1	MCC-Gly6-Thr-Glu3-Pro-Leu-Ala3-Leu	[39]
ADC Info	BB-1705	Undisclosed	EGFR	Eribulin	Undisclosed	[40]
ADC Info	FOR-46	Anti-CD46 fully human Anti-ody	CD46	Monomethyl auristatin E	Undisclosed	[41]
ADC Info	LM-302	Anti-CLDN18.2 mAb	CLDN18.2	Monomethyl auristatin E	Undisclosed	[42]
ADC Info	Pertuzumab zuvotolimod	Pertuzumab	ERBB2	Maytansinoid derivative	Undisclosed	[43]
ADC Info	RC-118	Undisclosed	CLDN18.2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[44]
ADC Info	RC-88	Undisclosed	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[45]
ADC Info	XMT-1592	Undisclosed	SLC34A2	Auristatin F hydroxypropylamide (AF-HPA)	Cys-13 ADC linker	[46]
ADC Info	REGN5093-M114	REGN5093	MET	Maytansine derivative M24	Undisclosed	[47]
ADC Info	Luveltamab tazevibulin	Luveltamab	FOLR1	SC209	Val-Cit-PABA	[48]
ADC Info	Anetumab ravtansine	Anetumab	MSLN	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[49]
ADC Info	CDX-014	Anti-TIM1 CDX-014 mAb	HAVCR1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[50]
ADC Info	DX126-262	DX-CHO9	ERBB2	Tubulysin B derivative	Undisclosed	[51]
ADC Info	CBP-1008	Undisclosed	FOLR1; TRPV6	Monomethyl auristatin E	Undisclosed	[52]
ADC Info	BAT-8001	BAT0606	ERBB2	Maytansinoid derivative	6-Maleimidocaproic acid	[53]
ADC Info	LM-305	Undisclosed	GPRC5D	Monomethyl auristatin E	Mc-Val-Cit-PABC	[54]
ADC Info	IMGC-936	MGA021	ADAM9	DM21-C	Tripeptide linker	[55]

Phase 1

Click To Hide/Show 30 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	BIIB-015	Anti-TDGF1 mAb huB3F6	TDGF1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[56]
ADC Info	AGS-67E	AGS67C	CD37	Monomethyl auristatin E	Mc-Val-Cit-PABC	[57]
ADC Info	PF-06804103	T-(kK183C+K290C)	ERBB2	Auristatin 0101	Mc-Val-Cit-PABC	[58]
ADC Info	Aprutumab ixadotin	Aprutumab	FGFR2	Auristatin W derivative	N-5-carboxypentyl	[59]
ADC Info	Cofetuzumab pelidotin	Cofetuzumab	PTK7	Auristatin 0101	Mc-Val-Cit-PABC	[60]
ADC Info	Iladatuzumab vedotin	Iladatuzumab	CD79B	Monomethyl auristatin E	Mc-Val-Cit-PABC	[61]
ADC Info	MRG-001	Chimeric Anti-CD20 mAb	MS4A1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[62]
ADC Info	OMTX-705	OMTX005	FAP	TAM470	Mc-Val-Cit-PABC-PEG3	[63]
ADC Info	PYX-201	Undisclosed	FN1	Auristatin 0101	Mc-Val-Cit-PABC	[64]
ADC Info	RG-7841	MLYE4489A	LY6E	Monomethyl auristatin E	Mc-Val-Cit-PABC	[65]
ADC Info	Samrotamab vedotin	Samrotamab	LRRC15	Monomethyl auristatin E	Mc-Val-Cit-PABC	[66]
ADC Info	SGN-B7H4V	Humanized Anti-B7-H4 SGNB7H4V mAb	VTCN1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[67]
ADC Info	SGN-PDL1V	Humanized Anti-PD-L1 SGN-PDL1V mAb	CD274	Monomethyl auristatin E	Mc-Val-Cit-PABC	[68]
ADC Info	SHR-A1201	Trastuzumab	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[69]
ADC Info	Sirtratumab vedotin	Sirtratumab	SLITRK6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[70]
ADC Info	SYSA-1801	Anti-CLDN18.2 mAb SYSA-1801	CLDN18.2	Monomethyl auristatin E	PEG3-Val-Cit-PABC	[71]
ADC Info	SGN-B6A	Human ITGB6 SGN-B6A mAb	ITGB6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[72]
ADC Info	16A5-MCC-DM1	MBH-1309	LY75	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[73]
ADC Info	Zanidatamab zovodotin	Zanidatamab	HER2 ECD2; HER2 ECD4	ZD02044	Mc-PEG3-Val-Cit	[74]
ADC Info	AMG-224	Anti-human BCMA IgG1 Anti-ody	TNFRSF17	Mertansine DM1	Noncleavable linker	[75]
ADC Info	ASN-004	Anti-5T4 scFv-Fc Anti-ody	TPBG	Auristatin F hydroxypropylamide (AF-HPA)	Undisclosed	[76]
ADC Info	Losatuxizumab vedotin	Losatuxizumab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[77]
ADC Info	MEN-1309	MBH-1309	LY75	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[78]
ADC Info	SGN-CD228A	Humanized Anti-CD228 SGN-CD228A mAb	MELTF	Monomethyl auristatin E	Beta-Glucuronidase cleavable linker	[79]
ADC Info	SGN-CD48A	Humanized Anti-SLAMF2 SGN-CD48A mAb	CD48	Monomethyl auristatin E	Beta-Glucuronidase cleavable linker	[80]
ADC Info	SHR-A1403	SHR-A1403 mAb	MET	SHR152852	Uncleavable linker	[81]
ADC Info	TRPH-222	Undisclosed	CD22	Maytansinoid	Undisclosed	[82]
ADC Info	CPO-102	Undisclosed	CLDN18.2	Monomethyl auristatin E	Undisclosed	[83]
ADC Info	F0002-ADC	Brentuximab	TNFRSF8	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[84]
ADC Info	HS630	Undisclosed	ERBB2	Mertansine DM1	Undisclosed	[85]

Clinical candidate

Click To Hide/Show 91 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Cirmtuzumab vedotin	Cirmtuzumab	ROR1	Monomethyl auristatin E	Lysine-linker	[86]
ADC Info	Brentuximab-8	Brentuximab	TNFRSF8	Monomethyl auristatin E	Alkyl phosphoramide-PEG24-Val-Cit-PAB	[87]
ADC Info	Brentuximab-7	Brentuximab	TNFRSF8	Monomethyl auristatin E	Alkyl phosphoramide-PEG12-Val-Cit-PAB	[87]
ADC Info	Septuximab vedotin	Septuximab	FZD7	Monomethyl auristatin E	Mc-Val-Cit-PABC	[88]
ADC Info	SHR-A1307	Anti-EGFR mAb hR3-YTE	EGFR	SHR152852	L2-MC	[89]
ADC Info	RN927C	Humanized Anti-Trop-2 hIgG1 Anti-ody	TACSTD2	Auristatin 0101	AcLys-Val-Cit-PABC	[90]
ADC Info	RN765C	EGFR Ab-L	EGFR	Auristatin 0101	AcLys-Val-Cit-PABC	[91]
ADC Info	Alpha-CLDN-VC0101	Undisclosed	CLDN18.2	Auristatin 0101	Mc-Val-Cit-PABC	[92]
ADC Info	HuRH105-SSPDB-DM4	Undisclosed	ENG	Mertansine DM4	Sulfo-SPDB	[93]
ADC Info	RC68-PY-Val-Cit-PABC-MMAE	RC68	EGFR	Monomethyl auristatin E	PY-VC-PABC	[94]
ADC Info	RC68-Mc-Val-Cit-PABC-MMAE	RC68	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[94]
ADC Info	BVD-TEM8 ADC	Anti-TEM8 mAb m825	ANTXR1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[95]
ADC Info	IMAB027-Val-Cit-MMAE	IMAB027	CLDN6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[96]
ADC Info	Bstrongximab ADC	Bstrongximab	Undisclosed	Monomethyl auristatin E	Mc-Val-Cit-PABC	[97]
ADC Info	GB7008-01-Val-Cit-MMAE	GB7008-01	CLDN6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[98]
ADC Info	Atezolizumab ADC	Atezolizumab	CD274	Monomethyl auristatin E	Mc-Val-Cit-PABC	[99]
ADC Info	S3F-CL-MMAE	Anti-sTn mAb S3F	Undisclosed	Monomethyl auristatin E	Mc-Val-Cit-PABC	[100]
ADC Info	DAR8-alphaCD30-mDPR-Gluc-MMAE	Anti-CD30 DAR8-alphaCD30-mDPR-gluc-MMAE mAb	TNFRSF8	Monomethyl auristatin E	Quaternary ammonium linker Gluc	[101]
ADC Info	A7R-ADC-MMAE	Anti-IL7R mAb A7R	IL7R	Monomethyl auristatin E	Mal-PEG12-Val-Cit-PABC	[102]
ADC Info	Anti-endosialin-Mc-Val-Cit-PABC-MMAE	Undisclosed	CD248	Monomethyl auristatin E	Mc-Val-Cit-PABC	[103]
ADC Info	YH-012	Undisclosed	ERBB2; TACSTD2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[104]
ADC Info	YH-013	Undisclosed	EGFR; MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[105]
ADC Info	BA-3361	Undisclosed	NECTIN4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[106]
ADC Info	REGN2878-DM1	REGN2878	PRLR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[107]
ADC Info	IIIA4-USAN	Anti-EPHA3 mAb IIIA4	EPHA3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[108]
ADC Info	ICAM1-DM1 ADC	Anti-ICAM1 mAb	ICAM1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[109]
ADC Info	DS6-DM1	Anti-MUC1 mAb DS6	MUC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[110]
ADC Info	Anti-EGFR-PEG4-Mal-DM1	Anti-EGFR mAb rat IgG2a	EGFR	Mertansine DM1	PEG4-Mal	[111]
ADC Info	Zt/g4-Maytansinoid	Undisclosed	MST1R	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[112]
ADC Info	PTM-001-ADC	Undisclosed	Undisclosed	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[113]
ADC Info	HuRH105-SMCC-DM1	Undisclosed	ENG	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[93]
ADC Info	SG3-Val-Cit-MMAF8	SG3	TNFRSF17	Monomethyl auristatin F	Mc-Val-Cit-PABC	[114]
ADC Info	SG2-Val-Cit-MMAF8	SG2	TNFRSF17	Monomethyl auristatin F	Mc-Val-Cit-PABC	[114]
ADC Info	SG1-Val-Cit-MMAF8	SG1	TNFRSF17	Monomethyl auristatin F	Mc-Val-Cit-PABC	[114]
ADC Info	EV20/MMAF	EV20	ERBB3	Monomethyl auristatin F	Maleimido-caproyl	[115]
ADC Info	DAR8-alphaCD30-mDPR-GlucQ-AE	Anti-CD30 DAR8-alphaCD30-mDPR-glucQ-AE mAb	TNFRSF8	Auristatin E	Quaternary ammonium linker GlucQ	[101]
ADC Info	DAR8-alphaCD30-mDPR-Gluc-DMTub	Anti-CD30 DAR8-alphaCD30-mDPR-gluc-DMTub mAb	TNFRSF8	DMTub	Quaternary ammonium linker Gluc	[101]
ADC Info	MI-130004	Trastuzumab	ERBB2	PM050489	6-(2,5-dioxopyrrol-1-yl)-N-Propylhexanamide	[116]
ADC Info	MI-130110	Anti-CD13 TEA1/8 mAb	ANPEP	PM050489	6-(2,5-dioxopyrrol-1-yl)-N-Propylhexanamide	[117]
ADC Info	DAR8-alphaCD30-mDPR-GlucQ-Tub	Anti-CD30 DAR8-alphaCD30-mDPR-glucQ-Tub mAb	TNFRSF8	Tubulysin analogue 3	Quaternary ammonium linker GlucQ	[101]
ADC Info	CD38-077	STI-5171	CD38	Duostatin 5.2	Non-polyethylene glycol linker	[118]
ADC Info	BCMA-077	Undisclosed	TNFRSF17	Duostatin 5.2	Proprietary Concortis linker	[119]
ADC Info	BCMA-024	Undisclosed	TNFRSF17	Duostatin 5.2	Proprietary Concortis linker	[119]
ADC Info	1959-SSS-DM3	Undisclosed	LGALS3BP	Maytansinoid DM3	Undisclosed	[120]
ADC Info	MP-1959-ADC	Anti-LGALS3BP mAb 1959-sss	LGALS3BP	Maytansinoid	Undisclosed	[121]
ADC Info	CBX-13	Undisclosed	Undisclosed	Mertansine DM4	Undisclosed	[122]
ADC Info	Anti-HER2 antibody-drug conjugate (Spirea)	Trastuzumab	ERBB2	Monomethyl auristatin E	Undisclosed	[123]
ADC Info	Pab-001-MMAE	Pab-001	MUC1	Monomethyl auristatin E	Undisclosed	[124]
ADC Info	OBI-998	OBI-898	Undisclosed	Monomethyl auristatin E	Maleimide and PEGylated cleavable linker	[125]
ADC Info	IMAB362-Val-Cit-MMAE	IMAB362	CLDN18.2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[126]
ADC Info	Cirmtuzumab-ADC-7	Cirmtuzumab	ROR1	Monomethyl auristatin E	Undisclosed	[127]
ADC Info	DM002	Undisclosed	ERBB3; MUC1	Monomethyl auristatin E	Undisclosed	[128]
ADC Info	DM001	Undisclosed	TACSTD2; EGFR	Monomethyl auristatin E	Undisclosed	[129]
ADC Info	N41mab-Val-Cit-MMAE	Undisclosed	NECTIN4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[130]
ADC Info	ST1	Undisclosed	Undisclosed	Monomethyl auristatin E	Undisclosed	[131]
ADC Info	JY207	Undisclosed	CD47; CD274	Monomethyl auristatin E	Undisclosed	[132]
ADC Info	Hertuzumab vedotin	Hertuzumab	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[133]
ADC Info	NN-3201	Undisclosed	KIT	Monomethyl auristatin E	Undisclosed	[134]
ADC Info	LCB-97	Undisclosed	AFF4	Monomethyl auristatin E	Undisclosed	[135]
ADC Info	LCB-84	Undisclosed	TACSTD2	Monomethyl auristatin E	Undisclosed	[136]
ADC Info	LCB-67	Undisclosed	DLK1	Monomethyl auristatin E	Undisclosed	[136]
ADC Info	Anti-NaPi3b antibody-drug conjugate (Genentech/Roche)	Undisclosed	SLC34A2	Monomethyl auristatin E	Undisclosed	[137]
ADC Info	DM003	Undisclosed	PTK7; EGFR	Monomethyl auristatin E	Undisclosed	[138]
ADC Info	MSLN ADC (Development Center for Biotechnology)	Undisclosed	MSLN	Monomethyl auristatin E	Undisclosed	[139]
ADC Info	CBX-15	Undisclosed	PARP1	Monomethyl auristatin E	Undisclosed	[122]
ADC Info	DM004	Undisclosed	TPBG; MET	Monomethyl auristatin E	Undisclosed	[140]
ADC Info	BSA01	Undisclosed	EGFR; MUC1	Monomethyl auristatin E	Undisclosed	[141]
ADC Info	BCG033	Undisclosed	TACSTD2; PTK7	Monomethyl auristatin E	Undisclosed	[142]
ADC Info	BCG022	Undisclosed	ERBB3; MET	Monomethyl auristatin E	Undisclosed	[143]
ADC Info	CD46 CAB-ADC	Undisclosed	CD46	Monomethyl auristatin E	Mc-Val-Cit-PABC	[144]
ADC Info	ARC-02	Undisclosed	CD79B	Monomethyl auristatin E	Undisclosed	[145]
ADC Info	MSLN MMAE	Undisclosed	MSLN	Monomethyl auristatin E	Undisclosed	[146]
ADC Info	B7H3-MMAE	Undisclosed	CD276	Monomethyl auristatin E	Undisclosed	[147]
ADC Info	APLP2/HER2 antibody-drug conjugate	Undisclosed	APLP2; ERBB2	Mertansine DM1	Undisclosed	[148]
ADC Info	CTAT-ADC	Undisclosed	ERBB2	Mertansine DM1	Undisclosed	[149]
ADC Info	Humanized Anti-HER2 Mab-Maytansine Conjugate	Undisclosed	ERBB2	Mertansine DM1	Undisclosed	[150]
ADC Info	MP-HER3-ADC	Undisclosed	ERBB3	Monomethyl auristatin F	Undisclosed	[151]
ADC Info	AVP10	Undisclosed	TNFRSF8	Monomethyl auristatin F	Undisclosed	[152]
ADC Info	NC-6201	NCAB001	EGFR	E7974	Undisclosed	[153]
ADC Info	An2-anti-HER2-Doxetaxel	ANG4043	ERBB2	Docetaxel	Undisclosed	[154]
ADC Info	APH-0912	Undisclosed	Undisclosed	Docetaxel	Hydrophilic linker containing sugar molecules	[155]
ADC Info	DAN-405	Undisclosed	FOLH1	Cabazitaxel	Undisclosed	[156]
ADC Info	Trastuzumab-deBouganin	Trastuzumab	ERBB2	DeBouganin	Undisclosed	[157]
ADC Info	SMP-656	Undisclosed	ERBB2	Eribulin	Unique hydrophilic Linker	[158]
ADC Info	CBT-3112	Undisclosed	DCLK1	Paclitaxel	Undisclosed	[159]
ADC Info	33B7-Saporin	Anti-PTGFRN mAb 33B7	PTGFRN	Saporin	Undisclosed	[160]
ADC Info	LY3343544	Emibetuzumab	MET	Monomethyl auristatin E	Undisclosed	[161]
ADC Info	Araris ADC	Enfortumab	NECTIN4	Monomethyl auristatin E	Cathepsin B cleavable linker	[162]
ADC Info	MP-EV-20	EV20	ERBB3	Monomethyl auristatin F	Undisclosed	[163]
ADC Info	AG 02 saporin conjugate	Anti-CSP-1 mAb AG02	Undisclosed	Saporin	Undisclosed	[164]
ADC Info	huPr1-vcMMAE	Anti-TMEFF2 mAb huPr1	TMEFF2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[165]

Investigative

Click To Hide/Show 1875 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Mirvetuximab-SPP-DM1	Mirvetuximab	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[166]
ADC Info	Mirvetuximab-SMCC-DM1	Mirvetuximab	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[166]
ADC Info	HuFR1-48-SMCC-DM1	Anti-FOLR1 huFR1-48	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[166]
ADC Info	HuFR1-49-SMCC-DM1	Anti-FOLR1 huFR1-49	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[166]
ADC Info	HuFR1-57-SMCC-DM1	Anti-FOLR1 huFR1-57	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[166]
ADC Info	HuFR1-65-SMCC-DM1	Anti-FOLR1 huFR1-65	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[166]
ADC Info	54E-Val-Cit-MMAE	Anit-TF mAb 54E	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	43Ea-Val-Cit-MMAE	Anit-TF mAb 43Ea	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	43D7-Val-Cit-MMAE	Anit-TF mAb 43D7	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	43B1-Val-Cit-MMAE	Anit-TF mAb 43B1	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	39A-Val-Cit-MMAE	Anit-TF mAb 39A	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	29E-Val-Cit-MMAE	Anit-TF mAb 29E	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	25G1-Val-Cit-MMAE	Anit-TF mAb 25G1	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	25A3-Val-Cit-MMAE	Anit-TF mAb 25A3	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	25A-Val-Cit-MMAE	Anit-TF mAb 25A	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	rcEDB-ADC	Reverse chimeric (rc) Anti-EDB-FN L19	FN1	Auristatin 0101	Mc-Val-Cit-PABC	[168]
ADC Info	PODO447-ADC	PODO447	PODXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[169]
ADC Info	Anti-PIEZO1-MMAE	Anti-PIEZO1 mAb	PIEZO1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[170]
ADC Info	C12G1-DM1	Anti-NECTIN2 mAb c12G1	NECTIN2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[171]
ADC Info	HzMUC1-MMAE	HzMUC1	MUC1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[172]
ADC Info	LSR-ADC	Anti-LSR mAb	LSR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[173]
ADC Info	LRG1-ADC 5	Magacizumab	LRG1	Monomethyl auristatin E	Dipeptide-diBrPD (dibromopyridazinedione )	[174]
ADC Info	1131-MMAE	C-1131	CT83	Monomethyl auristatin E	Mc-Val-Cit-PABC	[175]
ADC Info	Trastuzumab-SYNtansine	Trastuzumab	ERBB2	Ahx-maytansine	BCN-HydraSpace-Val-Cit-PABC	[176]
ADC Info	Tmab-SPP-DM1	Trastuzumab	ERBB2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[177]
ADC Info	Tmab-SSNPP-DM3	Trastuzumab	ERBB2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[177]
ADC Info	Tmab-SSNPP-DM4	Trastuzumab	ERBB2	Mertansine DM4	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[177]
ADC Info	Trastuzumab-AJICAP-maytansinoid	Trastuzumab	ERBB2	Mertansine DM1	AJICAP	[178]
ADC Info	Mil40-12B	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based linker 12B	[179]
ADC Info	ADAPT6-ABD-mcDM1	ADAPT6-ABD	ERBB2	Mertansine DM1	Maleimidocaproyl (Ser3-Gly)3	[180]
ADC Info	HA15-1C25F	Anti-SLITRK6 mAb Ha15-1c25	SLITRK6	Monomethyl auristatin F	Maleimido-caproyl	[181]
ADC Info	HA15-1C25E	Anti-SLITRK6 mAb Ha15-1c25	SLITRK6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[182]
ADC Info	HA15-1ABE16F	Anti-SLITRK6 mAb Ha15-1abe16	SLITRK6	Monomethyl auristatin F	Maleimido-caproyl	[181]
ADC Info	HA15-1ABE16E	Anti-SLITRK6 mAb Ha15-1abe16	SLITRK6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[182]
ADC Info	HA15-10AC14F	Anti-SLITRK6 mAb Ha15-10ac14	SLITRK6	Monomethyl auristatin F	Maleimido-caproyl	[181]
ADC Info	HA15-10AC14E	Anti-SLITRK6 mAb Ha15-10ac14	SLITRK6	Monomethyl auristatin E	Mc-Val-Cit-PABC	[182]
ADC Info	GPC1-ADC-MMAE	Anti-GPC1 GPC1-ADC (MMAE) mAb	GPC1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[183]
ADC Info	GPC1-ADC-MMAF	Anti-GPC1 GPC1-ADC mAb	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[184]
ADC Info	LR004-Val-Cit-MMAE	LR004	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[185]
ADC Info	EDB-ADC	Anti-EDB-FN L19	FN1	Auristatin 0101	Mc-Val-Cit-PABC	[168]
ADC Info	4C9-DM1	Anti-KIT mAb 4C9	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[171]
ADC Info	NN2101-DM1	NN2101	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[186]
ADC Info	CDH6-SPDB-DM4	Human Anti-CDH6 mAb	CDH6	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[187]
ADC Info	1F6-Val-Cit-PABC-MMAF	Anti-CD70 mAb IF6	CD70	Monomethyl auristatin F	Mal-Val-Cit-PABC	[188]
ADC Info	1F6-Ile-Pro-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Ile-Pro	[188]
ADC Info	1F6-Me3-Lys-Pro-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Me3Lys-Pro	[188]
ADC Info	1F6-NorVal- (D)Asp-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-NorVal-D-Asp	[188]
ADC Info	1F6-beta-Ala- (D)Asp-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-bata-Ala-D-Asp	[188]
ADC Info	1F6-PhenylGly- (D)Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-PhenylGly-D-Lys	[188]
ADC Info	1F6-Met- (D)Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Met-D-Lys	[188]
ADC Info	1F6-Asn- (D)Lys-AM	Anti-CD70 mAb IF6	CD70	Auristatin M	Mal-Asn-D-Lys	[188]
ADC Info	1F6-Met- (D)Lys-AW	Anti-CD70 mAb IF6	CD70	L-Alanyl-L-tryptophan	Mal-Met-D-Lys	[188]
ADC Info	CBR96-Phe-Lys-MMAE	Anti-Lewis-Y mAb cBR96	Undisclosed	Monomethyl auristatin E	Mc-Phe-Lys-PABC	[189]
ADC Info	BT062-SPDB-DM4	Indatuximab	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[190]
ADC Info	AXL02	AXL Anti-ody YW327.6S2	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[191]
ADC Info	AXL-733-MMAE	AXL-733	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-726-M101L-MMAE	AXL-726-M101L	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-613-MMAE	AXL-613	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-511-MMAE	AXL-511	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-183-N52Q-MMAE	AXL-183-N52Q	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-154-M103L-MMAE	AXL-154-M103L	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	AXL-148-MMAE	AXL-148	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	ASG-15MF	Sirtratumab	SLITRK6	Monomethyl auristatin F	Maleimido-caproyl	[181]
ADC Info	Anti-IL13RA2-ADC	Anti-IL13RA2 PF-06473811 mAb	IL13RA2	Auristatin 0101	Mc-Val-Cit-PABC	[193]
ADC Info	HuIgG1-SPDB-DM4	Undisclosed	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[166]
ADC Info	Trastuzumab DVD-ADC	Trastuzumab	ERBB2	Monomethyl auristatin F	Hexapeptide linker ASTKGP	[194]
ADC Info	PD-L1 ADC 1	Avelumab	CD274	Monomethyl auristatin E	Mc-Val-Ala-PABC	[99]
ADC Info	PD-L1 ADC 2	Avelumab	CD274	Monomethyl auristatin E	Mc-Val-Cit-PABC	[99]
ADC Info	PD-L1 ADC 3	Atezolizumab	CD274	Monomethyl auristatin E	Mc-Val-Ala-PABC	[99]
ADC Info	T-CpHK-Tet-ADC	Trastuzumab-CpHK	ERBB2	Monomethyl auristatin E	Tetrazine-PEG5-Val-Ala-PABC	[195]
ADC Info	T-CpHK-Mal-ADC	Trastuzumab-CpHK	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[195]
ADC Info	Anti-HER2 DVD-IgG1-h38c2-K99C_MMAF	Anti-HER2 DVD-IgG1-H38c2-K99C	ERBB2	Monomethyl auristatin F	Dibromomaleimide-PEG4	[196]
ADC Info	Anti-HER2 DVD-Fab-h38c2-K99C_MMAF	Anti-HER2 DVD-Fab-h38c2-K99C	ERBB2	Monomethyl auristatin F	Dibromomaleimide-PEG4	[196]
ADC Info	Anti-HER2 DVD-IgG1_MMAF	Anti-HER2 DVD-IgG1	ERBB2	Monomethyl auristatin F	Dibromomaleimide-PEG4	[196]
ADC Info	Anti-HER2 DVD-Fab_MMAF	Anti-HER2 DVD-Fab	ERBB2	Monomethyl auristatin F	Dibromomaleimide-PEG4	[196]
ADC Info	Mil40-12A	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based linker 12A	[179]
ADC Info	Mil40-12C	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based linker 12C	[179]
ADC Info	Tras-Gly5-May	Trastuzumab	ERBB2	Mertansine DM1	Gly5	[197]
ADC Info	Fcab-2-MMAE	Fcab-2	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	Fcab-3-MMAE	Fcab-3	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	HuFc-MMAE	Anti-EGFR huFc	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	C-Fab-MMAE	Cetuximab Fab	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	C-IgG-Val-Cit-MMAE	Cetuximab	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	40H3-MCVCPAB-MMAE	Anti-EGFR mAb 40H3	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[199]
ADC Info	40H3-SMCC-DM1	Anti-EGFR mAb 40H3	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[199]
ADC Info	Cet-DM1	Cetuximab	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[200]
ADC Info	1F6-Ile-Val-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Ile-Val	[188]
ADC Info	1F6-Asp-Val-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Asp-Val	[188]
ADC Info	1F6-His-Val-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-His-Val	[188]
ADC Info	1F6-Met-Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Met-Lys	[188]
ADC Info	1F6-Asn-Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Asn-Lys	[188]
ADC Info	1F6-Pro- (D)Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Pro-D-Lys	[188]
ADC Info	1F6-Met- (D)Lys-MMAF	Anti-CD70 mAb IF6	CD70	Monomethyl auristatin F	Mal-Met-D-Lys	[188]
ADC Info	1F6-Asn- (D)Lys-MMAF	Anti-CD70 mAb IF6	CD70	Monomethyl auristatin F	Mal-Asn-D-Lys	[188]
ADC Info	1F6-Met- (D)Lys-AM	Anti-CD70 mAb IF6	CD70	Auristatin M	Mal-Met-D-Lys	[188]
ADC Info	1F6-Asn- (D)Lys-AW	Anti-CD70 mAb IF6	CD70	L-Alanyl-L-tryptophan	Mal-Asn-D-Lys	[188]
ADC Info	MAb-DMBA-SIL-MMAE	Cetuximab	EGFR	Monomethyl auristatin E	DMBA-SIL	[201]
ADC Info	Alb-DMBA-SIL-MMAE	Alb	ALB	Monomethyl auristatin E	DMBA-SIL	[201]
ADC Info	GMF-1A3-MMAE	Anti-cleaved-AREG 1A3 Anti-ody	AREG	Monomethyl auristatin E	Mc-Val-Cit-PABC	[202]
ADC Info	Anti-N3-vc0101	Anti-NOTCH3 mAb	NOTCH3	Auristatin 0101	Mc-Val-Cit-PABC	[203]
ADC Info	M9346A Sulfo-SPDB DM4	Mirvetuximab	FOLR1	Mertansine DM4	Sulfo-SPDB	[166]
ADC Info	Anti-FcRL5-SPDB-DM4	Anti-FcRL5 mAb	FCRL5	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[204]
ADC Info	Anti-CD22-SPDB-DM4	Anti-CD22 Anti-ody (LC-K149C)	CD22	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[205]
ADC Info	Anti-CD22-K149C-MBT-DM4	Anti-CD22 Anti-ody (LC-K149C)	CD22	Mertansine DM4	MBT	[205]
ADC Info	IMB-102	Undisclosed	CTSD	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[206]
ADC Info	Oberotatug ravtansine	Undisclosed	LY75	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[207]
ADC Info	OBA01	Zaptuzumab	TNFRSF10B	Monomethyl auristatin E	PY-MAA-Val-Cit-PABC	[208]
ADC Info	TTZ-Mc-NPV-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Mc-Asn-Pro-Val-PABC	[209]
ADC Info	Adcitmer	Trastuzumab	ERBB2	Monomethyl auristatin E	Pyridino-caproic-Val-Cit-PABC	[210]
ADC Info	Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	BCN-HydraSpace-Val-Cit-PABC	[176]
ADC Info	MF-TTZ-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Dibromomethyl pyridine-Val-Cit-PABC	[211]
ADC Info	FGM-TTZ-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[211]
ADC Info	NC-ADC	Trastuzumab	ERBB2	Monomethyl auristatin E	Divinylpyrimidine-PEG4	[212]
ADC Info	C-ADC	Trastuzumab	ERBB2	Monomethyl auristatin E	Divinylpyrimidine-PEG4-Val-Ala-PABC	[212]
ADC Info	PCM-MET01-MMAE	PCM-MET01	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[213]
ADC Info	Mil40-12B	Mil40	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[179]
ADC Info	Magacizumab PD-MMAE ADC 5	Magacizumab	LRG1	Monomethyl auristatin E	Mepstra-PD-PEG3-Mal-Cit-PABC	[174]
ADC Info	1F-Val-Cit-MMAE	Anit-TF mAb 1F	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[167]
ADC Info	SS1-Val-Cit-MMAE	Anti-MSLN IgG1-SS1	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[214]
ADC Info	CHS7-Val-Cit-MMAE	Anti-MSLN IgG1-CHS7	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[214]
ADC Info	CHS5-Val-Cit-MMAE	Anti-MSLN IgG1-CHS5	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[214]
ADC Info	ALA12-Val-Cit-MMAE	Anti-MSLN IgG1-ALA12	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[214]
ADC Info	T-Fc-Val-Cit-MMAE	Human Anti-FGFR1 Fc	FGFR1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[215]
ADC Info	Anti-CD7 MMAE ADC	Human Anti-CD7 mAb IgG1	CD7	Monomethyl auristatin E	PermaLink-PEG4-Val-Cit-PAB	[216]
ADC Info	PCM5B14-MMAE	H5B14	MST1R	Monomethyl auristatin E	Mc-Val-Cit-PABC	[217]
ADC Info	F7-ADC	F7-Chimeric Ab	FZD7	Monomethyl auristatin E	Mc-Val-Cit-PABC	[88]
ADC Info	CDX3379-MMAE	CDX3379	ERBB3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[218]
ADC Info	MF-BTX-MMAE	Brentuximab	TNFRSF8	Monomethyl auristatin E	Dibromomethyl pyridine-Val-Cit-PABC	[219]
ADC Info	ADC-AVP-04	AVP04	Undisclosed	Monomethyl auristatin E	Maleimide-functionalized TCO	[220]
ADC Info	¹¹¹In-DTPA-D2B-DAR4-MMAE	Anti-PSMA IgG1 mAb D2B	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[221]
ADC Info	¹¹¹In-DTPA-D2B-DAR2-MMAE	Anti-PSMA IgG1 mAb D2B	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[221]
ADC Info	Anti-FcRL5-Mc-vcPAB-MMAE	Anti-FcRL5 mAb	FCRL5	Monomethyl auristatin E	Mc-Val-Cit-PABC	[222]
ADC Info	DMOT4039A	AMA(MMOT0530A)	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[223]
ADC Info	S7-E430G ADC	9G8-7D12-Fc with E430G	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[224]
ADC Info	S7 ADC	9G8-7D12-Fc	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[224]
ADC Info	7H5-Val-Cit-MMAE	Anti-TIP1 mAb 7H5	TAX1BP3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[225]
ADC Info	Tmab-SPDP-DM1	Trastuzumab	ERBB2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[177]
ADC Info	BT062-SPP-DM1	Indatuximab	SDC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[190]
ADC Info	BT062-SMCC-DM1	Indatuximab	SDC1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[190]
ADC Info	MD1.22-DM1	mD1.22	env	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[226]
ADC Info	LR-DM1	LR004	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[227]
ADC Info	hJAA-F11 ADC	JAA-F11	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[228]
ADC Info	IgG78-DM1	Anti-CD248 mAb IgG78	CD248	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[229]
ADC Info	DL35D-DM1	DL35D	env; env	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[226]
ADC Info	AMG-595	Chimeric Anti-EGFRvIII AMG-595 mAb	EGFRvIII	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[230]
ADC Info	Zt/g4-DM1	Anti-RON Zt/g4 (IgG1 kappa)	MST1R	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[112]
ADC Info	Anti-SSTR2 ADC	Anti-human and mouse SSTR2 mAb (IgG1 kappa)	SSTR2	Mertansine DM1	Sulfo-SMCC	[231]
ADC Info	FMOD-ADC	Anti-FMOD mAb	FMOD	Mertansine DM1	Sulfo-SMCC	[232]
ADC Info	Anti-EGFR-Sulfo-SMCC-DM1	Anti-EGFR mAb	EGFR	Mertansine DM1	Sulfo-SMCC	[233]
ADC Info	Anti-CD47 mAb (IgG2b/kappa)-DM1	Anti-CD47 mAb (IgG2b/kappa)-	CD47	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[234]
ADC Info	Anti-CD22-K149C-MPEO-DM1	Anti-CD22 Anti-ody (LC-K149C)	CD22	Mertansine DM1	MPEO	[205]
ADC Info	Anti-CD22-K149C-DM1	Anti-CD22 Anti-ody (LC-K149C)	CD22	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[205]
ADC Info	IMB-101	Undisclosed	CTSD	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[206]
ADC Info	ZV-0501	ZV05	TPBG	Monomethyl auristatin F	Maleimido-caproyl	[235]
ADC Info	CD70-MMAF-ADC	Vorsetuzumab	CD70	Monomethyl auristatin F	Maleimido-caproyl	[236]
ADC Info	Anti-TrkB DVD-ADC	TrkB-DVD (h38C2)	NTRK2	Monomethyl auristatin F	Hexapeptide linker ASTKGP	[194]
ADC Info	T-C-F (DAR 3.7)	Trastuzumab	ERBB2	Monomethyl auristatin F	Maleimido-caproyl	[237]
ADC Info	LCB-ADC1	Isoprenylated trastuzumab	ERBB2	Monomethyl auristatin F	Isoprene-PEG3-beta-Glu-PABC	[238]
ADC Info	DAR2-ARC-ADC	Human hCLL-1 Anti-ody genetically fused with CD38	COLEC10	Monomethyl auristatin F	NAD-based dinucleotide linker	[239]
ADC Info	Anti-TrkB mAb 641 ADC	Anti-TrkB mAb 641	NTRK2	Monomethyl auristatin F	Hexapeptide linker ASTKGP	[194]
ADC Info	CD46-ADC	Anti-CD46 mAb 23AG2	CD46	Monomethyl auristatin F	Mc-Val-Cit-PABC	[240]
ADC Info	Denintuzumab mafodotin	Undisclosed	CD19	Monomethyl auristatin F	Maleimido-caproyl	[241]
ADC Info	DAR4-ARC-ADC	Undisclosed	COLEC10	Monomethyl auristatin F	NAD-based dinucleotide linker	[239]
ADC Info	T-N-F (DAR 3.2)	Trastuzumab	ERBB2	Aldehyde-tagged MMAF	Undisclosed	[237]
ADC Info	T-N-F (DAR 1.6)	Trastuzumab	ERBB2	Aldehyde-tagged MMAF	Undisclosed	[237]
ADC Info	1F6-Asn- (D)Lys-AF	Anti-CD70 mAb IF6	CD70	Auristatin F	Mal-Asn-D-Lys	[188]
ADC Info	Erbitux-MHT-71	Cetuximab	EGFR	Auristatin F	MHT-71	[242]
ADC Info	4D5-AF (CUAAC)	Anti-HER2/neu mAb 4D5	ERBB2	Auristatin F	N6-(2-azidoethoxy)carbonyl-L-lysine	[243]
ADC Info	Anti-HER2 scFv-Fc (Ser396Sec)-CN29	Anti-HER2 scFv-Fc (Ser396Sec)	ERBB2	Monomethyl auristatin F derivative peptide (CN29)	Lodoacetamido-caproyl	[244]
ADC Info	MET/MET-M114	Biparatopic METxMET Anti-ody	MET; MET	Maytansine derivative M24	Succinate-Val-Cit-PABC	[22]
ADC Info	Anti-HER2 DVD-IgG1-Tiancimycin	Anti-HER2 DVD-IgG1	ERBB2	Tiancimycin	DVD-PEG4-Triazol	[245]
ADC Info	SC16.3-DL1	SC16.3	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.4-DL1	SC16.4	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.5-DL1	SC16.5	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.7-DL1	SC16.7	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.8-DL1	SC16.8	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.10-DL1	SC16.10	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.11-DL1	SC16.11	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.13-DL1	SC16.13	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.15-DL1	SC16.15	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.18-DL1	SC16.18	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.19-DL1	SC16.19	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.20-DL1	SC16.20	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.21-DL1	SC16.21	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.22-DL1	SC16.22	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.23-DL1	SC16.23	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.25-DL1	SC16.25	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.26-DL1	SC16.26	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.29-DL1	SC16.29	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.30-DL1	SC16.30	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.31-DL1	SC16.31	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.34-DL1	SC16.34	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.35-DL1	SC16.35	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.36-DL1	SC16.36	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.38-DL1	SC16.38	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.41-DL1	SC16.41	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.42-DL1	SC16.42	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.45-DL1	SC16.45	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.47-DL1	SC16.47	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.49-DL1	SC16.49	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.50-DL1	SC16.50	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.52-DL1	SC16.52	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.55-DL1	SC16.55	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.56-DL1	SC16.56	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.57-DL1	SC16.57	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.58-DL1	SC16.58	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.61-DL1	SC16.61	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.62-DL1	SC16.62	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.63-DL1	SC16.63	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.65-DL1	SC16.65	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.67-DL1	SC16.67	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.68-DL1	SC16.68	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.72-DL1	SC16.72	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.73-DL1	SC16.73	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.78-DL1	SC16.78	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.79-DL1	SC16.79	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.80-DL1	SC16.80	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.81-DL1	SC16.81	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.84-DL1	SC16.84	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.88-DL1	SC16.88	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.101-DL1	SC16.101	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.103-DL1	SC16.103	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.104-DL1	SC16.104	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.105-DL1	SC16.105	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.106-DL1	SC16.106	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.107-DL1	SC16.107	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.108-DL1	SC16.108	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.109-DL1	SC16.109	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.110-DL1	SC16.110	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.111-DL1	SC16.111	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.113-DL1	SC16.113	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.114-DL1	SC16.114	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.115-DL1	SC16.115	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.116-DL1	SC16.116	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.117-DL1	SC16.117	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.118-DL1	SC16.118	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.120-DL1	SC16.120	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.121-DL1	SC16.121	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.122-DL1	SC16.122	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.123-DL1	SC16.123	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.124-DL1	SC16.124	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.125-DL1	SC16.125	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.126-DL1	SC16.126	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.129-DL1	SC16.129	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.130-DL1	SC16.130	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.131-DL1	SC16.131	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.132-DL1	SC16.132	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.133-DL1	SC16.133	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.134-DL1	SC16.134	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.135-DL1	SC16.135	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.136-DL1	SC16.136	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.137-DL1	SC16.137	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.138-DL1	SC16.138	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.139-DL1	SC16.139	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.140-DL1	SC16.140	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.141-DL1	SC16.141	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.142-DL1	SC16.142	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.143-DL1	SC16.143	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.144-DL1	SC16.144	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.147-DL1	SC16.147	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.148-DL1	SC16.148	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.149-DL1	SC16.149	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	SC16.150-DL1	SC16.150	DLL3	SG2000 derivative PBD 1	Mal-PEG8-Val-Ala	[246]
ADC Info	HuM25-vcMMAE-E2	HuM25	LRRC15	Monomethyl auristatin E	Mc-Val-Cit-PABC	[247]
ADC Info	HuM25-vcMMAE-DAR4	HuM25	LRRC15	Monomethyl auristatin E	Mc-Val-Cit-PABC	[247]
ADC Info	HuAD208.4.1-vcMMAE-DAR4	huAD208.4.1	LRRC15	Monomethyl auristatin E	Mc-Val-Cit-PABC	[247]
ADC Info	HuAD208.14.1-vcMMAE-DAR4	huAD208.14.1	LRRC15	Monomethyl auristatin E	Mc-Val-Cit-PABC	[247]
ADC Info	HuM25-mcMMAF-E2	HuM25	LRRC15	Monomethyl auristatin F	Maleimido-caproyl	[247]
ADC Info	chmAb-A B7-H3-ADC	chmAb-A	CD276	Monomethyl auristatin E	Mc-Val-Cit-PABC	[248]
ADC Info	chmAb-B B7-H3-ADC	chmAb-B	CD276	Monomethyl auristatin E	Mc-Val-Cit-PABC	[248]
ADC Info	chmAb-C B7-H3-ADC	chmAb-C	CD276	Monomethyl auristatin E	Mc-Val-Cit-PABC	[248]
ADC Info	chmAb-D B7-H3-ADC	chmAb-D	CD276	Monomethyl auristatin E	Mc-Val-Cit-PABC	[248]
ADC Info	QD6/B09-AZ1508	QD6/B09	EGFR; MET	QD6/B09-AZ1508	QD6/B09-AZ1508	[249]
ADC Info	RAA22/B09-AZ1508	RAA22/B09	EGFR; MET	RAA22/B09-AZ1508	RAA22/B09-AZ1508	[249]
ADC Info	muDS6-DM1	Anti-CA6 mAb muDS6	MUC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[250]
ADC Info	muDS6-SSNPP-MM1-202	Anti-CA6 mAb muDS6	MUC1	Mertansine DM1	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[250]
ADC Info	huDS6v1.01-DM4	huDS6v1.01	MUC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[250]
ADC Info	huDS6v1.21-DM4	huDS6v1.21	MUC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[250]
ADC Info	28E4-DM1	2.80E+05	MUC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[250]
ADC Info	HAZcPB-DM1	HAZcPB	MUC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[250]
ADC Info	SSaPB-DM1	SSaPB	MUC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[250]
ADC Info	CNTO95-DM1	CNTO95	ITGAV	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[251]
ADC Info	F105-DM1	F105	ITGAV	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[251]
ADC Info	CNTO95-SPP-DM1	CNTO95	ITGAV	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[251]
ADC Info	F105-SPP-DM1	F105	ITGAV	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[251]
ADC Info	CNTO95-SPDB-DM4	CNTO95	ITGAV	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[251]
ADC Info	F105-SPDB-DM4	F105	ITGAV	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[251]
ADC Info	nBT062-SMCC-DM1	Indatuximab	SDC1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[252]
ADC Info	nBT062-SPP-DM1	Indatuximab	SDC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[252]
ADC Info	B-B4-SPP-DM1	Anti-CD138 mAb B-B4	SDC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[252]
ADC Info	nBT062-SPDB-DM4	Indatuximab	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[252]
ADC Info	B-B4-SMCC-DM1	Anti-CD138 mAb B-B4	SDC1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[252]
ADC Info	B-B4-SPDB-DM4	Anti-CD138 mAb B-B4	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[252]
ADC Info	huMov19-PEG4-Mal-DM1	huMov19	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	FR1-21-PEG4-Mal-DM1	FR1-21	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	Mov19-PEG4-Mal-DM1	Mov19	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	Farletuzumab-PEG4-Mal-DM1	Farletuzumab	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	FR1-48-PEG4-Mal-DM1	FR1-48	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	FR1-49-PEG4-Mal-DM1	FR1-49	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	FR1-57-PEG4-Mal-DM1	FR1-57	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	FR1-65-PEG4-Mal-DM1	FR1-65	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	huMOV19v1.6-PEG4-Mal-DM1	huMOV19v1.6	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	huMOV19v1.0-PEG4-Mal-DM1	huMOV19v1.0	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	huFR1-21-PEG4-Mal-DM1	huFR1-21	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	muFR1-21-PEG4-Mal-DM1	mu-FR1-21	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	muFR1-9-PEG4-Mal-DM1	mu-FR1-9	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	muFR1-13-PEG4-Mal-DM1	mu-FR1-13	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	muFR1-22-PEG4-Mal-DM1	mu-FR1-22	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	muFR1-23-PEG4-Mal-DM1	mu-FR1-23	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	huFR1-23-PEG4-Mal-DM1	huFR1-23	FOLR1	Mertansine DM1	PEG4-Mal	[253]
ADC Info	huMov19-SMCC-DM1	huMov19	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	FR1-21-SMCC-DM1	FR1-21	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	Mov19-SMCC-DM1	Mov19	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	Farletuzumab-SMCC-DM1	Farletuzumab	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	FR1-48-SMCC-DM1	FR1-48	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	FR1-49-SMCC-DM1	FR1-49	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	FR1-57-SMCC-DM1	FR1-57	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	FR1-65-SMCC-DM1	FR1-65	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	huMOV19v1.6-SMCC-DM1	huMOV19v1.6	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	huMOV19v1.0-SMCC-DM1	huMOV19v1.0	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	huFR1-21-SMCC-DM1	huFR1-21	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	muFR1-21-SMCC-DM1	mu-FR1-21	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	muFR1-9-SMCC-DM1	mu-FR1-9	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	muFR1-13-SMCC-DM1	mu-FR1-13	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	muFR1-22-SMCC-DM1	mu-FR1-22	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	muFR1-23-SMCC-DM1	mu-FR1-23	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	huFR1-23-SMCC-DM1	huFR1-23	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	huMov19-SIA-DM1	huMov19	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	FR1-21-SIA-DM1	FR1-21	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	Mov19-SIA-DM1	Mov19	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	Farletuzumab-SIA-DM1	Farletuzumab	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	FR1-48-SIA-DM1	FR1-48	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	FR1-49-SIA-DM1	FR1-49	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	FR1-57-SIA-DM1	FR1-57	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	FR1-65-SIA-DM1	FR1-65	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	huMOV19v1.6-SIA-DM1	huMOV19v1.6	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	huMOV19v1.0-SIA-DM1	huMOV19v1.0	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	huFR1-21-SIA-DM1	huFR1-21	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	muFR1-21-SIA-DM1	mu-FR1-21	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	muFR1-9-SIA-DM1	mu-FR1-9	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	muFR1-13-SIA-DM1	mu-FR1-13	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	muFR1-22-SIA-DM1	mu-FR1-22	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	muFR1-23-SIA-DM1	mu-FR1-23	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	huFR1-23-SIA-DM1	huFR1-23	FOLR1	Mertansine DM1	N-succinimidyl iodoacetate (SIA)	[253]
ADC Info	huMov19-SPP-DM1	huMov19	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	FR1-21-SPP-DM1	FR1-21	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	Mov19-SPP-DM1	Mov19	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	Farletuzumab-SPP-DM1	Farletuzumab	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	FR1-48-SPP-DM1	FR1-48	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	FR1-49-SPP-DM1	FR1-49	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	FR1-57-SPP-DM1	FR1-57	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	FR1-65-SPP-DM1	FR1-65	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	huMOV19v1.6-SPP-DM1	huMOV19v1.6	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	huMOV19v1.0-SPP-DM1	huMOV19v1.0	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	huFR1-21-SPP-DM1	huFR1-21	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	muFR1-21-SPP-DM1	mu-FR1-21	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	muFR1-9-SPP-DM1	mu-FR1-9	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	muFR1-13-SPP-DM1	mu-FR1-13	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	muFR1-22-SPP-DM1	mu-FR1-22	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	muFR1-23-SPP-DM1	mu-FR1-23	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	huFR1-23-SPP-DM1	huFR1-23	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	huMov19-sulfo-SPDB-DM4 (DAR3.8)	huMov19	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	FR1-21-sulfo-SPDB-DM4	FR1-21	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	Mov19-sulfo-SPDB-DM4	Mov19	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	Farletuzumab-sulfo-SPDB-DM4	Farletuzumab	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	FR1-48-sulfo-SPDB-DM4	FR1-48	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	FR1-49-sulfo-SPDB-DM4	FR1-49	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	FR1-57-sulfo-SPDB-DM4	FR1-57	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	FR1-65-sulfo-SPDB-DM4	FR1-65	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	huMOV19v1.6-sulfo-SPDB-DM4	huMOV19v1.6	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	huMOV19v1.0-sulfo-SPDB-DM4	huMOV19v1.0	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	huFR1-21-sulfo-SPDB-DM4	huFR1-21	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	muFR1-21-sulfo-SPDB-DM4	mu-FR1-21	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	muFR1-9-sulfo-SPDB-DM4	mu-FR1-9	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	muFR1-13-sulfo-SPDB-DM4	mu-FR1-13	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	muFR1-22-sulfo-SPDB-DM4	mu-FR1-22	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	muFR1-23-sulfo-SPDB-DM4	mu-FR1-23	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	huFR1-23-sulfo-SPDB-DM4	huFR1-23	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	huMov19-SPDB-DM4	huMov19	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-21-SPDB-DM4	FR1-21	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	Mov19-SPDB-DM4	Mov19	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	Farletuzumab-SPDB-DM4	Farletuzumab	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-48-SPDB-DM4	FR1-48	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-49-SPDB-DM4	FR1-49	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-57-SPDB-DM4	FR1-57	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-65-SPDB-DM4	FR1-65	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	huMOV19v1.6-SPDB-DM4	huMOV19v1.6	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	huMOV19v1.0-SPDB-DM4	huMOV19v1.0	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	huFR1-21-SPDB-DM4	huFR1-21	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	muFR1-21-SPDB-DM4	mu-FR1-21	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	muFR1-9-SPDB-DM4	mu-FR1-9	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	muFR1-13-SPDB-DM4	mu-FR1-13	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	muFR1-22-SPDB-DM4	mu-FR1-22	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	muFR1-23-SPDB-DM4	mu-FR1-23	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	huFR1-23-SPDB-DM4	huFR1-23	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	FR1-21-PEG4-Mal-DM4	FR1-21	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	Mov19-PEG4-Mal-DM4	Mov19	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	Farletuzumab-PEG4-Mal-DM4	Farletuzumab	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	FR1-48-PEG4-Mal-DM4	FR1-48	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	FR1-49-PEG4-Mal-DM4	FR1-49	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	FR1-57-PEG4-Mal-DM4	FR1-57	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	FR1-65-PEG4-Mal-DM4	FR1-65	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huMOV19v1.6-PEG4-Mal-DM4	huMOV19v1.6	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huMOV19v1.0-PEG4-Mal-DM4	huMOV19v1.0	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huFR1-21-PEG4-Mal-DM4	huFR1-21	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	muFR1-21-PEG4-Mal-DM4	mu-FR1-21	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	muFR1-9-PEG4-Mal-DM4	mu-FR1-9	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	muFR1-13-PEG4-Mal-DM4	mu-FR1-13	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	muFR1-22-PEG4-Mal-DM4	mu-FR1-22	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	muFR1-23-PEG4-Mal-DM4	mu-FR1-23	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huFR1-23-PEG4-Mal-DM4	huFR1-23	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huMov19-sulfo-SPDB-DM4 (DAR6.8)	huMov19	FOLR1	Mertansine DM4	Sulfo-SPDB	[253]
ADC Info	M9346A-SMCC-DM1	Mirvetuximab	FOLR1	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[253]
ADC Info	M9346A-SPP-DM1	Mirvetuximab	FOLR1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[253]
ADC Info	M9346A-SPDB-DM4	Mirvetuximab	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[253]
ADC Info	LCB14-0648	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	LCB14-0648 linker	[254]
ADC Info	LCB14-0663	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	LCB14-0663 linker	[254]
ADC Info	LCB14-0664	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	LCB14-0664 linker	[254]
ADC Info	LCB14-6e	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin E	LCB14-6e linker	[254]
ADC Info	Anti-CD19(LC)-G7VIM-2i	DI-B4-(LC)-GGGGGGG-CVIM	CD19	Monomethyl auristatin F	Anti-CD19(LC)-G7VIM-2i linker	[254]
ADC Info	Blinatumomab-2i	Blinatumomab	CD19; CD3D	Monomethyl auristatin F	Blinatumomab-2i linker	[254]
ADC Info	Inebilizumab-2i	Inebilizumab	CD19	Monomethyl auristatin F	Inebilizumab-2i linker	[254]
ADC Info	Tafasitamab-2i	Tafasitamab	CD19	Monomethyl auristatin F	Tafasitamab-2i linker	[254]
ADC Info	Obexelimab-2i	Obexelimab	CD19	Monomethyl auristatin F	Obexelimab-2i linker	[254]
ADC Info	MDX-1342-2i	MDX-1342	CD19	Monomethyl auristatin F	MDX-1342-2i linker	[254]
ADC Info	MDX-1435-2i	MDX-1435	CD19	Monomethyl auristatin F	MDX-1435-2i linker	[254]
ADC Info	cHD37-2i	cHD37	CD19	Monomethyl auristatin F	cHD37-2i linker	[254]
ADC Info	AFM-11-2i	AFM-11	CD19	Monomethyl auristatin F	AFM-11-2i linker	[254]
ADC Info	AFM-12-2i	AFM-12	CD19	Monomethyl auristatin F	AFM-12-2i linker	[254]
ADC Info	GBR401-2i	GBR401	CD19	Monomethyl auristatin F	GBR401-2i linker	[254]
ADC Info	Denintuzumab-2i	Denintuzumab	CD19	Monomethyl auristatin F	Denintuzumab-2i linker	[254]
ADC Info	Anti-CD19(LC)-G7VIM-4i	DI-B4-(LC)-GGGGGGG-CVIM	CD19	Monomethyl auristatin F	Anti-CD19(LC)-G7VIM-4i linker	[254]
ADC Info	Blinatumomab-4i	Blinatumomab	CD19; CD3D	Monomethyl auristatin F	Blinatumomab-4i linker	[254]
ADC Info	Inebilizumab-4i	Inebilizumab	CD19	Monomethyl auristatin F	Inebilizumab-4i linker	[254]
ADC Info	Tafasitamab-4i	Tafasitamab	CD19	Monomethyl auristatin F	Tafasitamab-4i linker	[254]
ADC Info	Obexelimab-4i	Obexelimab	CD19	Monomethyl auristatin F	Obexelimab-4i linker	[254]
ADC Info	MDX-1342-4i	MDX-1342	CD19	Monomethyl auristatin F	MDX-1342-4i linker	[254]
ADC Info	MDX-1435-4i	MDX-1435	CD19	Monomethyl auristatin F	MDX-1435-4i linker	[254]
ADC Info	cHD37-4i	cHD37	CD19	Monomethyl auristatin F	cHD37-4i linker	[254]
ADC Info	AFM-11-4i	AFM-11	CD19	Monomethyl auristatin F	AFM-11-4i linker	[254]
ADC Info	AFM-12-4i	AFM-12	CD19	Monomethyl auristatin F	AFM-12-4i linker	[254]
ADC Info	GBR401-4i	GBR401	CD19	Monomethyl auristatin F	GBR401-4i linker	[254]
ADC Info	Denintuzumab-4i	Denintuzumab	CD19	Monomethyl auristatin F	Denintuzumab-4i linker	[254]
ADC Info	Anti-CD19(LC)-G7VIM-3i	DI-B4-(LC)-GGGGGGG-CVIM	CD19	Monomethyl auristatin F	Anti-CD19(LC)-G7VIM-3i linker	[254]
ADC Info	Blinatumomab-3i	Blinatumomab	CD19; CD3D	Monomethyl auristatin F	Blinatumomab-3i linker	[254]
ADC Info	Inebilizumab-3i	Inebilizumab	CD19	Monomethyl auristatin F	Inebilizumab-3i linker	[254]
ADC Info	Tafasitamab-3i	Tafasitamab	CD19	Monomethyl auristatin F	Tafasitamab-3i linker	[254]
ADC Info	Obexelimab-3i	Obexelimab	CD19	Monomethyl auristatin F	Obexelimab-3i linker	[254]
ADC Info	MDX-1342-3i	MDX-1342	CD19	Monomethyl auristatin F	MDX-1342-3i linker	[254]
ADC Info	MDX-1435-3i	MDX-1435	CD19	Monomethyl auristatin F	MDX-1435-3i linker	[254]
ADC Info	cHD37-3i	cHD37	CD19	Monomethyl auristatin F	cHD37-3i linker	[254]
ADC Info	AFM-11-3i	AFM-11	CD19	Monomethyl auristatin F	AFM-11-3i linker	[254]
ADC Info	AFM-12-3i	AFM-12	CD19	Monomethyl auristatin F	AFM-12-3i linker	[254]
ADC Info	GBR401-3i	GBR401	CD19	Monomethyl auristatin F	GBR401-3i linker	[254]
ADC Info	Denintuzumab-3i	Denintuzumab	CD19	Monomethyl auristatin F	Denintuzumab-3i linker	[254]
ADC Info	Anti-CD19(LC)-G7VIM-6e	DI-B4-(LC)-GGGGGGG-CVIM	CD19	Monomethyl auristatin E	Anti-CD19(LC)-G7VIM-6e linker	[254]
ADC Info	Blinatumomab-6e	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-6e linker	[254]
ADC Info	Inebilizumab-6e	Inebilizumab	CD19	Monomethyl auristatin E	Inebilizumab-6e linker	[254]
ADC Info	Tafasitamab-6e	Tafasitamab	CD19	Monomethyl auristatin E	Tafasitamab-6e linker	[254]
ADC Info	Obexelimab-6e	Obexelimab	CD19	Monomethyl auristatin E	Obexelimab-6e linker	[254]
ADC Info	MDX-1342-6e	MDX-1342	CD19	Monomethyl auristatin E	MDX-1342-6e linker	[254]
ADC Info	MDX-1435-6e	MDX-1435	CD19	Monomethyl auristatin E	MDX-1435-6e linker	[254]
ADC Info	cHD37-6e	cHD37	CD19	Monomethyl auristatin E	cHD37-6e linker	[254]
ADC Info	AFM-11-6e	AFM-11	CD19	Monomethyl auristatin E	AFM-11-6e linker	[254]
ADC Info	AFM-12-6e	AFM-12	CD19	Monomethyl auristatin E	AFM-12-6e linker	[254]
ADC Info	GBR401-6e	GBR401	CD19	Monomethyl auristatin E	GBR401-6e linker	[254]
ADC Info	Denintuzumab-6e	Denintuzumab	CD19	Monomethyl auristatin E	Denintuzumab-6e linker	[254]
ADC Info	ADC14-0810	Cetuximab (LC) G7-CVIM	EGFR	Monomethyl auristatin F	ADC14-0810 linker	[255]
ADC Info	LCB14-0645	Cetuximab (LV) G7-CVIM	EGFR	Monomethyl auristatin F	LCB14-0645 linker	[255]
ADC Info	Cetuximab (LC)-2i	Cetuximab (LC)	EGFR	Monomethyl auristatin F	Cetuximab(LC)-2i linker	[255]
ADC Info	Cetuximab (LC) G7-CVIM-3i	Cetuximab (LC) G7-CVIM	EGFR	Monomethyl auristatin F	Cetuximab(LC) G7-CVIM-3i linker	[255]
ADC Info	Cetuximab (LV) G7-CVIM-3i	Cetuximab (LV) G7-CVIM	EGFR	Monomethyl auristatin F	Cetuximab(LV) G7-CVIM-3i linker	[255]
ADC Info	Cetuximab (LC)-3i	Cetuximab (LC)	EGFR	Monomethyl auristatin F	Cetuximab(LC)-3i linker	[255]
ADC Info	Cetuximab (LC) G7-CVIM-4i	Cetuximab (LC) G7-CVIM	EGFR	Monomethyl auristatin F	Cetuximab(LC) G7-CVIM-4i linker	[255]
ADC Info	Cetuximab (LV) G7-CVIM-4i	Cetuximab (LV) G7-CVIM	EGFR	Monomethyl auristatin F	Cetuximab(LV) G7-CVIM-4i linker	[255]
ADC Info	Cetuximab (LC)-4i	Cetuximab (LC)	EGFR	Monomethyl auristatin F	Cetuximab(LC)-4i linker	[255]
ADC Info	Cetuximab (LC) G7-CVIM-6e	Cetuximab (LC) G7-CVIM	EGFR	Monomethyl auristatin E	Cetuximab(LC) G7-CVIM-6e linker	[255]
ADC Info	Cetuximab (LV) G7-CVIM-6e	Cetuximab (LV) G7-CVIM	EGFR	Monomethyl auristatin E	Cetuximab(LV) G7-CVIM-6e linker	[255]
ADC Info	Cetuximab (LC)-6e	Cetuximab (LC)	EGFR	Monomethyl auristatin E	Cetuximab(LC)-6e linker	[255]
ADC Info	MYK-3	BA03	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[256]
ADC Info	BA03-MC-MMAE	BA03	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[256]
ADC Info	BA03-MCC-MMAE	BA03	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[256]
ADC Info	TF-mAb-DM1	TF-mAb-SC1	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H29-DM1	TF-mAb-H29	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H30-DM1	TF-mAb-H30	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H31-DM1	TF-mAb-H31	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H32-DM1	TF-mAb-H32	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H33-DM1	TF-mAb-H33	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H34-DM1	TF-mAb-H34	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H35-DM1	TF-mAb-H35	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H36-DM1	TF-mAb-H36	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H37-DM1	TF-mAb-H37	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H38-DM1	TF-mAb-H38	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H39-DM1	TF-mAb-H39	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H40-DM1	TF-mAb-H40	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H41-DM1	TF-mAb-H41	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H42-DM1	TF-mAb-H42	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H43-DM1	TF-mAb-H43	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H44-DM1	TF-mAb-H44	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H45-DM1	TF-mAb-H45	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H46-DM1	TF-mAb-H46	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H47-DM1	TF-mAb-H47	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-H48-DM1	TF-mAb-H48	F3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[257]
ADC Info	TF-mAb-MMAE	TF-mAb-SC1	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H29-MMAE	TF-mAb-H29	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H30-MMAE	TF-mAb-H30	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H31-MMAE	TF-mAb-H31	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H32-MMAE	TF-mAb-H32	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H33-MMAE	TF-mAb-H33	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H34-MMAE	TF-mAb-H34	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H35-MMAE	TF-mAb-H35	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H36-MMAE	TF-mAb-H36	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H37-MMAE	TF-mAb-H37	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H38-MMAE	TF-mAb-H38	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H39-MMAE	TF-mAb-H39	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H40-MMAE	TF-mAb-H40	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H41-MMAE	TF-mAb-H41	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H42-MMAE	TF-mAb-H42	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H43-MMAE	TF-mAb-H43	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H44-MMAE	TF-mAb-H44	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H45-MMAE	TF-mAb-H45	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H46-MMAE	TF-mAb-H46	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H47-MMAE	TF-mAb-H47	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	TF-mAb-H48-MMAE	TF-mAb-H48	F3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[257]
ADC Info	RGCLN18.2-MC-Val-Cit-PAB-MMAE	RGCLN18.2	CLDN18.2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[258]
ADC Info	RGCLN18.2-D07-Val-Cit-PAB-MMAE	RGCLN18.2	CLDN18.2	Monomethyl auristatin E	D07-Val-Cit-PABC	[258]
ADC Info	RGCLN18.2-PY-Val-Cit-PAB-MMAE	RGCLN18.2	CLDN18.2	Monomethyl auristatin E	PY-VC-PABC	[258]
ADC Info	IMAB362-MC-Val-Cit-PAB-MMAE	IMAB362	CLDN18.2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[258]
ADC Info	WO2017089895A1 ADC1	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC1 linker	[259]
ADC Info	WO2017089895A1 ADC2	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC2 linker	[259]
ADC Info	WO2017089895A1 ADC3	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC3 linker	[259]
ADC Info	WO2017089895A1 ADC4	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC4 linker	[259]
ADC Info	WO2017089895A1 ADC5	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC5 linker	[259]
ADC Info	WO2017089895A1 ADC6	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC6 linker	[259]
ADC Info	WO2017089895A1 ADC7	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC7 linker	[259]
ADC Info	WO2017089895A1 ADC8	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC8 linker	[259]
ADC Info	WO2017089895A1 ADC9	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC9 linker	[259]
ADC Info	WO2017089895A1 ADC10	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC10 linker	[259]
ADC Info	WO2017089895A1 ADC11	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC11 linker	[259]
ADC Info	WO2017089895A1 ADC12	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC12 linker	[259]
ADC Info	WO2017089895A1 ADC13	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC13 linker	[259]
ADC Info	WO2017089895A1 ADC14	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC14 linker	[259]
ADC Info	WO2017089895A1 ADC15	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC15 linker	[259]
ADC Info	WO2017089895A1 ADC16	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC16 linker	[259]
ADC Info	WO2017089895A1 ADC17	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC17 linker	[259]
ADC Info	WO2017089895A1 ADC18	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC18 linker	[259]
ADC Info	WO2017089895A1 ADC19	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC19 linker	[259]
ADC Info	WO2017089895A1 ADC20	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC20 linker	[259]
ADC Info	WO2017089895A1 ADC86	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC86 linker	[259]
ADC Info	WO2017089895A1 ADC87	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC87 linker	[259]
ADC Info	WO2017089895A1 ADC23	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC23 linker	[259]
ADC Info	WO2017089895A1 ADC24	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC24 linker	[259]
ADC Info	WO2017089895A1 ADC25	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC25 linker	[259]
ADC Info	WO2017089895A1 ADC26	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC26 linker	[259]
ADC Info	WO2017089895A1 ADC27	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC27 linker	[259]
ADC Info	WO2017089895A1 ADC28	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC28 linker	[259]
ADC Info	WO2017089895A1 ADC29	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC29 linker	[259]
ADC Info	WO2017089895A1 ADC30	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC30 linker	[259]
ADC Info	WO2017089895A1 ADC31	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC31 linker	[259]
ADC Info	WO2017089895A1 ADC32	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC32 linker	[259]
ADC Info	WO2017089895A1 ADC33	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC33 linker	[259]
ADC Info	WO2017089895A1 ADC34	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC34 linker	[259]
ADC Info	WO2017089895A1 ADC35	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC35 linker	[259]
ADC Info	WO2017089895A1 ADC36	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC36 linker	[259]
ADC Info	WO2017089895A1 ADC37	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC37 linker	[259]
ADC Info	WO2017089895A1 ADC38	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC38 linker	[259]
ADC Info	WO2017089895A1 ADC39	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC39 linker	[259]
ADC Info	WO2017089895A1 ADC40	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC40 linker	[259]
ADC Info	WO2017089895A1 ADC41	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC41 linker	[259]
ADC Info	WO2017089895A1 ADC42	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC42 linker	[259]
ADC Info	WO2017089895A1 ADC43	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC43 linker	[259]
ADC Info	WO2017089895A1 ADC44	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC44 linker	[259]
ADC Info	WO2017089895A1 ADC45	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC45 linker	[259]
ADC Info	WO2017089895A1 ADC46	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC46 linker	[259]
ADC Info	WO2017089895A1 ADC47	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC47 linker	[259]
ADC Info	WO2017089895A1 ADC48	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC48 linker	[259]
ADC Info	WO2017089895A1 ADC49	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC49 linker	[259]
ADC Info	WO2017089895A1 ADC50	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC50 linker	[259]
ADC Info	WO2017089895A1 ADC51	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC51 linker	[259]
ADC Info	WO2017089895A1 ADC52	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC52 linker	[259]
ADC Info	WO2017089895A1 ADC53	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC53 linker	[259]
ADC Info	WO2017089895A1 ADC54	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC54 linker	[259]
ADC Info	WO2017089895A1 ADC55	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC55 linker	[259]
ADC Info	WO2017089895A1 ADC76	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC76 linker	[259]
ADC Info	WO2017089895A1 ADC88	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC88 linker	[259]
ADC Info	WO2017089895A1 ADC89	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC89 linker	[259]
ADC Info	WO2017089895A1 ADC90	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC90 linker	[259]
ADC Info	WO2017089895A1 ADC91	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC91 linker	[259]
ADC Info	WO2017089895A1 ADC60	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC60 linker	[259]
ADC Info	WO2017089895A1 ADC61	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC61 linker	[259]
ADC Info	WO2017089895A1 ADC62	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC62 linker	[259]
ADC Info	WO2017089895A1 ADC63	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089895A1_ADC63 linker	[259]
ADC Info	WO2017089895A1 ADC77	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089895A1_ADC77 linker	[259]
ADC Info	WO2017089895A1 ADC64	Cetuximab	EGFR	Monomethyl auristatin F	WO2017089895A1_ADC64 linker	[259]
ADC Info	WO2017089895A1 ADC65	Cetuximab	EGFR	Monomethyl auristatin E	WO2017089895A1_ADC65 linker	[259]
ADC Info	WO2017089895A1 ADC66	Cetuximab	EGFR	Monomethyl auristatin F	WO2017089895A1_ADC66 linker	[259]
ADC Info	WO2017089895A1 ADC67	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	WO2017089895A1_ADC67 linker	[259]
ADC Info	WO2017089895A1 ADC68	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin E	WO2017089895A1_ADC68 linker	[259]
ADC Info	WO2017089895A1 ADC69	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	WO2017089895A1_ADC69 linker	[259]
ADC Info	WO2017089895A1 ADC70	Rituximab	MS4A1	Monomethyl auristatin F	WO2017089895A1_ADC70 linker	[259]
ADC Info	WO2017089895A1 ADC71	Rituximab	MS4A1	Monomethyl auristatin E	WO2017089895A1_ADC71 linker	[259]
ADC Info	WO2017089895A1 ADC72	Rituximab	MS4A1	Monomethyl auristatin F	WO2017089895A1_ADC72 linker	[259]
ADC Info	WO2017089895A1 ADC73	Depatuxizumab	EGFRvIII	Monomethyl auristatin F	WO2017089895A1_ADC73 linker	[259]
ADC Info	WO2017089895A1 ADC74	Depatuxizumab	EGFRvIII	Monomethyl auristatin E	WO2017089895A1_ADC74 linker	[259]
ADC Info	WO2017089895A1 ADC75	Depatuxizumab	EGFRvIII	Monomethyl auristatin F	WO2017089895A1_ADC75 linker	[259]
ADC Info	WO2021044208A1 ADC2	Anti-ROR1 mAb C2E3	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC2 linker	[260]
ADC Info	WO2021044208A1 ADC3	Anti-ROR1 mAb C2E3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC3 linker	[260]
ADC Info	WO2021044208A1 ADC4	Anti-ROR1 mAb C2E3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC4 linker	[260]
ADC Info	WO2021044208A1 ADC5	Anti-ROR1 mAb C2E3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC5 linker	[260]
ADC Info	WO2021044208A1 ADC9	Anti-ROR1 mAb 2A2	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC9 linker	[260]
ADC Info	WO2021044208A1 ADC10	Anti-ROR1 mAb 2A2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC10 linker	[260]
ADC Info	WO2021044208A1 ADC 2A2-4	Anti-ROR1 mAb 2A2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC 2A2-4 linker	[260]
ADC Info	WO2021044208A1 ADC 2A2-5	Anti-ROR1 mAb 2A2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC 2A2-5 linker	[260]
ADC Info	WO2021044208A1 ADC AB4-2	Anti-ROR1 mAb AB4	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC AB4-2 linker	[260]
ADC Info	WO2021044208A1 ADC AB4-3	Anti-ROR1 mAb AB4	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC AB4-3 linker	[260]
ADC Info	WO2021044208A1 ADC AB4-4	Anti-ROR1 mAb AB4	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC AB4-4 linker	[260]
ADC Info	WO2021044208A1 ADC AB4-5	Anti-ROR1 mAb AB4	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC AB4-5 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2-2	Anti-ROR1 mAb A2F2	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC A2F2-2 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2-3	Anti-ROR1 mAb A2F2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2-3 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2-4	Anti-ROR1 mAb A2F2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2-4 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2-5	Anti-ROR1 mAb A2F2	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2-5 linker	[260]
ADC Info	WO2021044208A1 ADC A2F3-2	Anti-ROR1 mAb A2F3	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC A2F3-2 linker	[260]
ADC Info	WO2021044208A1 ADC A2F3-3	Anti-ROR1 mAb A2F3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F3-3 linker	[260]
ADC Info	WO2021044208A1 ADC A2F3-4	Anti-ROR1 mAb A2F3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F3-4 linker	[260]
ADC Info	WO2021044208A1 ADC BA6-2	Anti-ROR1 mAb BA6	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC BA6-2 linker	[260]
ADC Info	WO2021044208A1 ADC BA6-3	Anti-ROR1 mAb BA6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC BA6-3 linker	[260]
ADC Info	WO2021044208A1 ADC BA6-4	Anti-ROR1 mAb BA6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC BA6-4 linker	[260]
ADC Info	WO2021044208A1 ADC BA6-5	Anti-ROR1 mAb BA6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC BA6-5 linker	[260]
ADC Info	WO2021044208A1 ADC CC9-2	Anti-ROR1 mAb CC9	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC CC9-2 linker	[260]
ADC Info	WO2021044208A1 ADC CC9-3	Anti-ROR1 mAb CC9	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC CC9-3 linker	[260]
ADC Info	WO2021044208A1 ADC CC9-4	Anti-ROR1 mAb CC9	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC CC9-4 linker	[260]
ADC Info	WO2021044208A1 ADC CC9-5	Anti-ROR1 mAb CC9	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC CC9-5 linker	[260]
ADC Info	WO2021044208A1 ADC DG6-2	Anti-ROR1 mAb DG6	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC DG6-2 linker	[260]
ADC Info	WO2021044208A1 ADC DG6-3	Anti-ROR1 mAb DG6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC DG6-3 linker	[260]
ADC Info	WO2021044208A1 ADC DG6-5	Anti-ROR1 mAb DG6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC DG6-5 linker	[260]
ADC Info	WO2021044208A1 ADC D2B12-2	Anti-ROR1 mAb D2B12	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC D2B12-2 linker	[260]
ADC Info	WO2021044208A1 ADC D2B12-3	Anti-ROR1 mAb D2B12	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC D2B12-3 linker	[260]
ADC Info	WO2021044208A1 ADC D2B12-4	Anti-ROR1 mAb D2B12	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC D2B12-4 linker	[260]
ADC Info	WO2021044208A1 ADC D2B12-5	Anti-ROR1 mAb D2B12	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC D2B12-5 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2 M1-2	Anti-ROR1 mAb A2F2 M1	ROR1	Monomethyl auristatin F	WO2021044208A1_ADC A2F2 M1-2 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2 M1-3	Anti-ROR1 mAb A2F2 M1	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2 M1-3 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2 M1-4	Anti-ROR1 mAb A2F2 M1	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2 M1-4 linker	[260]
ADC Info	WO2021044208A1 ADC A2F2 M1-5	Anti-ROR1 mAb A2F2 M1	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F2 M1-5 linker	[260]
ADC Info	RC88-PY-MAA-Val-Cit-PAB-MMAE	Anti-MSLN mAb	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[261]
ADC Info	RC88-PY-MAA-Val-Cit-PAB-MMAD	Anti-MSLN mAb	MSLN	Monomethyl auristatin D	Mc-Val-Cit-PABC	[261]
ADC Info	RC88-Mc-Val-Cit-PAB-MMAE	Anti-MSLN mAb	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[261]
ADC Info	RC88-Mc-Val-Cit-PAB-MMAD	Anti-MSLN mAb	MSLN	Monomethyl auristatin D	Mc-Val-Cit-PABC	[261]
ADC Info	Mirvetuximab-SPDB-DM4	Mirvetuximab	FOLR1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[262]
ADC Info	CAC10-Gly5-MAY	Brentuximab	TNFRSF8	Mertansine DM1	Gly5	[197]
ADC Info	B-B4-DM1	Cantuzumab	SDC1	Mertansine DM1	Undisclosed	[263]
ADC Info	AXL-171-MMAE	AXL-171	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[192]
ADC Info	ADC MMAE/F 4+2	Trastuzumab N297A	ERBB2	Monomethyl auristatin E+Monomethyl auristatin F	DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC	[264]
ADC Info	ADC MMAE/F 2+4	Trastuzumab N297A	ERBB2	Monomethyl auristatin E+Monomethyl auristatin F	DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC	[264]
ADC Info	Trastuzumab-Man-beta-1,4GlcNAc-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc	[265]
ADC Info	Trastuzumab-Glc-beta-1,4GlcNAc-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Glc-beta-1,4GlcNAc	[265]
ADC Info	Trastuzumab-Gal-beta-1,4GlcNAc-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Gal-beta-1,4-GlcNAc	[265]
ADC Info	Trastuzumab-MMAE conjugate DAR2	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB	[266]
ADC Info	Trastuzumab-MMAE conjugate DAR4	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB	[266]
ADC Info	Trastuzumab-MMAE conjugate DAR6	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB	[266]
ADC Info	Trastuzumab-MMAE conjugate DAR8	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB	[266]
ADC Info	Trastuzumab-MMAE conjugate DAR12	Trastuzumab	ERBB2	Monomethyl auristatin E	Man-beta-1,4-GlcNAc-DBCO-PEG5-VC-PAB	[266]
ADC Info	Fcab-1-MMAE	Fcab-1	EGFR	Monomethyl auristatin E	Gly3-Val-Cit-PABC	[198]
ADC Info	ADC MMAE/F 2+2	Trastuzumab N297A	ERBB2	Monomethyl auristatin E+Monomethyl auristatin F	DBCO-PEG3-Glu-Val-Cit-PABC; TCO-PEG3-Glu-Val-Cit-PABC	[264]
ADC Info	PeptibodyC19-PEG4-Val-Cit-MMAE	Peptibody C19	FGFR1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[267]
ADC Info	HB22.7-SAP	Anti-CD22 mAb HB22.7	CD22	Saporin	Undisclosed	[268]
ADC Info	Anti-N3(i)-vc0101	Anti-NOTCH3(i) mAb	NOTCH3	Auristatin 0101	Mc-Val-Cit-PABC	[203]
ADC Info	Anti-ICOS-MMAE	Murine Anti-ICOS Anti-ody	ICOS	Monomethyl auristatin E	Undisclosed	[269]
ADC Info	CHS8-Val-Cit-MMAE	Anti-MSLN IgG1-CHS8	MSLN	Monomethyl auristatin E	Mc-Val-Cit-PABC	[214]
ADC Info	2G4-DM1	Anti-KIT mAb 2G4	KIT	Mertansine DM1	Undisclosed	[270]
ADC Info	T-K-F (DAR 3.9)	Trastuzumab	ERBB2	Monomethyl auristatin F	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[237]
ADC Info	LCB-ADC3	Isoprenylated trastuzumab	ERBB2	Monomethyl auristatin F	Bridged PEG4-valine-alanine	[238]
ADC Info	LCB-ADC2	Isoprenylated trastuzumab	ERBB2	Monomethyl auristatin F	Isoprene-PEG3,3,3-beta-Glu-PABC	[238]
ADC Info	Eribulin ADC (Jiangsu hengrui)	Undisclosed	Undisclosed	Eribulin	Undisclosed	[271]
ADC Info	Monoclonal antibody HB2-saporin conjugate	Anti-CD7 mAb HB2	CD7	Saporin	Undisclosed	[272]
ADC Info	Anti-CD30 monoclonal antibody-saporin conjugate	Anti-CD30 mAb Ber-H2	TNFRSF8	Saporin	Undisclosed	[273]
ADC Info	Anti-CD38 IT OKT10-SAPORIN	Undisclosed	CD38	Saporin	Undisclosed	[274]
ADC Info	GENA-111-AF	GENA-111	TNFRSF17	Monomethyl auristatin F	Undisclosed	[275]
ADC Info	NS Cys-vc-MMAE	Undisclosed	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	Cetux Cys-vc-MMAE	Glyco-engineered cetuximab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	Glyco-cetuximab Fab-vc-MMAE	Glyco-engineered cetuximab Fab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	Cetux Fc/Fab-vc-MMAE	Glyco-engineered cetuximab Fc/Fab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	IC1-MMAE	Chimeric ICAM1 Anti-ody (clone #R6.5)	ICAM1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[277]
ADC Info	IC1-MMAF	Chimeric ICAM1 Anti-ody (clone #R6.5)	ICAM1	Monomethyl auristatin F	Maleimido-caproyl	[277]
ADC Info	IC1-DM4	Chimeric ICAM1 Anti-ody (clone #R6.5)	ICAM1	Mertansine DM4	Mal-EBE-Mal	[277]
ADC Info	IC1-DM1	Chimeric ICAM1 Anti-ody (clone #R6.5)	ICAM1	Mertansine DM1	Mal-EBE-Mal	[277]
ADC Info	ADC Trast-7	Trastuzumab	ERBB2	Monomethyl auristatin E	Undisclosed	[278]
ADC Info	ADC Trast-10	Trastuzumab	ERBB2	Monomethyl auristatin E	Bis-BCN-modified Val-Cit-PABC linker 10	[278]
ADC Info	MMAE-IgG1 17	Anti-ENPP1 IgG1 17	ENPP1	Monomethyl auristatin E	Undisclosed	[279]
ADC Info	MMAE-IgG1 3G12	Anti-ENPP1 IgG1 3G12	ENPP1	Monomethyl auristatin E	Undisclosed	[279]
ADC Info	AB-3A4-Val-Cit-MMAE	Anti-KAAG1 mAb AB-3A4	KAAG1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[280]
ADC Info	IGN-786	Anti-SAIL mAb	TSPO	Monomethyl auristatin F	Maleimido-caproyl	[281]
ADC Info	AVID-300	Panitumumab	EGFR	Mertansine DM1	Undisclosed	[282]
ADC Info	1711 (scFv)-SNAP-AuriF	1711/425 scFv-SNAP	EGFR	Auristatin F	BG based linker	[283]
ADC Info	MMAE.VC.SA.617	Undisclosed	FOLH1	Monomethyl auristatin E	Undisclosed	[284]
ADC Info	CLDN1 ADC	Anti-CLDN1 mAb 6F6	CLDN1	Monomethyl auristatin E	Undisclosed	[285]
ADC Info	1959-sss/DM4	Undisclosed	LGALS3BP	Mertansine DM4	Undisclosed	[286]
ADC Info	ZHER2-ABD-mcMMAF	ZHER2-ABD	ERBB2	Monomethyl auristatin F	Maleimido-caproyl	[287]
ADC Info	ZHER2-ABD-mcMMAE	ZHER2-ABD	ERBB2	Monomethyl auristatin E	Maleimido-caproyl	[287]
ADC Info	ITcetuximab	Cetuximab	EGFR	Saporin	Undisclosed	[288]
ADC Info	Bevacizumab vedotin	Bevacizumab	VEGFA	Monomethyl auristatin E	Mc-Val-Cit-PABC	[289]
ADC Info	Anti-DOG1-DM4-ADC	Anti-DOG1 mAb	ANO1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[290]
ADC Info	A5/158-vc-MMAE	A5/158	MRC2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[291]
ADC Info	mesoADC	Anti-GSDME mAb	GSDME	Monomethyl auristatin E	Mc-Val-Cit-PABC	[292]
ADC Info	3A5-mc-VC-PAB-MMAE	Anti-MUC16 Anti-ody 3A5	MUC16	Monomethyl auristatin E	Mc-Val-Cit-PABC	[293]
ADC Info	3A5-55 ADC	Anti-MUC16 Anti-ody 3A5	MUC16	Maytansine derivative 55	Mal-EBE-Mal	[293]
ADC Info	3A5-56 ADC	Anti-MUC16 Anti-ody 3A5	MUC16	Maytansine derivative 56	Mal-EBE-Mal	[293]
ADC Info	3A5-57 ADC	Anti-MUC16 Anti-ody 3A5	MUC16	Maytansine derivative 57	Maleimido-caproyl	[293]
ADC Info	MUC16-55 ADC	Anti-MUC16 mAb	MUC16	Maytansine derivative 55	Mal-EBE-Mal	[293]
ADC Info	MUC16-56 ADC	Anti-MUC16 mAb	MUC16	Maytansine derivative 56	Mal-EBE-Mal	[293]
ADC Info	Cys-linker-MMAE-based ADC 11	Mil40	ERBB2	Monomethyl auristatin E	Cys-11 ADC linker	[294]
ADC Info	Cys-linker-MMAE-based ADC 12	Mil40	ERBB2	Monomethyl auristatin E	Cys-12 ADC linker	[294]
ADC Info	Cys-linker-MMAE-based ADC 13	Mil40	ERBB2	Monomethyl auristatin E	Cys-13 ADC linker	[294]
ADC Info	Cys-linker-MMAE-based ADC 14	Mil40	ERBB2	Monomethyl auristatin E	Cys-14 ADC linker	[294]
ADC Info	Cys-linker-MMAE-based ADC 15	Mil40	ERBB2	Monomethyl auristatin E	Mc-PABC	[294]
ADC Info	Cys-linker-MMAE-based ADC 16	Mil40	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[294]
ADC Info	P38B-DM1	P38B	PDPN	Mertansine DM1	Azide-modified dibenzocyclooctyne(DBCO)-albumin(HAS)	[295]
ADC Info	GPC-1-ADC	Anti-GPC1 mAb clone 01a033	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[296]
ADC Info	10D7-MMAE	Anti-CDCP1 mAb 10D7	CDCP1	Monomethyl auristatin E	Undisclosed	[297]
ADC Info	CD4-Val-Cit-MMAE	Anti-CD4 mAb	CD4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[298]
ADC Info	Trastuzumab-iCME	Trastuzumab	ERBB2	Membrane-impermable colchinolmethyl ether (iCME) cytotoxin	Pacific blue fluorophore-SH based linker	[299]
ADC Info	2G10 RED-106 maytansine 2	Anti-PLAUR mAb 2G10	PLAUR	Mertansine DM1	RED-106	[300]
ADC Info	2G10 RED-106 maytansine 4	Anti-PLAUR mAb 2G10	PLAUR	Mertansine DM1	RED-106	[300]
ADC Info	2G10 RED-425 maytansine 4	Anti-PLAUR mAb 2G10	PLAUR	Mertansine DM1	RED-425	[300]
ADC Info	2G10 RED-432 maytansine 4	Anti-PLAUR mAb 2G10	PLAUR	Mertansine DM1	RED-432	[300]
ADC Info	2G10 RED-244 MMAE 2	Anti-PLAUR mAb 2G10	PLAUR	Monomethyl auristatin E	RED-244	[300]
ADC Info	2G10 RED-244 MMAE 4	Anti-PLAUR mAb 2G10	PLAUR	Monomethyl auristatin E	RED-244	[300]
ADC Info	2G10 RED-412 MMAE 4	Anti-PLAUR mAb 2G10	PLAUR	Monomethyl auristatin E	RED-412	[300]
ADC Info	2G10 RED-388 MMAE 4	Anti-PLAUR mAb 2G10	PLAUR	Monomethyl auristatin E	RED-388	[300]
ADC Info	2G10 RED-426 MMAE 4	Anti-PLAUR mAb 2G10	PLAUR	Monomethyl auristatin E	RED-426	[300]
ADC Info	IgG1 (trastuzumab)-vc-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[301]
ADC Info	IgG1 (H32)-vc-MMAE	Anti-HER2 IgG1(H32)	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[301]
ADC Info	IgG1 (GH2-20)-vc-MMAE	Anti-HER2 IgG1(GH2-20)	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[301]
ADC Info	IgG1 (GH2-61)-vc-MMAE	Anti-HER2 IgG1(GH2-61)	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[301]
ADC Info	IgG1 (GH2-75)-vc-MMAE	Anti-HER2 IgG1(GH2-75)	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[301]
ADC Info	ch735-Py-DM1	Chimeric human mAb ch735	Undisclosed	Mertansine DM1	TCO-PEG3-Mal	[302]
ADC Info	T-Py-DM1	Trastuzumab	Undisclosed	Mertansine DM1	TCO-PEG3-Mal	[302]
ADC Info	IgG1 (trastuzumab)-AL1-MMAE	Trastuzumab-AL1	ERBB2	Monomethyl auristatin E	Undisclosed	[301]
ADC Info	IgG1 (H32)-AL1-MMAE	Anti-HER2 IgG1(H32)-AL1	ERBB2	Monomethyl auristatin E	Undisclosed	[301]
ADC Info	IgG1 (GH2-20)-AL1-MMAE	Anti-HER2 IgG1(GH2-20)-AL1	ERBB2	Monomethyl auristatin E	Undisclosed	[301]
ADC Info	IgG1 (GH2-61)-AL1-MMAE	Anti-HER2 IgG1(GH2-61)-AL1	ERBB2	Monomethyl auristatin E	Undisclosed	[301]
ADC Info	IgG1 (GH2-75)-AL1-MMAE	Anti-HER2 IgG1(GH2-75)-AL1	ERBB2	Monomethyl auristatin E	Undisclosed	[301]
ADC Info	SNS-622-DM1	SNS-622	ASPH	Mertansine DM1	Maleimido-caproyl	[303]
ADC Info	SNS-622-MMAE	SNS-622	ASPH	Monomethyl auristatin E	Mc-Val-Cit-PABC	[303]
ADC Info	DAB4-DM1	DAB4	SSB	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[304]
ADC Info	DAB4-DM4	DAB4	SSB	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[304]
ADC Info	Sal5-DM4	Sal5	EGFR; ERBB3	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[304]
ADC Info	DAB4-MMAE	DAB4	SSB	Monomethyl auristatin E	Mc-Val-Cit-PABC	[304]
ADC Info	Sal5-MMAE	Sal5	EGFR; ERBB3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[304]
ADC Info	DAB4-MMAF	DAB4	SSB	Monomethyl auristatin F	Mc-Val-Cit-PABC	[304]
ADC Info	⁸⁹Zr-DFO-T-DM1	Zr-labeled trastuzumab	ERBB2	Mertansine DM1	Undisclosed	[305]
ADC Info	Zt/g4-MMAE	Anti-RON Zt/g4 (IgG1 kappa)	MST1R	Monomethyl auristatin E	Mc-Val-Cit-PABC	[306]
ADC Info	Promiximab-MMAE	Promiximab	NCAM1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[307]
ADC Info	EGFRvIII-16	Anti-EGFRvIII mAb	EGFRvIII	DM1 derivative 16	Mc-Val-Cit-PABC	[308]
ADC Info	EGFRvIII-MCC-DM1	Anti-EGFRvIII mAb	EGFRvIII	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[308]
ADC Info	PSMA-15	Anti-PSMA mAb	FOLH1	DM1 derivative 15	Mc-Val-Cit-PABC	[308]
ADC Info	PSMA-16	Anti-PSMA mAb	FOLH1	DM1 derivative 16	Mc-Val-Cit-PABC	[308]
ADC Info	PRLR-16	Anti-PRLR mAb	PRLR	DM1 derivative 16	Mc-Val-Cit-PABC	[308]
ADC Info	Trastuzumab/nab-paclitaxel	Trastuzumab	ERBB2	Paclitaxel	Undisclosed	[309]
ADC Info	GPC-1 ADC 1	Anti-GPC1 mAb 01a033	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 2	Anti-GPC1 mAb 01a002	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 3	Anti-GPC1 mAb 02a035	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 4	Anti-GPC1 mAb 02a034	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 5	Anti-GPC1 mAb 02a014	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 6	Anti-GPC1 mAb 02a002	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 7	Anti-GPC1 mAb 02a010	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 8	Anti-GPC1 mAb 01a016	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 9	Anti-GPC1 mAb 02b006	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 10	Anti-GPC1 mAb 01a021	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 11	Anti-GPC1 mAb 02a022	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 12	Anti-GPC1 mAb 01a009	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 13	Anti-GPC1 mAb 01a030	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 14	Anti-GPC1 mAb 01a017	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 15	Anti-GPC1 mAb 01a007	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 16	Anti-GPC1 mAb 01a042	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 17	Anti-GPC1 mAb 01a026	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	GPC-1 ADC 18	Anti-GPC1 mAb 02a006	GPC1	Monomethyl auristatin F	Mc-Val-Cit-PABC	[310]
ADC Info	Docetaxel-trastuzumab	Trastuzumab	ERBB2	Docetaxel	Undisclosed	[311]
ADC Info	M9346A-CX-DM1	Mirvetuximab	FOLR1	Mertansine DM1	triglycyl peptide linker CX	[312]
ADC Info	M9346A-4a-Cxxx-Mal-CX-DM1	Mirvetuximab (engineered cysteine LC-C205)	FOLR1	Mertansine DM1	Cxxx-Mal-CX	[312]
ADC Info	M9346A-4b-Cxxx-Mal-CX-DM1	Mirvetuximab (engineered cysteine LC-C400)	FOLR1	Mertansine DM1	Cxxx-Mal-CX	[312]
ADC Info	M9346A-4c-Cxxx-Mal-CX-DM1	Mirvetuximab (engineered cysteine HC-C118)	FOLR1	Mertansine DM1	Cxxx-Mal-CX	[312]
ADC Info	M9346A-4d-Cxxx-Mal-CX-DM1	Mirvetuximab (engineered cysteine HC-C239)	FOLR1	Mertansine DM1	Cxxx-Mal-CX	[312]
ADC Info	hBU12-mc-MMAF	Anti-CD19 mAb hBU12	CD19	Monomethyl auristatin F	Mc-Val-Cit-PABC	[313]
ADC Info	CC2B-h15H3-gluc-MMAE	Anti-ITGA5 mAb CC2B-h15H3	ITGA5	Monomethyl auristatin E	Quaternary ammonium linker Gluc	[313]
ADC Info	h15H3-gluc-MMAE	Anti-ITGA5 mAb h15H3	ITGA5	Monomethyl auristatin E	Quaternary ammonium linker Gluc	[313]
ADC Info	HcHAb18-DM1	HcHAb18	BSG	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[314]
ADC Info	CNTO95-SSNPB-DM4	CNTO95	ITGAV	Mertansine DM4	N-sulfosuccinimidyl-4-(5-nitro-2 pyridyldithio) butyrate (SSNPB)	[251]
ADC Info	F105-SSNPB-DM4	F105	ITGAV	Mertansine DM4	N-sulfosuccinimidyl-4-(5-nitro-2 pyridyldithio) butyrate (SSNPB)	[251]
ADC Info	CNTO95-SSNPP-DM4	CNTO95	ITGAV	Mertansine DM4	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[251]
ADC Info	F105-SSNPP-DM4	F105	ITGAV	Mertansine DM4	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[251]
ADC Info	CNTO95-SPP-DM4	CNTO95	ITGAV	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[251]
ADC Info	F105-SPP-DM4	F105	ITGAV	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[251]
ADC Info	huMov19-3-sulfo-Mal-DM4 (DAR 3.7)	huMov19	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	FR1-21-3-sulfo-Mal-DM4	FR1-21	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	Mov19-3-sulfo-Mal-DM4	Mov19	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	Farletuzumab-3-sulfo-Mal-DM4	Farletuzumab	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	FR1-48-3-sulfo-Mal-DM4	FR1-48	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	FR1-49-3-sulfo-Mal-DM4	FR1-49	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	FR1-57-3-sulfo-Mal-DM4	FR1-57	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	FR1-65-3-sulfo-Mal-DM4	FR1-65	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	huMOV19v1.6-3-sulfo-Mal-DM4	huMOV19v1.6	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	huMOV19v1.0-3-sulfo-Mal-DM4	huMOV19v1.0	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	huFR1-21-3-sulfo-Mal-DM4	huFR1-21	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	muFR1-21-3-sulfo-Mal-DM4	mu-FR1-21	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	muFR1-9-3-sulfo-Mal-DM4	mu-FR1-9	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	muFR1-13-3-sulfo-Mal-DM4	mu-FR1-13	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	muFR1-22-3-sulfo-Mal-DM4	mu-FR1-22	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	muFR1-23-3-sulfo-Mal-DM4	mu-FR1-23	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	huFR1-23-3-sulfo-Mal-DM4	huFR1-23	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	huMov19-PEG4-Mal-DM4	huMov19	FOLR1	Mertansine DM4	PEG4-Mal	[253]
ADC Info	huMov19-3-sulfo-Mal-DM4 (DAR 8.23)	huMov19	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	M9346A-sulfo-Mal-DM4	Mirvetuximab	FOLR1	Mertansine DM4	3-sulfo-Mal	[253]
ADC Info	1C1-mcMMAF	Anti-EPHA2 mAb 1C1	EPHA2	Monomethyl auristatin F	Maleimido-caproyl	[315]
ADC Info	WO2021044208A1 ADC A2F3-5	Anti-ROR1 mAb A2F3	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC A2F3-5 linker	[260]
ADC Info	WO2021044208A1 ADC DG6-4	Anti-ROR1 mAb DG6	ROR1	Monomethyl auristatin E	WO2021044208A1_ADC DG6-4 linker	[260]
ADC Info	WO2007011968A2 cAC10-9a	Brentuximab	TNFRSF8	Monomethyl auristatin E	WO2007011968A2_cAC10-9a linker	[316]
ADC Info	WO2007011968A2 c1F6-9a	Anti-CD70 mAb c1F6	CD70	Monomethyl auristatin E	WO2007011968A2_c1F6-9a linker	[316]
ADC Info	WO2007011968A2 cAC10-9b	Brentuximab	TNFRSF8	Monomethyl auristatin F	WO2007011968A2_cAC10-9b linker	[316]
ADC Info	WO2007011968A2 c1F6-9b	Anti-CD70 mAb c1F6	CD70	Monomethyl auristatin F	WO2007011968A2_c1F6-9b linker	[316]
ADC Info	WO2015095755A1 h1F6-1.3	Anti-CD70 mAb h1F6	CD70	Monomethyl auristatin E	WO2015095755A1_h1F6-1.3 linker	[317]
ADC Info	WO2015095755A1 cAC10-1.3	Brentuximab	TNFRSF8	Monomethyl auristatin E	WO2015095755A1_cAC10-1.3 linker	[317]
ADC Info	WO2015095755A1 h1F6-2.0	Anti-CD70 mAb h1F6	CD70	Monomethyl auristatin E	WO2015095755A1_h1F6-2.0 linker	[317]
ADC Info	WO2015095755A1 cAC10-2.0	Brentuximab	TNFRSF8	Monomethyl auristatin E	WO2015095755A1_cAC10-2.0 linker	[317]
ADC Info	AAJ8D6-Mc-Val-Cit-MMAE	AAJ8D6	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[318]
ADC Info	AAJ8D6-D07-Val-Cit-PAB-MMAE	AAJ8D6	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[318]
ADC Info	AAJ8D6-PY-Val-Cit-MMAE	AAJ8D6	MET	Monomethyl auristatin E	PY-VC-PABC	[318]
ADC Info	ABT-700-Mc-Val-Cit-MMAE	Telisotuzumab	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[318]
ADC Info	lgG1-Mc-Val-Cit-MMAE	Anti-MET lgG1	MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[318]
ADC Info	h1F6-mcMMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Maleimido-caproyl	[319]
ADC Info	h1F6-MC-vc-PABC-MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Mc-Val-Cit-PABC	[319]
ADC Info	h1F6-MC-vc-PABC-MMAF DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Mc-Val-Cit-PABC	[319]
ADC Info	h1F6-1 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Dpr-MA	[319]
ADC Info	h1F6-1 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Dpr-MA	[319]
ADC Info	h1F6-2 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Glu-Dpr-MA	[319]
ADC Info	h1F6-2 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Glu-Dpr-MA	[319]
ADC Info	h1F6-3 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Dpr-MA	[319]
ADC Info	h1F6-3 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Dpr-MA	[319]
ADC Info	h1F6-4 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Dpr-MA	[319]
ADC Info	h1F6-4 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Dpr-MA	[319]
ADC Info	h1F6-5 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-5 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-6 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-6 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-7 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Lys-MDpr	[319]
ADC Info	h1F6-7 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-Lys-MDpr	[319]
ADC Info	h1F6-8 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thiazole-Glu-Lys-MDpr	[319]
ADC Info	h1F6-9 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Glu-EDA-MDpr	[319]
ADC Info	h1F6-10 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Glu-EDA-MDpr	[319]
ADC Info	h1F6-11 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Ile-EDA-MDpr	[319]
ADC Info	h1F6-12 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Ile-EDA-MDpr	[319]
ADC Info	h1F6-13 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Thiazole-Glu-EDA-MDpr	[319]
ADC Info	h1F6-14 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Asp-Ala-Lys-MDpr	[319]
ADC Info	h1F6-15 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Ala-Lys-MDpr	[319]
ADC Info	h1F6-16 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	PhosphoThr-Ala-Lys-MDpr	[319]
ADC Info	h1F6-17 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Asn-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-18 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-19 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Asp-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-20 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-21 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	hSer-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-22 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	ValoH-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-23 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	PhosphoThr-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-24 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Pyrazole-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-25 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Triazole-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-26 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Asn-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-27 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Asp-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-28 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Fur-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-29 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	ValOH-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-30 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Ser-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-31 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	hSer-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-32 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-IleLeu-Dpr-MDpr	[319]
ADC Info	h1F6-33 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Ile-Leu-Dpr-MDpr	[319]
ADC Info	h1F6-34 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Phe-Leu-Dpr-MDpr	[319]
ADC Info	h1F6-35 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-LeuPhe-Dpr-MDpr	[319]
ADC Info	h1F6-36 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Leu-Phe-Dpr-MDpr	[319]
ADC Info	h1F6-37 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Phe-Phe-Dpr-MDpr	[319]
ADC Info	h1F6-38 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-LysAla-Dpr-MDpr	[319]
ADC Info	h1F6-39 MMAE	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Lys-Dpr-MDpr	[319]
ADC Info	h1F6-1 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Dpr-MA	[319]
ADC Info	h1F6-2 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Glu-Dpr-MA	[319]
ADC Info	h1F6-3 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Dpr-MA	[319]
ADC Info	h1F6-4 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Glu-Dpr-MA	[319]
ADC Info	h1F6-5 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-6 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-7 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Glu-Lys-MDpr	[319]
ADC Info	h1F6-8 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thiazole-Glu-Lys-MDpr	[319]
ADC Info	h1F6-9 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Glu-EDA-MDpr	[319]
ADC Info	h1F6-10 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Glu-EDA-MDpr	[319]
ADC Info	h1F6-11 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Ile-EDA-MDpr	[319]
ADC Info	h1F6-12 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Ile-EDA-MDpr	[319]
ADC Info	h1F6-13 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thiazole-Glu-EDA-MDpr	[319]
ADC Info	h1F6-14 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Asp-Ala-Lys-MDpr	[319]
ADC Info	h1F6-15 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Glu-Ala-Lys-MDpr	[319]
ADC Info	h1F6-16 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	PhosphoThr-Ala-Lys-MDpr	[319]
ADC Info	h1F6-17 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Asn-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-18 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Glu-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-19 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Asp-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-20 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Glu-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-21 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	hSer-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-22 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	ValoH-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-23 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	PhosphoThr-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-24 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Pyrazole-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-25 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Triazole-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-26 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Asn-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-27 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Asp-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-28 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Fur-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-29 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	ValOH-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-30 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Ser-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-31 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	hSer-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-32 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-IleLeu-Dpr-MDpr	[319]
ADC Info	h1F6-33 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Ile-Leu-Dpr-MDpr	[319]
ADC Info	h1F6-34 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Glu-Phe-Leu-Dpr-MDpr	[319]
ADC Info	h1F6-35 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-LeuPhe-Dpr-MDpr	[319]
ADC Info	h1F6-36 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Phe-Leu-Phe-Dpr-MDpr	[319]
ADC Info	h1F6-37 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Glu-Phe-Phe-Dpr-MDpr	[319]
ADC Info	h1F6-38 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-LysAla-Dpr-MDpr	[319]
ADC Info	h1F6-39 MMAF	Vorsetuzumab	CD70	Monomethyl auristatin F	Thr-Lys-Dpr-MDpr	[319]
ADC Info	h1F6-MC-vc-PABC-MMAF DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Mc-Val-Cit-PABC	[319]
ADC Info	h1F6-13 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thiazole-Glu-EDA-MDpr	[319]
ADC Info	h1F6-12 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Thr-Ile-EDA-MDpr	[319]
ADC Info	h1F6-11 MMAE DAR8	Vorsetuzumab	CD70	Monomethyl auristatin E	Phe-Ile-EDA-MDpr	[319]
ADC Info	h1F6-17 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Asn-AlaGlu-Dpr-MDpr	[319]
ADC Info	h1F6-20 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Glu-Ala-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-24 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	Pyrazole-Glu-Dpr-MDpr	[319]
ADC Info	h1F6-29 MMAE DAR4	Vorsetuzumab	CD70	Monomethyl auristatin E	ValOH-Glu-Dpr-MDpr	[319]
ADC Info	hL49-ADC	Humanized Anti-CD228 SGN-CD228A mAb	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_27D_Ala-ADC	hL49_27D_Ala	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_27D_Gln-ADC	hL49_27D_Gln	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_27D_Tyr-ADC	hL49_27D_Tyr	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_34_Ala-ADC	hL49_34_Ala	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_34_Gln-ADC	hL49_34_Gln	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_34_Tyr-ADC	hL49_34_Tyr	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_3x_Ala-ADC	hL49_3x_Ala	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_3x_Gln-ADC	hL49_3x_Gln	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	hL49_3x_Tyr-ADC	hL49_3x_Tyr	MELTF	Monomethyl auristatin E	mp-dLAE-PABC	[320]
ADC Info	M69-MMAE	Anti-Matriptase mAb M69	ST14	Monomethyl auristatin E	Mc-Val-Cit-PABC	[321]
ADC Info	Zapadcine-1	Zaptuzumab	TNFRSF10B	Monomethyl auristatin D	PY-VC-PABC	[322]
ADC Info	Wild type nBT062-DM4	Indatuximab	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[323]
ADC Info	Half nBT062-DM4	Indatuximab (C226S + C229S)	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[323]
ADC Info	Stable nBT062-DM4	Indatuximab (S228P + R409K)	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[323]
ADC Info	Bispecific nBT062-natalizumab-DM4	Bispecific nBT062-natalizumab	SDC1; ITGA4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[323]
ADC Info	scFvF7-Fc-vcMMAE	Anti-FGFR2 scFv ECD_FGFR2	FGFR2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[324]
ADC Info	Alpha-CD30-7	Anti-CD30 mAb	TNFRSF8	Tubulysin 7	Glucuronide quaternary ammonium linker 7	[325]
ADC Info	Alpha-CD30-8	Anti-CD30 mAb	TNFRSF8	Tubulysin 8	Glucuronide quaternary ammonium linker 8	[325]
ADC Info	Alpha-CD30-9	Anti-CD30 mAb	TNFRSF8	Tubulysin 9	Glucuronide quaternary ammonium linker 9	[325]
ADC Info	VCit ADC 3a	Anti-HER2 mAb glutamine 295 (Q295)	ERBB2	Monomethyl auristatin F	DBCO-PEG-VCit-PABC	[326]
ADC Info	EVCit ADC 3c	Anti-HER2 mAb glutamine 295 (Q295)	ERBB2	Monomethyl auristatin F	DBCO-PEG-EVCit-PABC	[326]
ADC Info	EGFR-MMAU ADC	Cetuximab	EGFR	Glucuronyl-monomethyl-auristatin E (MMAU)	Mc-Val-Cit-PABC	[327]
ADC Info	HER2-MMAU ADC	Trastuzumab	ERBB2	Glucuronyl-monomethyl-auristatin E (MMAU)	Mc-Val-Cit-PABC	[327]
ADC Info	GABRP Ab-DM1 ADC	GABRP-Ab	GABRP	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[328]
ADC Info	Anti-alpha10-SAP	Anti-integrin alpha10 mAb	ITGA10	Saporin	Undisclosed	[329]
ADC Info	ADC Mil40-6	Mil40	ERBB2	Monomethyl auristatin E	Silyl ether-based linker	[330]
ADC Info	Anti-CXCR4 ADC 513	Anti-CXCR4 mAb m17	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 518	Anti-CXCR4 mAb m17	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 510	Anti-CXCR4 mAb m17	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 519	Anti-CXCR4 mAb m17	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 381	Anti-CXCR4 mAb m17	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 553	Anti-CXCR4 mAb h17-NA	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 554	Anti-CXCR4 mAb h17-NS	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 555	Anti-CXCR4 mAb h17-NQ	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 556	Anti-CXCR4 mAb h17-NV.TS	CXCR4	Auristatin 0101	AcLys-Val-Cit-PABC	[331]
ADC Info	Anti-CXCR4 ADC 669	Anti-CXCR4 mAb h17-NQ	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 670	Anti-CXCR4 mAb h17-NV.TS	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 671	Anti-CXCR4 mAb h17-NA	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 672	Anti-CXCR4 mAb h17-NS	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 711	Anti-CXCR4 mAb h17-NA	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 712	Anti-CXCR4 mAb h17-NA	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 713	Anti-CXCR4 mAb h17-NV.TS	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Anti-CXCR4 ADC 714	Anti-CXCR4 mAb h17-NV.TS	CXCR4	Aur0131	AmPEG6C2	[331]
ADC Info	Cetux Cys-vc-MMAE	Cetuximab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	Cetux Fab-vc-MMAE	Cetuximab Fab (conjugate to glycan residues)	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	Cetux Fc/Fab-vc-MMAE	Cetuximab (Fc/Fab labeled with Neu5NAz)	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[276]
ADC Info	ScFvGPIIb/IIIa-MMAE	Anti-ITGA2B scFv	ITGB3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[332]
ADC Info	MMAE-9F7-F11 ADC	Anti-HER3 mAb 9F7-F11	ERBB3	Monomethyl auristatin E	Mc-Val-Cit-PABC	[333]
ADC Info	RBGO1-mcF	Anti-RAGE mAb RBGO1	AGER	Monomethyl auristatin F	Maleimido-caproyl	[334]
ADC Info	TTZ-1-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	DSPh-Val-Ala-PABC	[335]
ADC Info	TTZ-2-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	DSPh-Val-Cit-PABC	[335]
ADC Info	TTZ-3-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	DSPh-PEG12-Val-Ala-PABC	[335]
ADC Info	TTZ-4-MMAE	Trastuzumab	ERBB2	Monomethyl auristatin E	DSPh-PEG12-Val-Cit-PABC	[335]
ADC Info	Trastuzumab-DVP-linker-MMAE 1	Trastuzumab	ERBB2	Monomethyl auristatin E	DVP-based linker 1f	[336]
ADC Info	Trastuzumab-Val-Cit linker-MMAE 2	Trastuzumab	ERBB2	Monomethyl auristatin E	Val-Cit linker 2e	[336]
ADC Info	Trastuzumab-DVP-linker-MMAE 3	Trastuzumab	ERBB2	Monomethyl auristatin E	DVP-based linker 3	[336]
ADC Info	Trastuzumab-DVP-linker-MMAE 4	Trastuzumab	ERBB2	Monomethyl auristatin E	DVP-based linker 4	[336]
ADC Info	B10v5 225-M-vc-MMAE	B10v5 225-M	EGFR; MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[337]
ADC Info	B10v5 225-H-vc-MMAE	B10v5 225-H	EGFR; MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[337]
ADC Info	B10 225-M-vc-MMAE	B10 225-M	EGFR; MET	Monomethyl auristatin E	Mc-Val-Cit-PABC	[337]
ADC Info	Cetuximab-vc-MMAE	Cetuximab	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[337]
ADC Info	Mil40-15	Mil40	ERBB2	Monomethyl auristatin E	Mc-PABC	[294]
ADC Info	M25ADCMMAF	Anti-ALPPL2 mAb M25	ALPG	Monomethyl auristatin F	Mc-Val-Cit-PABC	[338]
ADC Info	M25ADCMMAE	Anti-ALPPL2 mAb M25	ALPG	Monomethyl auristatin E	Mc-Val-Cit-PABC	[338]
ADC Info	FOLR1-Mal-PEG2-Val-Cit-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG2-Val-Cit-PABC	[339]
ADC Info	FOLR1-Mal-PEG8-Val-Cit-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG8-Val-Cit-PABC	[339]
ADC Info	FOLR1-Mal-Caproyl-Val-Cit-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	FOLR1-Mal-PEG2-Ala-Ala-Asn-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG2-Ala-Ala-Asn-PABC	[339]
ADC Info	FOLR1-Mal-PEG4-tria-PEG3-Dis-dim-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG4-triazole-PEG3-Disulfidyl-dimethyl-PABC	[339]
ADC Info	FOLR1-Mal-PEG4-tria-PEG3-Sulfo-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG4-triazole-PEG3-Sulfonamide	[339]
ADC Info	FOLR1-Mal-PEG2-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG2	[339]
ADC Info	FOLR1-Mal-PEG4-Eribulin	Farletuzumab	FOLR1	Eribulin	Mal-PEG4	[339]
ADC Info	FOLR1-Suc/SPAAC-PEG4-Val-Cit-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Succinamide-SPAAC-PEG4-Val-Cit-PABC	[339]
ADC Info	FOLR1-Suc/SPAAC-PEG3-Dis-dim-PABC-Eribulin	Farletuzumab	FOLR1	Eribulin	Succinamide-SPAAC-PEG3-Disylfidyl-dimethyl-PABC	[339]
ADC Info	FOLR1-Suc/SPAAC-PEG3-Sulfonamide-Eribulin	Farletuzumab	FOLR1	Eribulin	Succinamide-SPAAC-PEG3-Sulfonamide	[339]
ADC Info	FOLR1-Suc/SPAAC-PEG2-Eribulin	Farletuzumab	FOLR1	Eribulin	Succinamide-SPAAC-PEG2	[339]
ADC Info	FOLR1-Suc/SPAAC-PEG4-Eribulin	Farletuzumab	FOLR1	Eribulin	Succinamide-SPAAC-PEG4	[339]
ADC Info	FOLR1-Mal-PEG-Val-Cit-PABC-Cryptophycin	Farletuzumab	FOLR1	Cryptophycin	Mal-PEG-Val-Cit-PABC	[339]
ADC Info	FOLR1-Mal-Caproyl-Val-Cit-PABC-MMAE	Farletuzumab	FOLR1	Monomethyl auristatin E	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	FOLR1-Mal-Caproyl-Val-Cit-PABC-MMAF	Farletuzumab	FOLR1	Monomethyl auristatin F	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-PEG2-Val-Cit-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG2-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-PEG8-Val-Cit-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG8-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-Caproyl-Val-Cit-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-PEG2-Ala-Ala-Asn-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG2-Ala-Ala-Asn-PABC	[339]
ADC Info	MSLN-Mal-PEG4-tria-PEG3-Dis-dim-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG4-triazole-PEG3-Disulfidyl-dimethyl-PABC	[339]
ADC Info	MSLN-Mal-PEG4-tria-PEG3-Sulfo-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG4-triazole-PEG3-Sulfonamide	[339]
ADC Info	MSLN-Mal-PEG2-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG2	[339]
ADC Info	MSLN-Mal-PEG4-Eribulin	Amatuximab	MSLN	Eribulin	Mal-PEG4	[339]
ADC Info	MSLN-Suc/SPAAC-PEG4-Val-Cit-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Succinamide-SPAAC-PEG4-Val-Cit-PABC	[339]
ADC Info	MSLN-Suc/SPAAC-PEG3-Dis-dim-PABC-Eribulin	Amatuximab	MSLN	Eribulin	Succinamide-SPAAC-PEG3-Disylfidyl-dimethyl-PABC	[339]
ADC Info	MSLN-Suc/SPAAC-PEG3-Sulfonamide-Eribulin	Amatuximab	MSLN	Eribulin	Succinamide-SPAAC-PEG3-Sulfonamide	[339]
ADC Info	MSLN-Suc/SPAAC-PEG2-Eribulin	Amatuximab	MSLN	Eribulin	Succinamide-SPAAC-PEG2	[339]
ADC Info	MSLN-Suc/SPAAC-PEG4-Eribulin	Amatuximab	MSLN	Eribulin	Succinamide-SPAAC-PEG4	[339]
ADC Info	MSLN-Mal-PEG-Val-Cit-PABC-Cryptophycin	Amatuximab	MSLN	Cryptophycin	Mal-PEG-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-Caproyl-Val-Cit-PABC-MMAE	Amatuximab	MSLN	Monomethyl auristatin E	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	MSLN-Mal-Caproyl-Val-Cit-PABC-MMAF	Amatuximab	MSLN	Monomethyl auristatin F	Maleimide-Caproyl-Val-Cit-PABC	[339]
ADC Info	Farletuzumab-sulfo SPDB-DM4	Farletuzumab	FOLR1	Mertansine DM4	Sulfo-SPDB	[339]
ADC Info	Crown Ether ADC 4a	Brentuximab	TNFRSF8	Monomethyl auristatin E	6-Amino-alpha-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 4b	Brentuximab	TNFRSF8	Monomethyl auristatin E	6-Amino-beta-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 4c	Brentuximab	TNFRSF8	Monomethyl auristatin E	6-Amino-gama-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 4d	Brentuximab	TNFRSF8	Monomethyl auristatin E	3-Amino-alpha-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 4e	Brentuximab	TNFRSF8	Monomethyl auristatin E	3-Amino-beta-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 4f	Brentuximab	TNFRSF8	Monomethyl auristatin E	3-Amino-gama-cyclodextrin-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 5a	Brentuximab	TNFRSF8	Monomethyl auristatin E	1-Aza-24-crown-8-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 5b	Brentuximab	TNFRSF8	Monomethyl auristatin E	1-Aza-42-crown-14-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 6a	Brentuximab	TNFRSF8	Monomethyl auristatin E	PEG(8u)-Val-Cit-PABC	[340]
ADC Info	Crown Ether ADC 6b	Brentuximab	TNFRSF8	Monomethyl auristatin E	PEG(24u)-Val-Cit-PABC	[340]
ADC Info	Ch14.18-MMAE	Anti-GD2 mAb ch14.18	Undisclosed	Monomethyl auristatin E	Mc-Val-Cit-PABC	[341]
ADC Info	Ch14.18-MMAF	Anti-GD2 mAb ch14.18	Undisclosed	Monomethyl auristatin F	Mc-Val-Cit-PABC	[341]
ADC Info	HER2-acetal-ADC 11	Trastuzumab	ERBB2	Monomethyl auristatin F	Clravable-acetal based linker 11	[342]
ADC Info	HER2-acetal-ADC 12	Trastuzumab	ERBB2	Monomethyl auristatin F	Clravable-TAMRA-acetal based linker 12	[342]
ADC Info	HER2-azide-alkyne MMAE conjugate	Trastuzumab	ERBB2	Monomethyl auristatin E	Azide-alkyne based linker 10a	[343]
ADC Info	HER2-cyclopropene-tetrazine MMAE conjugate	Trastuzumab	ERBB2	Monomethyl auristatin E	Cyclopropene-tetrazine based linker 10b	[343]
ADC Info	HER2-norbornene-tetrazine MMAE conjugate	Trastuzumab	ERBB2	Monomethyl auristatin E	Norbornene-tetrazine based linker 10c	[343]
ADC Info	5E3-Saporin ADC	Anti-SEMA4A mAb 5E3	SEMA4A	Saporin	Undisclosed	[344]
ADC Info	5E3-vedotin	Anti-SEMA4A mAb 5E3	SEMA4A	Monomethyl auristatin E	Mc-Val-Cit-PABC	[344]
ADC Info	5E3-emtansine	Anti-SEMA4A mAb 5E3	SEMA4A	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[344]
ADC Info	Trastuzumab biosimilar mil40 12a	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based Val-Ala-PABC linker 12a	[345]
ADC Info	Trastuzumab biosimilar mil40 12b	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based Val-Ala-PABC linker 12b	[345]
ADC Info	Trastuzumab biosimilar mil40 12c	Mil40	ERBB2	Monomethyl auristatin E	Maleamic methyl ester-based Val-Cit-PABC linker 12c	[345]
ADC Info	T-FcBP-DM1	Trastuzumab	ERBB2	Mertansine DM1	N-terminal norbornene group pFcBP linker	[346]
ADC Info	T-D8-1508	Trastuzumab	ERBB2	AZ-1508	Cysteine D8	[347]
ADC Info	T-D6-1508	Trastuzumab	ERBB2	AZ-1508	Cysteine D6	[347]
ADC Info	T-D4-1508	Trastuzumab	ERBB2	AZ-1508	Cysteine D4	[347]
ADC Info	T-D2-1508	Trastuzumab	ERBB2	AZ-1508	Cysteine D2	[347]
ADC Info	N-D8-1508	NIP228	EGFR; ERBB3	AZ-1508	Cysteine D8	[347]
ADC Info	N-D6-1508	NIP228	EGFR; ERBB3	AZ-1508	Cysteine D6	[347]
ADC Info	N-D4-1508	NIP228	EGFR; ERBB3	AZ-1508	Cysteine D4	[347]
ADC Info	N-D2-1508	NIP228	EGFR; ERBB3	AZ-1508	Cysteine D2	[347]
ADC Info	THL4-mpeoDM1	Anti-DLL4 mAb THL4 (V207C, A121C)	DLL4	Mertansine DM1	BIMPRO	[348]
ADC Info	TH2-mpeoDM1	Anti-DLL4 mAb TH2 (A121C)	DLL4	Mertansine DM1	BIMPRO	[348]
ADC Info	TL2-mpeoDM1	Anti-DLL4 mAb TL2 (V207C)	DLL4	Mertansine DM1	BIMPRO	[348]
ADC Info	THL4-vcMMAE	Anti-DLL4 mAb THL4 (V207C, A121C)	DLL4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[348]
ADC Info	H3L2-mpeoDM1	Anti-DLL4 mAb H3L2	DLL4	Mertansine DM1	BIMPRO	[348]
ADC Info	CTX-MMAE	Cetuximab	EGFR	Monomethyl auristatin E	PD-Val-Cit-PABC	[349]
ADC Info	H32-DM1_3.0	Anti-HER2 mAb H32	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[350]
ADC Info	H32-DM1_3.3	Anti-HER2 mAb H32	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[350]
ADC Info	H32-DM1_3.7	Anti-HER2 mAb H32	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[350]
ADC Info	H32-DM1_3.8	Anti-HER2 mAb H32	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[350]
ADC Info	H32-VCMMAE_2.1	Anti-HER2 mAb H32	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[350]
ADC Info	H32-VCMMAE_3.2	Anti-HER2 mAb H32	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[350]
ADC Info	H32-VCMMAE_3.8	Anti-HER2 mAb H32	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[350]
ADC Info	H32-VCMMAE_6.6	Anti-HER2 mAb H32	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[350]
ADC Info	HER2 ADC-18	Trastuzumab	ERBB2	Monomethyl auristatin E	Vinylsulfonamide based linker 15	[351]
ADC Info	HER2 ADC-19	Trastuzumab	ERBB2	Monomethyl auristatin E	Vinylsulfonamide based linker 16	[351]
ADC Info	HER2 ADC-20	Trastuzumab	ERBB2	Monomethyl auristatin E	Vinylsulfonamide based linker 17	[351]
ADC Info	EGFR ADC-21	Cetuximab	EGFR	Monomethyl auristatin E	Vinylsulfonamide based linker 15	[351]
ADC Info	EGFR ADC-22	Cetuximab	EGFR	Monomethyl auristatin E	Vinylsulfonamide based linker 16	[351]
ADC Info	EGFR ADC-23	Cetuximab	EGFR	Monomethyl auristatin E	Vinylsulfonamide based linker 17	[351]
ADC Info	T-DM1-IR700	Trastuzumab	ERBB2	Mertansine DM1 plus IRDye700DX	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[352]
ADC Info	Trastuzumab I253Q-MMAE	Trastuzumab I253Q	ERBB2	Monomethyl auristatin E	Dansylcadaverine-BCN based linker	[353]
ADC Info	Trastuzumab deglycosylated WT-MMAE	Trastuzumab I253Q	ERBB2	Monomethyl auristatin E	Dansylcadaverine deglycosylated-BCN based linker	[353]
ADC Info	HER2-gsADC-1	CHO-S2G2F-Tras (Ab1)	ERBB2	Monomethyl auristatin E	ThioPz linker 6a	[354]
ADC Info	HER2-gsADC-2	CHO-S2G2F-Tras (Ab1)	ERBB2	Monomethyl auristatin E	2-Aminobenzamide oxime	[354]
ADC Info	HER2-gsADC-3	CHO-S2G2F-Tras (Ab1)	ERBB2	Monomethyl auristatin E	Hydroxylamine derivative 6c	[354]
ADC Info	HER2-gsADC-4	CHO-S2G2F-Tras (Ab1)	ERBB2	Monomethyl auristatin E	PEGylation linker 6n	[354]
ADC Info	HER2-gsADC-5	Azido-tagged trastuzumab (Ab2)	ERBB2	Monomethyl auristatin E	Azadibenzocylooctyne-amine derivative 6d	[354]
ADC Info	HER2-gsADC-6	Azido-tagged trastuzumab (Ab2)	ERBB2	Monomethyl auristatin E	Bicyclononyne derivative 6e	[354]
ADC Info	HER2-gsADC-7	Azido-tagged trastuzumab (Ab2)	ERBB2	Monomethyl auristatin E	PEGylation linker 6m	[354]
ADC Info	HER2-gsADC-8	Azido-tagged trastuzumab (Ab2)	ERBB2	Monomethyl auristatin E	Glycosyl PEGylation linker 6r	[354]
ADC Info	HER2-gsADC-9	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	Linear alkyne 6f	[354]
ADC Info	HER2-gsADC-10	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6g	[354]
ADC Info	HER2-gsADC-11	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6h	[354]
ADC Info	HER2-gsADC-12	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6i	[354]
ADC Info	HER2-gsADC-13	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6j	[354]
ADC Info	HER2-gsADC-14	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6k	[354]
ADC Info	HER2-gsADC-15	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6l	[354]
ADC Info	HER2-gsADC-16	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	PEGylation linker 6m	[354]
ADC Info	HER2-gsADC-17	Azido-tagged trastuzumab (Ab3)	ERBB2	Monomethyl auristatin E	Noncleavable linker 6t	[354]
ADC Info	HER2-gsADC-18	CHO-G2F-Tras (Ab4)	ERBB2	Monomethyl auristatin E	ThioPz linker 6a	[354]
ADC Info	HER2-gsADC-19	CHO-G2F-Tras (Ab4)	ERBB2	Monomethyl auristatin E	2-Aminobenzamide oxime	[354]
ADC Info	HER2-gsADC-20	CHO-G2F-Tras (Ab4)	ERBB2	Monomethyl auristatin E	Hydroxylamine derivative 6c	[354]
ADC Info	HER2-gsADC-21	CHO-G2F-Tras (Ab4)	ERBB2	Monomethyl auristatin E	PEGylation linker 6n	[354]
ADC Info	HER2-gsADC-22	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	Linear alkyne 6f	[354]
ADC Info	HER2-gsADC-23	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6g	[354]
ADC Info	HER2-gsADC-24	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6h	[354]
ADC Info	HER2-gsADC-25	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6i	[354]
ADC Info	HER2-gsADC-26	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6j	[354]
ADC Info	HER2-gsADC-27	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6k	[354]
ADC Info	HER2-gsADC-28	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6l	[354]
ADC Info	HER2-gsADC-29	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	PEGylation linker 6m	[354]
ADC Info	HER2-gsADC-30	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	Glycosyl PEGylation linker 6o	[354]
ADC Info	HER2-gsADC-31	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	Glycosyl PEGylation linker 6p	[354]
ADC Info	HER2-gsADC-32	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	Glycosyl PEGylation linker 6q	[354]
ADC Info	HER2-gsADC-33	Azido-tagged trastuzumab (Ab5)	ERBB2	Monomethyl auristatin E	Glycosyl PEGylation linker 6r	[354]
ADC Info	HER2-gsADC-34	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	Linear alkyne 6f	[354]
ADC Info	HER2-gsADC-35	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6g	[354]
ADC Info	HER2-gsADC-36	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6h	[354]
ADC Info	HER2-gsADC-37	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6i	[354]
ADC Info	HER2-gsADC-38	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6j	[354]
ADC Info	HER2-gsADC-39	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6k	[354]
ADC Info	HER2-gsADC-40	Azido-tagged trastuzumab (Ab6)	ERBB2	Monomethyl auristatin E	PEGylation linker 6l	[354]
ADC Info	HER2-gsADC-41	Az-LacNAc-Tras Ab7	ERBB2	Monomethyl auristatin E	Bicyclononyne derivative 6e	[354]
ADC Info	HER2-gsADC-42	Az-LacNAc-Tras Ab7	ERBB2	Monomethyl auristatin E	PEGylation linker 6l	[354]
ADC Info	HER2-gsADC-43	Az-LacNAc-Tras Ab7	ERBB2	Monomethyl auristatin E	PEGylation linker 6m	[354]
ADC Info	HER2-gsADC-44	Az-LacNAc-Tras Ab7	ERBB2	Monomethyl auristatin E	Noncleavable linker 6s	[354]
ADC Info	HER2-gsADC-45	Az-LacNAc-Tras Ab7	ERBB2	Monomethyl auristatin E	Noncleavable linker 6t	[354]
ADC Info	HER2-gsADC-46	Trastuzumab	ERBB2	Monomethyl auristatin E	ThioPz linker 6a	[354]
ADC Info	HER2-gsADC-47	Trastuzumab	ERBB2	Monomethyl auristatin E	Hydroxylamine derivative 6c	[354]
ADC Info	HER2-gsADC-48	Trastuzumab	ERBB2	Monomethyl auristatin E	2-Aminobenzamide oxime	[354]
ADC Info	HER2-gsADC-49	Trastuzumab	ERBB2	Monomethyl auristatin E	Azadibenzocylooctyne-amine derivative 6d	[354]
ADC Info	HER2-gsADC-50	Trastuzumab	ERBB2	Monomethyl auristatin E	2-Aminobenzamidoxime without core-fucosylation	[354]
ADC Info	T-DM1-2.6	Trastuzumab	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[354]
ADC Info	AXL02-MMAE	Anti-AXL mAb AXL02	AXL	Monomethyl auristatin E	Mc-Val-Cit-PABC	[355]
ADC Info	NOV0712-DM4	Anti-CDH6 mAb NOV0712	CDH6	Mertansine DM4	Sulfo-SPDB	[356]
ADC Info	H01L02-DM4	Anti-CDH6 mAb H01L02	CDH6	Mertansine DM4	Sulfo-SPDB	[356]
ADC Info	hu4DFabv7-BMPEO-DM1	hu4DFabv7	ERBB2	Maytansinoid DM1	hu4DFabv7-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (A121C)-BMPEO-DM1	hu4DFabv8 (A121C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (A121C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (V110C)-BMPEO-DM1	hu4DFabv8 (V110C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (V110C)-BMPEO-DM1 linker	[357]
ADC Info	Thio-Tr (A121C)-BMPEO-DM1	Thio-Tr (A121C)	ERBB2	Maytansinoid DM1	Thio-Tr (A121C)-BMPEO-DM1 linker	[357]
ADC Info	2H9-A121C-BMPEO-DM1	Anti-HER2 antibody 2H9-A121C	ERBB2	Maytansinoid DM1	2H9-A121C-BMPEO-DM1 linker	[357]
ADC Info	Thio-3A5 (A121C)-BMPEO-DM1	Thio-3A5 (A121C)	MUC16	Maytansinoid DM1	Thio-3A5 (A121C)-BMPEO-DM1 linker	[357]
ADC Info	Anti-MUC16 antibody 3A5-BMPEO-DM1	Anti-MUC16 antibody 3A5	MUC16	Maytansinoid DM1	Anti-MUC16 antibody 3A5-BMPEO-DM1 linker	[357]
ADC Info	Thio-Tmab-BMPEO-DM1	Thio-Tmab	ERBB2	Maytansinoid DM1	Thio-Tmab-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (V110C)-MC-MMAF	hu4DFabv8 (V110C)	ERBB2	Monomethyl auristatin F	Maleimido-caproyl	[357]
ADC Info	hu4DFabv8 (V110C)-MC-MMAE	hu4DFabv8 (V110C)	ERBB2	Monomethyl auristatin E	Maleimido-caproyl	[357]
ADC Info	hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAF	hu4DFabv8 (V110C)	ERBB2	Monomethyl auristatin F	Mc-Val-Cit-PABC	[357]
ADC Info	hu4DFabv8 (V110C)-MC-Val-Cit-PAB-MMAE	hu4DFabv8 (V110C)	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[357]
ADC Info	hu4DFabv8 (L-V15C)-BMPEO-DM1	hu4DFabv8 (L-V15C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (L-V15C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (L-A43C)-BMPEO-DM1	hu4DFabv8 (L-A43C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (L-A43C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (L-A144C)-BMPEO-DM1	hu4DFabv8 (L-A144C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (L-A144C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (L-S168C)-BMPEO-DM1	hu4DFabv8 (L-S168C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (L-S168C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-A40C)-BMPEO-DM1	hu4DFabv8 (H-A40C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-A40C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-A88C)-BMPEO-DM1	hu4DFabv8 (H-A88C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-A88C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-S119C)-BMPEO-DM1	hu4DFabv8 (H-S119C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-S119C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-S122C)-BMPEO-DM1	hu4DFabv8 (H-S122C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-S122C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-A175C)-BMPEO-DM1	hu4DFabv8 (H-A175C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-A175C)-BMPEO-DM1 linker	[357]
ADC Info	hu4DFabv8 (H-S179C)-BMPEO-DM1	hu4DFabv8 (H-S179C)	ERBB2	Maytansinoid DM1	hu4DFabv8 (H-S179C)-BMPEO-DM1 linker	[357]
ADC Info	WO2017089890A1 ADC1	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC1 linker	[358]
ADC Info	WO2017089890A1 ADC2	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC2 linker	[358]
ADC Info	WO2017089890A1 ADC3	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC3 linker	[358]
ADC Info	WO2017089890A1 ADC4	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC4 linker	[358]
ADC Info	WO2017089890A1 ADC5	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC5 linker	[358]
ADC Info	WO2017089890A1 ADC6	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC6 linker	[358]
ADC Info	WO2017089890A1 ADC7	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC7 linker	[358]
ADC Info	WO2017089890A1 ADC8	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC8 linker	[358]
ADC Info	WO2017089890A1 ADC9	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC9 linker	[358]
ADC Info	WO2017089890A1 ADC10	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC10 linker	[358]
ADC Info	WO2017089890A1 ADC11	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC11 linker	[358]
ADC Info	WO2017089890A1 ADC12	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC12 linker	[358]
ADC Info	WO2017089890A1 ADC13	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC13 linker	[358]
ADC Info	WO2017089890A1 ADC14	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC14 linker	[358]
ADC Info	WO2017089890A1 ADC15	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC15 linker	[358]
ADC Info	WO2017089890A1 ADC16	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC16 linker	[358]
ADC Info	WO2017089890A1 ADC17	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC17 linker	[358]
ADC Info	WO2017089890A1 ADC18	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC18 linker	[358]
ADC Info	WO2017089890A1 ADC19	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC19 linker	[358]
ADC Info	WO2017089890A1 ADC20	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC20 linker	[358]
ADC Info	WO2017089890A1 ADC86	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC86 linker	[358]
ADC Info	WO2017089890A1 ADC87	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC87 linker	[358]
ADC Info	WO2017089890A1 ADC23	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC23 linker	[358]
ADC Info	WO2017089890A1 ADC24	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC24 linker	[358]
ADC Info	WO2017089890A1 ADC25	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC25 linker	[358]
ADC Info	WO2017089890A1 ADC26	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC26 linker	[358]
ADC Info	WO2017089890A1 ADC27	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC27 linker	[358]
ADC Info	WO2017089890A1 ADC28	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC28 linker	[358]
ADC Info	WO2017089890A1 ADC29	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC29 linker	[358]
ADC Info	WO2017089890A1 ADC30	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC30 linker	[358]
ADC Info	WO2017089890A1 ADC31	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC31 linker	[358]
ADC Info	WO2017089890A1 ADC32	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC32 linker	[358]
ADC Info	WO2017089890A1 ADC33	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC33 linker	[358]
ADC Info	WO2017089890A1 ADC34	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC34 linker	[358]
ADC Info	WO2017089890A1 ADC35	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC35 linker	[358]
ADC Info	WO2017089890A1 ADC36	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC36 linker	[358]
ADC Info	WO2017089890A1 ADC37	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC37 linker	[358]
ADC Info	WO2017089890A1 ADC38	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC38 linker	[358]
ADC Info	WO2017089890A1 ADC39	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC39 linker	[358]
ADC Info	WO2017089890A1 ADC40	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC40 linker	[358]
ADC Info	WO2017089890A1 ADC41	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC41 linker	[358]
ADC Info	WO2017089890A1 ADC42	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC42 linker	[358]
ADC Info	WO2017089890A1 ADC43	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC43 linker	[358]
ADC Info	WO2017089890A1 ADC44	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC44 linker	[358]
ADC Info	WO2017089890A1 ADC45	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC45 linker	[358]
ADC Info	WO2017089890A1 ADC46	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC46 linker	[358]
ADC Info	WO2017089890A1 ADC47	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC47 linker	[358]
ADC Info	WO2017089890A1 ADC48	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC48 linker	[358]
ADC Info	WO2017089890A1 ADC49	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC49 linker	[358]
ADC Info	WO2017089890A1 ADC50	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC50 linker	[358]
ADC Info	WO2017089890A1 ADC51	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC51 linker	[358]
ADC Info	WO2017089890A1 ADC52	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC52 linker	[358]
ADC Info	WO2017089890A1 ADC53	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC53 linker	[358]
ADC Info	WO2017089890A1 ADC54	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC54 linker	[358]
ADC Info	WO2017089890A1 ADC55	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC55 linker	[358]
ADC Info	WO2017089890A1 ADC76	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC76 linker	[358]
ADC Info	WO2017089890A1 ADC88	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC88 linker	[358]
ADC Info	WO2017089890A1 ADC89	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC89 linker	[358]
ADC Info	WO2017089890A1 ADC90	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC90 linker	[358]
ADC Info	WO2017089890A1 ADC91	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC91 linker	[358]
ADC Info	WO2017089890A1 ADC60	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC60 linker	[358]
ADC Info	WO2017089890A1 ADC61	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC61 linker	[358]
ADC Info	WO2017089890A1 ADC62	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC62 linker	[358]
ADC Info	WO2017089890A1 ADC63	Trastuzumab	ERBB2	Monomethyl auristatin E	WO2017089890A1_ADC63 linker	[358]
ADC Info	WO2017089890A1 ADC77	Trastuzumab	ERBB2	Monomethyl auristatin F	WO2017089890A1_ADC77 linker	[358]
ADC Info	WO2017089890A1 ADC64	Cetuximab	EGFR	Monomethyl auristatin F	WO2017089890A1_ADC64 linker	[358]
ADC Info	WO2017089890A1 ADC65	Cetuximab	EGFR	Monomethyl auristatin E	WO2017089890A1_ADC65 linker	[358]
ADC Info	WO2017089890A1 ADC66	Cetuximab	EGFR	Monomethyl auristatin F	WO2017089890A1_ADC66 linker	[358]
ADC Info	WO2017089890A1 ADC67	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	WO2017089890A1_ADC67 linker	[358]
ADC Info	WO2017089890A1 ADC68	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin E	WO2017089890A1_ADC68 linker	[358]
ADC Info	WO2017089890A1 ADC69	Anti-CD19 mAb DI-B4	CD19	Monomethyl auristatin F	WO2017089890A1_ADC69 linker	[358]
ADC Info	WO2017089890A1 ADC70	Rituximab	MS4A1	Monomethyl auristatin F	WO2017089890A1_ADC70 linker	[358]
ADC Info	WO2017089890A1 ADC71	Rituximab	MS4A1	Monomethyl auristatin E	WO2017089890A1_ADC71 linker	[358]
ADC Info	WO2017089890A1 ADC72	Rituximab	MS4A1	Monomethyl auristatin F	WO2017089890A1_ADC72 linker	[358]
ADC Info	WO2017089890A1 ADC73	Depatuxizumab	EGFR	Monomethyl auristatin F	WO2017089890A1_ADC73 linker	[358]
ADC Info	WO2017089890A1 ADC74	Depatuxizumab	EGFR	Monomethyl auristatin E	WO2017089890A1_ADC74 linker	[358]
ADC Info	WO2017089890A1 ADC75	Depatuxizumab	EGFR	Monomethyl auristatin F	WO2017089890A1_ADC75 linker	[358]
ADC Info	Anti-BCMA 15B2GL-mcMMAF	Anti-BCMA antibody 15B2GL	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA 15B2WT-mcMMAF	Anti-BCMA antibody 15B2WT	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA I09-mcMMAF	Anti-BCMA antibody I09	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA L15-mcMMAF	Anti-BCMA antibody L15	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA M02-mcMMAF	Anti-BCMA antibody M02	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA N22-mcMMAF	Anti-BCMA antibody N22	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA P10-mcMMAF	Anti-BCMA antibody P10	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	Anti-BCMA J6M0-mcMMAF	Anti-BCMA antibody J6M0	TNFRSF17	Monomethyl auristatin F	Maleimido-caproyl	[359]
ADC Info	2C3 WT-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 WT	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 A114N-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 A114N	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 Y436S-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 Y436S	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 S440N-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 S440N	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 S442N-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 S442N	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 NGT-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 NGT	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	2C3 S298N Y300S-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 2C3 S298N Y300S	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	TEM1 Clone 187 WT-Mc-Val-Cit-PABC-MMAE	Anti-TEM1 mAb Clone 187 WT	CD248	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	TEM1 Clone 187 A114N-Mc-Val-Cit-PABC-MMAE	Anti-TEM1 mAb Clone 187 A114N	CD248	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	HER2 WT-Mc-Val-Cit-PABC-MMAE	Anti-HER2 mAb WT	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	A114N-Mc-Val-Cit-PABC-MMAE	Anti-HER2 mAb A114N	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	NNAS-Mc-Val-Cit-PABC-MMAE	Anti-HER2 mAb NNAS	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	A114N NNAS-Mc-Val-Cit-PABC-MMAE	Anti-HER2 mAb A114N NNAS	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	HER2 S298N/T299A/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-HER2 mAb S298N/T299A/Y300S	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	H66-Mc-Val-Cit-PABC-MMAE	Anti-TRAC mAb H66	TRAC	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	H66 S298N/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-TRAC mAb H66 S298N/Y300S	TRAC	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	H66 S298N/T299A/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-TRAC mAb H66 S298N/T299A/Y300S	TRAC	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	H66 N297Q/S298N/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-TRAC mAb H66 N297Q/S298N/Y300S	TRAC	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	12G6 WT-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 12G6 WT	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	12G6 S298N/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 12G6 S298N/Y300S	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	12G6 S298N/T299A/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 12G6 S298N/T299A/Y300S	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	12G6 N297Q/S298N/Y300S-Mc-Val-Cit-PABC-MMAE	Anti-CD52 mAb 12G6 N297Q/S298N/Y300S	CD52	Monomethyl auristatin E	Mc-Val-Cit-PABC	[360]
ADC Info	Anti-HER-AO-Cys-MC-VC-PABC-MMAE	Anti-HER2 mAb WT	ERBB2	Monomethyl auristatin E	Anti-HER-AO-Cys-MC-VC-PABC-MMAE linker	[360]
ADC Info	Anti-FAP B11-MC-VC-PABC-MMAE	Anti-FAP mAb B11	FAP	Monomethyl auristatin E	Anti-FAP B11-MC-VC-PABC-MMAE linker	[360]
ADC Info	Anti-FAP B11-AO-Cys-MC-VC-PABC-MMAE	Anti-FAP mAb B11	FAP	Monomethyl auristatin E	Anti-FAP B11-AO-Cys-MC-VC-PABC-MMAE linker	[360]
ADC Info	WO2015177360A1 ADC-wt-vcMMAE	Anti-PSMA mAb wt	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[361]
ADC Info	WO2015177360A1 ADC-HC41-vcMMAE	Anti-PSMA mAb wt HC S41C	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[361]
ADC Info	WO2015177360A1 ADC-LC40-vcMMAE	Anti-PSMA mAb wt LC P40C	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[361]
ADC Info	WO2015177360A1 ADC-LC41-vcMMAE	Anti-PSMA mAb wt LC G41C	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[361]
ADC Info	WO2015177360A1 ADC-H8-HC40-vcMMAE	Anti-5T4 mAb H8 S40C	TPBG	Monomethyl auristatin E	Mc-Val-Cit-PABC	[361]
ADC Info	WO2015177360A1 ADC-wt-mcMMAF	Anti-PSMA mAb wt	FOLH1	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	WO2015177360A1 ADC-HC41-mcMMAF	Anti-PSMA mAb wt HC S41C	FOLH1	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	WO2015177360A1 ADC-LC40-mcMMAF	Anti-PSMA mAb wt LC P40C	FOLH1	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	WO2015177360A1 ADC-LC41-mcMMAF	Anti-PSMA mAb wt LC G41C	FOLH1	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	WO2015177360A1 ADC-H8-wt-mcMMAF	Anti-5T4 mAb H8 wt	TPBG	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	WO2015177360A1 ADC-H8-HC40-mcMMAF	Anti-5T4 mAb H8 S40C	TPBG	Monomethyl auristatin F	Maleimido-caproyl	[361]
ADC Info	h3G10.A57-h3G10 vcMMAD	h3G10.A57-h3G10	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10 vc0101	h3G10.A57-h3G10	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.2.72 vcMMAD	h3G10.A57-h3G10.2.72	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.2.72 vc0101	h3G10.A57-h3G10.2.72	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.2.72 vcMMAD	h3G10.1.91-h3G10.2.72	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.2.72 vc0101	h3G10.1.91-h3G10.2.72	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.2.72 vcMMAD	h3G10.2.37-h3G10.2.72	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.2.72 vc0101	h3G10.2.37-h3G10.2.72	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.A58 vcMMAD	h3G10.A57-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.A58 vc0101	h3G10.A57-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.A58 vcMMAD	h3G10.1.91-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.A58 vc0101	h3G10.1.91-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.A58 vcMMAD	h3G10.2.37-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.A58 vc0101	h3G10.2.37-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.A58 vcMMAD	h3G10.A57-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.A57-h3G10.A58 vc0101	h3G10.A57-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.A58 vcMMAD	h3G10.1.91-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.1.91-h3G10.A58 vc0101	h3G10.1.91-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.A58 vcMMAD	h3G10.2.37-h3G10.A58	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	h3G10.2.37-h3G10.A58 vc0101	h3G10.2.37-h3G10.A58	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	3G10-TG6-vcMMAD	3G10-TG6	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	6B6-TG6-vcMMAD	6B6-TG6	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	12A11-TG6-vcMMAD	12A11-TG6	CXCR4	Monomethyl auristatin D	Mc-Val-Cit-PABC	[362]
ADC Info	3G10-TG6-vc0101	3G10-TG6	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	6B6-TG6-vc0101	6B6-TG6	CXCR4	Auristatin 0101	Mc-Val-Cit-PABC	[362]
ADC Info	Trastuzumab-Compound 9	Trastuzumab	ERBB2	Mertansine DM1	Trastuzumab-Compound 9 linker	[363]
ADC Info	Pertuzumab-Compound 9	Pertuzumab	ERBB2	Mertansine DM1	Pertuzumab-Compound 9 linker	[363]
ADC Info	Rituximab-Compound 9	Rituximab	MS4A1	Mertansine DM1	Rituximab-Compound 9 linker	[363]
ADC Info	Alemtuzumab-Compound 9	Alemtuzumab	CD52	Mertansine DM1	Alemtuzumab-Compound 9 linker	[363]
ADC Info	Bevacizumab-Compound 9	Bevacizumab	VEGFA	Mertansine DM1	Bevacizumab-Compound 9 linker	[363]
ADC Info	Adalimumab-Compound 9	Adalimumab	TNF	Mertansine DM1	Adalimumab-Compound 9 linker	[363]
ADC Info	Cetuximab-Compound 9	Cetuximab	EGFR	Mertansine DM1	Cetuximab-Compound 9 linker	[363]
ADC Info	Amatuximab-Compound 9	Amatuximab	MSLN	Mertansine DM1	Amatuximab-Compound 9 linker	[363]
ADC Info	Blinatumomab-Compound 9	Blinatumomab	CD19; CD3D	Mertansine DM1	Blinatumomab-Compound 9 linker	[363]
ADC Info	Brentuximab-Compound 9	Brentuximab	TNFRSF8	Mertansine DM1	Brentuximab-Compound 9 linker	[363]
ADC Info	Sacituzumab-Compound 9	Sacituzumab	TACSTD2	Mertansine DM1	Sacituzumab-Compound 9 linker	[363]
ADC Info	Panitumumab-Compound 9	Panitumumab	EGFR	Mertansine DM1	Panitumumab-Compound 9 linker	[363]
ADC Info	Nimotuzumab-Compound 9	Nimotuzumab	EGFR	Mertansine DM1	Nimotuzumab-Compound 9 linker	[363]
ADC Info	Gemtuzumab-Compound 9	Gemtuzumab	CD33	Mertansine DM1	Gemtuzumab-Compound 9 linker	[363]
ADC Info	Golimumab-Compound 9	Golimumab	TNF	Mertansine DM1	Golimumab-Compound 9 linker	[363]
ADC Info	Ibritumomab-Compound 9	Ibritumomab	MS4A1	Mertansine DM1	Ibritumomab-Compound 9 linker	[363]
ADC Info	Infliximab-Compound 9	Infliximab	TNF	Mertansine DM1	Infliximab-Compound 9 linker	[363]
ADC Info	Ipilimumab-Compound 9	Ipilimumab	CTLA4	Mertansine DM1	Ipilimumab-Compound 9 linker	[363]
ADC Info	Ofatumumab-Compound 9	Ofatumumab	MS4A1	Mertansine DM1	Ofatumumab-Compound 9 linker	[363]
ADC Info	Tositumomab-Compound 9	Tositumomab	MS4A1	Mertansine DM1	Tositumomab-Compound 9 linker	[363]
ADC Info	Trastuzumab-Compound 17	Trastuzumab	ERBB2	Mertansine DM4	Trastuzumab-Compound 17 linker	[363]
ADC Info	Pertuzumab-Compound 17	Pertuzumab	ERBB2	Mertansine DM4	Pertuzumab-Compound 17 linker	[363]
ADC Info	Rituximab-Compound 17	Rituximab	MS4A1	Mertansine DM4	Rituximab-Compound 17 linker	[363]
ADC Info	Alemtuzumab-Compound 17	Alemtuzumab	CD52	Mertansine DM4	Alemtuzumab-Compound 17 linker	[363]
ADC Info	Bevacizumab-Compound 17	Bevacizumab	VEGFA	Mertansine DM4	Bevacizumab-Compound 17 linker	[363]
ADC Info	Adalimumab-Compound 17	Adalimumab	TNF	Mertansine DM4	Adalimumab-Compound 17 linker	[363]
ADC Info	Cetuximab-Compound 17	Cetuximab	EGFR	Mertansine DM4	Cetuximab-Compound 17 linker	[363]
ADC Info	Amatuximab-Compound 17	Amatuximab	MSLN	Mertansine DM4	Amatuximab-Compound 17 linker	[363]
ADC Info	Blinatumomab-Compound 17	Blinatumomab	CD19; CD3D	Mertansine DM4	Blinatumomab-Compound 17 linker	[363]
ADC Info	Brentuximab-Compound 17	Brentuximab	TNFRSF8	Mertansine DM4	Brentuximab-Compound 17 linker	[363]
ADC Info	Sacituzumab-Compound 17	Sacituzumab	TACSTD2	Mertansine DM4	Sacituzumab-Compound 17 linker	[363]
ADC Info	Panitumumab-Compound 17	Panitumumab	EGFR	Mertansine DM4	Panitumumab-Compound 17 linker	[363]
ADC Info	Nimotuzumab-Compound 17	Nimotuzumab	EGFR	Mertansine DM4	Nimotuzumab-Compound 17 linker	[363]
ADC Info	Gemtuzumab-Compound 17	Gemtuzumab	CD33	Mertansine DM4	Gemtuzumab-Compound 17 linker	[363]
ADC Info	Golimumab-Compound 17	Golimumab	TNF	Mertansine DM4	Golimumab-Compound 17 linker	[363]
ADC Info	Ibritumomab-Compound 17	Ibritumomab	MS4A1	Mertansine DM4	Ibritumomab-Compound 17 linker	[363]
ADC Info	Infliximab-Compound 17	Infliximab	TNF	Mertansine DM4	Infliximab-Compound 17 linker	[363]
ADC Info	Ipilimumab-Compound 17	Ipilimumab	CTLA4	Mertansine DM4	Ipilimumab-Compound 17 linker	[363]
ADC Info	Ofatumumab-Compound 17	Ofatumumab	MS4A1	Mertansine DM4	Ofatumumab-Compound 17 linker	[363]
ADC Info	Tositumomab-Compound 17	Tositumomab	MS4A1	Mertansine DM4	Tositumomab-Compound 17 linker	[363]
ADC Info	Trastuzumab-Compound 25	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 25 linker	[363]
ADC Info	Pertuzumab-Compound 25	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 25 linker	[363]
ADC Info	Rituximab-Compound 25	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 25 linker	[363]
ADC Info	Alemtuzumab-Compound 25	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 25 linker	[363]
ADC Info	Bevacizumab-Compound 25	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 25 linker	[363]
ADC Info	Adalimumab-Compound 25	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 25 linker	[363]
ADC Info	Cetuximab-Compound 25	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 25 linker	[363]
ADC Info	Amatuximab-Compound 25	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 25 linker	[363]
ADC Info	Blinatumomab-Compound 25	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 25 linker	[363]
ADC Info	Brentuximab-Compound 25	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 25 linker	[363]
ADC Info	Sacituzumab-Compound 25	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 25 linker	[363]
ADC Info	Panitumumab-Compound 25	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 25 linker	[363]
ADC Info	Nimotuzumab-Compound 25	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 25 linker	[363]
ADC Info	Gemtuzumab-Compound 25	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 25 linker	[363]
ADC Info	Golimumab-Compound 25	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 25 linker	[363]
ADC Info	Ibritumomab-Compound 25	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 25 linker	[363]
ADC Info	Infliximab-Compound 25	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 25 linker	[363]
ADC Info	Ipilimumab-Compound 25	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 25 linker	[363]
ADC Info	Ofatumumab-Compound 25	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 25 linker	[363]
ADC Info	Tositumomab-Compound 25	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 25 linker	[363]
ADC Info	Trastuzumab-Compound 31	Trastuzumab	ERBB2	Auristatin 0101	Trastuzumab-Compound 31 linker	[363]
ADC Info	Pertuzumab-Compound 31	Pertuzumab	ERBB2	Auristatin 0101	Pertuzumab-Compound 31 linker	[363]
ADC Info	Rituximab-Compound 31	Rituximab	MS4A1	Auristatin 0101	Rituximab-Compound 31 linker	[363]
ADC Info	Alemtuzumab-Compound 31	Alemtuzumab	CD52	Auristatin 0101	Alemtuzumab-Compound 31 linker	[363]
ADC Info	Bevacizumab-Compound 31	Bevacizumab	VEGFA	Auristatin 0101	Bevacizumab-Compound 31 linker	[363]
ADC Info	Adalimumab-Compound 31	Adalimumab	TNF	Auristatin 0101	Adalimumab-Compound 31 linker	[363]
ADC Info	Cetuximab-Compound 31	Cetuximab	EGFR	Auristatin 0101	Cetuximab-Compound 31 linker	[363]
ADC Info	Amatuximab-Compound 31	Amatuximab	MSLN	Auristatin 0101	Amatuximab-Compound 31 linker	[363]
ADC Info	Blinatumomab-Compound 31	Blinatumomab	CD19; CD3D	Auristatin 0101	Blinatumomab-Compound 31 linker	[363]
ADC Info	Brentuximab-Compound 31	Brentuximab	TNFRSF8	Auristatin 0101	Brentuximab-Compound 31 linker	[363]
ADC Info	Sacituzumab-Compound 31	Sacituzumab	TACSTD2	Auristatin 0101	Sacituzumab-Compound 31 linker	[363]
ADC Info	Panitumumab-Compound 31	Panitumumab	EGFR	Auristatin 0101	Panitumumab-Compound 31 linker	[363]
ADC Info	Nimotuzumab-Compound 31	Nimotuzumab	EGFR	Auristatin 0101	Nimotuzumab-Compound 31 linker	[363]
ADC Info	Gemtuzumab-Compound 31	Gemtuzumab	CD33	Auristatin 0101	Gemtuzumab-Compound 31 linker	[363]
ADC Info	Golimumab-Compound 31	Golimumab	TNF	Auristatin 0101	Golimumab-Compound 31 linker	[363]
ADC Info	Ibritumomab-Compound 31	Ibritumomab	MS4A1	Auristatin 0101	Ibritumomab-Compound 31 linker	[363]
ADC Info	Infliximab-Compound 31	Infliximab	TNF	Auristatin 0101	Infliximab-Compound 31 linker	[363]
ADC Info	Ipilimumab-Compound 31	Ipilimumab	CTLA4	Auristatin 0101	Ipilimumab-Compound 31 linker	[363]
ADC Info	Ofatumumab-Compound 31	Ofatumumab	MS4A1	Auristatin 0101	Ofatumumab-Compound 31 linker	[363]
ADC Info	Tositumomab-Compound 31	Tositumomab	MS4A1	Auristatin 0101	Tositumomab-Compound 31 linker	[363]
ADC Info	Trastuzumab-Compound 36	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 36 linker	[363]
ADC Info	Pertuzumab-Compound 36	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 36 linker	[363]
ADC Info	Rituximab-Compound 36	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 36 linker	[363]
ADC Info	Alemtuzumab-Compound 36	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 36 linker	[363]
ADC Info	Bevacizumab-Compound 36	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 36 linker	[363]
ADC Info	Adalimumab-Compound 36	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 36 linker	[363]
ADC Info	Cetuximab-Compound 36	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 36 linker	[363]
ADC Info	Amatuximab-Compound 36	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 36 linker	[363]
ADC Info	Blinatumomab-Compound 36	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 36 linker	[363]
ADC Info	Brentuximab-Compound 36	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 36 linker	[363]
ADC Info	Sacituzumab-Compound 36	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 36 linker	[363]
ADC Info	Panitumumab-Compound 36	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 36 linker	[363]
ADC Info	Nimotuzumab-Compound 36	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 36 linker	[363]
ADC Info	Gemtuzumab-Compound 36	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 36 linker	[363]
ADC Info	Golimumab-Compound 36	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 36 linker	[363]
ADC Info	Ibritumomab-Compound 36	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 36 linker	[363]
ADC Info	Infliximab-Compound 36	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 36 linker	[363]
ADC Info	Ipilimumab-Compound 36	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 36 linker	[363]
ADC Info	Ofatumumab-Compound 36	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 36 linker	[363]
ADC Info	Tositumomab-Compound 36	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 36 linker	[363]
ADC Info	Trastuzumab-Compound 55	Trastuzumab	ERBB2	Mertansine DM1	Trastuzumab-Compound 55 linker	[363]
ADC Info	Pertuzumab-Compound 55	Pertuzumab	ERBB2	Mertansine DM1	Pertuzumab-Compound 55 linker	[363]
ADC Info	Rituximab-Compound 55	Rituximab	MS4A1	Mertansine DM1	Rituximab-Compound 55 linker	[363]
ADC Info	Alemtuzumab-Compound 55	Alemtuzumab	CD52	Mertansine DM1	Alemtuzumab-Compound 55 linker	[363]
ADC Info	Bevacizumab-Compound 55	Bevacizumab	VEGFA	Mertansine DM1	Bevacizumab-Compound 55 linker	[363]
ADC Info	Adalimumab-Compound 55	Adalimumab	TNF	Mertansine DM1	Adalimumab-Compound 55 linker	[363]
ADC Info	Cetuximab-Compound 55	Cetuximab	EGFR	Mertansine DM1	Cetuximab-Compound 55 linker	[363]
ADC Info	Amatuximab-Compound 55	Amatuximab	MSLN	Mertansine DM1	Amatuximab-Compound 55 linker	[363]
ADC Info	Blinatumomab-Compound 55	Blinatumomab	CD19; CD3D	Mertansine DM1	Blinatumomab-Compound 55 linker	[363]
ADC Info	Brentuximab-Compound 55	Brentuximab	TNFRSF8	Mertansine DM1	Brentuximab-Compound 55 linker	[363]
ADC Info	Sacituzumab-Compound 55	Sacituzumab	TACSTD2	Mertansine DM1	Sacituzumab-Compound 55 linker	[363]
ADC Info	Panitumumab-Compound 55	Panitumumab	EGFR	Mertansine DM1	Panitumumab-Compound 55 linker	[363]
ADC Info	Nimotuzumab-Compound 55	Nimotuzumab	EGFR	Mertansine DM1	Nimotuzumab-Compound 55 linker	[363]
ADC Info	Gemtuzumab-Compound 55	Gemtuzumab	CD33	Mertansine DM1	Gemtuzumab-Compound 55 linker	[363]
ADC Info	Golimumab-Compound 55	Golimumab	TNF	Mertansine DM1	Golimumab-Compound 55 linker	[363]
ADC Info	Ibritumomab-Compound 55	Ibritumomab	MS4A1	Mertansine DM1	Ibritumomab-Compound 55 linker	[363]
ADC Info	Infliximab-Compound 55	Infliximab	TNF	Mertansine DM1	Infliximab-Compound 55 linker	[363]
ADC Info	Ipilimumab-Compound 55	Ipilimumab	CTLA4	Mertansine DM1	Ipilimumab-Compound 55 linker	[363]
ADC Info	Ofatumumab-Compound 55	Ofatumumab	MS4A1	Mertansine DM1	Ofatumumab-Compound 55 linker	[363]
ADC Info	Tositumomab-Compound 55	Tositumomab	MS4A1	Mertansine DM1	Tositumomab-Compound 55 linker	[363]
ADC Info	Trastuzumab-Compound 59	Trastuzumab	ERBB2	Mertansine DM4	Trastuzumab-Compound 59 linker	[363]
ADC Info	Pertuzumab-Compound 59	Pertuzumab	ERBB2	Mertansine DM4	Pertuzumab-Compound 59 linker	[363]
ADC Info	Rituximab-Compound 59	Rituximab	MS4A1	Mertansine DM4	Rituximab-Compound 59 linker	[363]
ADC Info	Alemtuzumab-Compound 59	Alemtuzumab	CD52	Mertansine DM4	Alemtuzumab-Compound 59 linker	[363]
ADC Info	Bevacizumab-Compound 59	Bevacizumab	VEGFA	Mertansine DM4	Bevacizumab-Compound 59 linker	[363]
ADC Info	Adalimumab-Compound 59	Adalimumab	TNF	Mertansine DM4	Adalimumab-Compound 59 linker	[363]
ADC Info	Cetuximab-Compound 59	Cetuximab	EGFR	Mertansine DM4	Cetuximab-Compound 59 linker	[363]
ADC Info	Amatuximab-Compound 59	Amatuximab	MSLN	Mertansine DM4	Amatuximab-Compound 59 linker	[363]
ADC Info	Blinatumomab-Compound 59	Blinatumomab	CD19; CD3D	Mertansine DM4	Blinatumomab-Compound 59 linker	[363]
ADC Info	Brentuximab-Compound 59	Brentuximab	TNFRSF8	Mertansine DM4	Brentuximab-Compound 59 linker	[363]
ADC Info	Sacituzumab-Compound 59	Sacituzumab	TACSTD2	Mertansine DM4	Sacituzumab-Compound 59 linker	[363]
ADC Info	Panitumumab-Compound 59	Panitumumab	EGFR	Mertansine DM4	Panitumumab-Compound 59 linker	[363]
ADC Info	Nimotuzumab-Compound 59	Nimotuzumab	EGFR	Mertansine DM4	Nimotuzumab-Compound 59 linker	[363]
ADC Info	Gemtuzumab-Compound 59	Gemtuzumab	CD33	Mertansine DM4	Gemtuzumab-Compound 59 linker	[363]
ADC Info	Golimumab-Compound 59	Golimumab	TNF	Mertansine DM4	Golimumab-Compound 59 linker	[363]
ADC Info	Ibritumomab-Compound 59	Ibritumomab	MS4A1	Mertansine DM4	Ibritumomab-Compound 59 linker	[363]
ADC Info	Infliximab-Compound 59	Infliximab	TNF	Mertansine DM4	Infliximab-Compound 59 linker	[363]
ADC Info	Ipilimumab-Compound 59	Ipilimumab	CTLA4	Mertansine DM4	Ipilimumab-Compound 59 linker	[363]
ADC Info	Ofatumumab-Compound 59	Ofatumumab	MS4A1	Mertansine DM4	Ofatumumab-Compound 59 linker	[363]
ADC Info	Tositumomab-Compound 59	Tositumomab	MS4A1	Mertansine DM4	Tositumomab-Compound 59 linker	[363]
ADC Info	Trastuzumab-Compound 64	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 64 linker	[363]
ADC Info	Pertuzumab-Compound 64	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 64 linker	[363]
ADC Info	Rituximab-Compound 64	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 64 linker	[363]
ADC Info	Alemtuzumab-Compound 64	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 64 linker	[363]
ADC Info	Bevacizumab-Compound 64	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 64 linker	[363]
ADC Info	Adalimumab-Compound 64	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 64 linker	[363]
ADC Info	Cetuximab-Compound 64	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 64 linker	[363]
ADC Info	Amatuximab-Compound 64	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 64 linker	[363]
ADC Info	Blinatumomab-Compound 64	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 64 linker	[363]
ADC Info	Brentuximab-Compound 64	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 64 linker	[363]
ADC Info	Sacituzumab-Compound 64	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 64 linker	[363]
ADC Info	Panitumumab-Compound 64	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 64 linker	[363]
ADC Info	Nimotuzumab-Compound 64	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 64 linker	[363]
ADC Info	Gemtuzumab-Compound 64	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 64 linker	[363]
ADC Info	Golimumab-Compound 64	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 64 linker	[363]
ADC Info	Ibritumomab-Compound 64	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 64 linker	[363]
ADC Info	Infliximab-Compound 64	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 64 linker	[363]
ADC Info	Ipilimumab-Compound 64	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 64 linker	[363]
ADC Info	Ofatumumab-Compound 64	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 64 linker	[363]
ADC Info	Tositumomab-Compound 64	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 64 linker	[363]
ADC Info	Trastuzumab-Compound 69	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 69 linker	[363]
ADC Info	Pertuzumab-Compound 69	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 69 linker	[363]
ADC Info	Rituximab-Compound 69	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 69 linker	[363]
ADC Info	Alemtuzumab-Compound 69	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 69 linker	[363]
ADC Info	Bevacizumab-Compound 69	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 69 linker	[363]
ADC Info	Adalimumab-Compound 69	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 69 linker	[363]
ADC Info	Cetuximab-Compound 69	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 69 linker	[363]
ADC Info	Amatuximab-Compound 69	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 69 linker	[363]
ADC Info	Blinatumomab-Compound 69	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 69 linker	[363]
ADC Info	Brentuximab-Compound 69	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 69 linker	[363]
ADC Info	Sacituzumab-Compound 69	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 69 linker	[363]
ADC Info	Panitumumab-Compound 69	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 69 linker	[363]
ADC Info	Nimotuzumab-Compound 69	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 69 linker	[363]
ADC Info	Gemtuzumab-Compound 69	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 69 linker	[363]
ADC Info	Golimumab-Compound 69	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 69 linker	[363]
ADC Info	Ibritumomab-Compound 69	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 69 linker	[363]
ADC Info	Infliximab-Compound 69	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 69 linker	[363]
ADC Info	Ipilimumab-Compound 69	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 69 linker	[363]
ADC Info	Ofatumumab-Compound 69	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 69 linker	[363]
ADC Info	Tositumomab-Compound 69	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 69 linker	[363]
ADC Info	Trastuzumab-Compound 75	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 75 linker	[363]
ADC Info	Pertuzumab-Compound 75	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 75 linker	[363]
ADC Info	Rituximab-Compound 75	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 75 linker	[363]
ADC Info	Alemtuzumab-Compound 75	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 75 linker	[363]
ADC Info	Bevacizumab-Compound 75	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 75 linker	[363]
ADC Info	Adalimumab-Compound 75	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 75 linker	[363]
ADC Info	Cetuximab-Compound 75	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 75 linker	[363]
ADC Info	Amatuximab-Compound 75	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 75 linker	[363]
ADC Info	Blinatumomab-Compound 75	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 75 linker	[363]
ADC Info	Brentuximab-Compound 75	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 75 linker	[363]
ADC Info	Sacituzumab-Compound 75	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 75 linker	[363]
ADC Info	Panitumumab-Compound 75	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 75 linker	[363]
ADC Info	Nimotuzumab-Compound 75	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 75 linker	[363]
ADC Info	Gemtuzumab-Compound 75	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 75 linker	[363]
ADC Info	Golimumab-Compound 75	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 75 linker	[363]
ADC Info	Ibritumomab-Compound 75	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 75 linker	[363]
ADC Info	Infliximab-Compound 75	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 75 linker	[363]
ADC Info	Ipilimumab-Compound 75	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 75 linker	[363]
ADC Info	Ofatumumab-Compound 75	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 75 linker	[363]
ADC Info	Tositumomab-Compound 75	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 75 linker	[363]
ADC Info	Trastuzumab-Compound 76	Trastuzumab	ERBB2	Monomethyl auristatin E	Trastuzumab-Compound 76 linker	[363]
ADC Info	Pertuzumab-Compound 76	Pertuzumab	ERBB2	Monomethyl auristatin E	Pertuzumab-Compound 76 linker	[363]
ADC Info	Rituximab-Compound 76	Rituximab	MS4A1	Monomethyl auristatin E	Rituximab-Compound 76 linker	[363]
ADC Info	Alemtuzumab-Compound 76	Alemtuzumab	CD52	Monomethyl auristatin E	Alemtuzumab-Compound 76 linker	[363]
ADC Info	Bevacizumab-Compound 76	Bevacizumab	VEGFA	Monomethyl auristatin E	Bevacizumab-Compound 76 linker	[363]
ADC Info	Adalimumab-Compound 76	Adalimumab	TNF	Monomethyl auristatin E	Adalimumab-Compound 76 linker	[363]
ADC Info	Cetuximab-Compound 76	Cetuximab	EGFR	Monomethyl auristatin E	Cetuximab-Compound 76 linker	[363]
ADC Info	Amatuximab-Compound 76	Amatuximab	MSLN	Monomethyl auristatin E	Amatuximab-Compound 76 linker	[363]
ADC Info	Blinatumomab-Compound 76	Blinatumomab	CD19; CD3D	Monomethyl auristatin E	Blinatumomab-Compound 76 linker	[363]
ADC Info	Brentuximab-Compound 76	Brentuximab	TNFRSF8	Monomethyl auristatin E	Brentuximab-Compound 76 linker	[363]
ADC Info	Sacituzumab-Compound 76	Sacituzumab	TACSTD2	Monomethyl auristatin E	Sacituzumab-Compound 76 linker	[363]
ADC Info	Panitumumab-Compound 76	Panitumumab	EGFR	Monomethyl auristatin E	Panitumumab-Compound 76 linker	[363]
ADC Info	Nimotuzumab-Compound 76	Nimotuzumab	EGFR	Monomethyl auristatin E	Nimotuzumab-Compound 76 linker	[363]
ADC Info	Gemtuzumab-Compound 76	Gemtuzumab	CD33	Monomethyl auristatin E	Gemtuzumab-Compound 76 linker	[363]
ADC Info	Golimumab-Compound 76	Golimumab	TNF	Monomethyl auristatin E	Golimumab-Compound 76 linker	[363]
ADC Info	Ibritumomab-Compound 76	Ibritumomab	MS4A1	Monomethyl auristatin E	Ibritumomab-Compound 76 linker	[363]
ADC Info	Infliximab-Compound 76	Infliximab	TNF	Monomethyl auristatin E	Infliximab-Compound 76 linker	[363]
ADC Info	Ipilimumab-Compound 76	Ipilimumab	CTLA4	Monomethyl auristatin E	Ipilimumab-Compound 76 linker	[363]
ADC Info	Ofatumumab-Compound 76	Ofatumumab	MS4A1	Monomethyl auristatin E	Ofatumumab-Compound 76 linker	[363]
ADC Info	Tositumomab-Compound 76	Tositumomab	MS4A1	Monomethyl auristatin E	Tositumomab-Compound 76 linker	[363]
ADC Info	Trastuzumab-Compound 77	Trastuzumab	ERBB2	Mertansine DM1	Trastuzumab-Compound 77 linker	[363]
ADC Info	Pertuzumab-Compound 77	Pertuzumab	ERBB2	Mertansine DM1	Pertuzumab-Compound 77 linker	[363]
ADC Info	Rituximab-Compound 77	Rituximab	MS4A1	Mertansine DM1	Rituximab-Compound 77 linker	[363]
ADC Info	Alemtuzumab-Compound 77	Alemtuzumab	CD52	Mertansine DM1	Alemtuzumab-Compound 77 linker	[363]
ADC Info	Bevacizumab-Compound 77	Bevacizumab	VEGFA	Mertansine DM1	Bevacizumab-Compound 77 linker	[363]
ADC Info	Adalimumab-Compound 77	Adalimumab	TNF	Mertansine DM1	Adalimumab-Compound 77 linker	[363]
ADC Info	Cetuximab-Compound 77	Cetuximab	EGFR	Mertansine DM1	Cetuximab-Compound 77 linker	[363]
ADC Info	Amatuximab-Compound 77	Amatuximab	MSLN	Mertansine DM1	Amatuximab-Compound 77 linker	[363]
ADC Info	Blinatumomab-Compound 77	Blinatumomab	CD19; CD3D	Mertansine DM1	Blinatumomab-Compound 77 linker	[363]
ADC Info	Brentuximab-Compound 77	Brentuximab	TNFRSF8	Mertansine DM1	Brentuximab-Compound 77 linker	[363]
ADC Info	Sacituzumab-Compound 77	Sacituzumab	TACSTD2	Mertansine DM1	Sacituzumab-Compound 77 linker	[363]
ADC Info	Panitumumab-Compound 77	Panitumumab	EGFR	Mertansine DM1	Panitumumab-Compound 77 linker	[363]
ADC Info	Nimotuzumab-Compound 77	Nimotuzumab	EGFR	Mertansine DM1	Nimotuzumab-Compound 77 linker	[363]
ADC Info	Gemtuzumab-Compound 77	Gemtuzumab	CD33	Mertansine DM1	Gemtuzumab-Compound 77 linker	[363]
ADC Info	Golimumab-Compound 77	Golimumab	TNF	Mertansine DM1	Golimumab-Compound 77 linker	[363]
ADC Info	Ibritumomab-Compound 77	Ibritumomab	MS4A1	Mertansine DM1	Ibritumomab-Compound 77 linker	[363]
ADC Info	Infliximab-Compound 77	Infliximab	TNF	Mertansine DM1	Infliximab-Compound 77 linker	[363]
ADC Info	Ipilimumab-Compound 77	Ipilimumab	CTLA4	Mertansine DM1	Ipilimumab-Compound 77 linker	[363]
ADC Info	Ofatumumab-Compound 77	Ofatumumab	MS4A1	Mertansine DM1	Ofatumumab-Compound 77 linker	[363]
ADC Info	Tositumomab-Compound 77	Tositumomab	MS4A1	Mertansine DM1	Tositumomab-Compound 77 linker	[363]
ADC Info	Trastuzumab-Compound 78	Trastuzumab	ERBB2	Auristatin 0101	Trastuzumab-Compound 78 linker	[363]
ADC Info	Pertuzumab-Compound 78	Pertuzumab	ERBB2	Auristatin 0101	Pertuzumab-Compound 78 linker	[363]
ADC Info	Rituximab-Compound 78	Rituximab	MS4A1	Auristatin 0101	Rituximab-Compound 78 linker	[363]
ADC Info	Alemtuzumab-Compound 78	Alemtuzumab	CD52	Auristatin 0101	Alemtuzumab-Compound 78 linker	[363]
ADC Info	Bevacizumab-Compound 78	Bevacizumab	VEGFA	Auristatin 0101	Bevacizumab-Compound 78 linker	[363]
ADC Info	Adalimumab-Compound 78	Adalimumab	TNF	Auristatin 0101	Adalimumab-Compound 78 linker	[363]
ADC Info	Cetuximab-Compound 78	Cetuximab	EGFR	Auristatin 0101	Cetuximab-Compound 78 linker	[363]
ADC Info	Amatuximab-Compound 78	Amatuximab	MSLN	Auristatin 0101	Amatuximab-Compound 78 linker	[363]
ADC Info	Blinatumomab-Compound 78	Blinatumomab	CD19; CD3D	Auristatin 0101	Blinatumomab-Compound 78 linker	[363]
ADC Info	Brentuximab-Compound 78	Brentuximab	TNFRSF8	Auristatin 0101	Brentuximab-Compound 78 linker	[363]
ADC Info	Sacituzumab-Compound 78	Sacituzumab	TACSTD2	Auristatin 0101	Sacituzumab-Compound 78 linker	[363]
ADC Info	Panitumumab-Compound 78	Panitumumab	EGFR	Auristatin 0101	Panitumumab-Compound 78 linker	[363]
ADC Info	Nimotuzumab-Compound 78	Nimotuzumab	EGFR	Auristatin 0101	Nimotuzumab-Compound 78 linker	[363]
ADC Info	Gemtuzumab-Compound 78	Gemtuzumab	CD33	Auristatin 0101	Gemtuzumab-Compound 78 linker	[363]
ADC Info	Golimumab-Compound 78	Golimumab	TNF	Auristatin 0101	Golimumab-Compound 78 linker	[363]
ADC Info	Ibritumomab-Compound 78	Ibritumomab	MS4A1	Auristatin 0101	Ibritumomab-Compound 78 linker	[363]
ADC Info	Infliximab-Compound 78	Infliximab	TNF	Auristatin 0101	Infliximab-Compound 78 linker	[363]
ADC Info	Ipilimumab-Compound 78	Ipilimumab	CTLA4	Auristatin 0101	Ipilimumab-Compound 78 linker	[363]
ADC Info	Ofatumumab-Compound 78	Ofatumumab	MS4A1	Auristatin 0101	Ofatumumab-Compound 78 linker	[363]
ADC Info	Tositumomab-Compound 78	Tositumomab	MS4A1	Auristatin 0101	Tositumomab-Compound 78 linker	[363]
ADC Info	Trastuzumab-Compound 79	Trastuzumab	ERBB2	Auristatin 0101	Trastuzumab-Compound 79 linker	[363]
ADC Info	Pertuzumab-Compound 79	Pertuzumab	ERBB2	Auristatin 0101	Pertuzumab-Compound 79 linker	[363]
ADC Info	Rituximab-Compound 79	Rituximab	MS4A1	Auristatin 0101	Rituximab-Compound 79 linker	[363]
ADC Info	Alemtuzumab-Compound 79	Alemtuzumab	CD52	Auristatin 0101	Alemtuzumab-Compound 79 linker	[363]
ADC Info	Bevacizumab-Compound 79	Bevacizumab	VEGFA	Auristatin 0101	Bevacizumab-Compound 79 linker	[363]
ADC Info	Adalimumab-Compound 79	Adalimumab	TNF	Auristatin 0101	Adalimumab-Compound 79 linker	[363]
ADC Info	Cetuximab-Compound 79	Cetuximab	EGFR	Auristatin 0101	Cetuximab-Compound 79 linker	[363]
ADC Info	Amatuximab-Compound 79	Amatuximab	MSLN	Auristatin 0101	Amatuximab-Compound 79 linker	[363]
ADC Info	Blinatumomab-Compound 79	Blinatumomab	CD19; CD3D	Auristatin 0101	Blinatumomab-Compound 79 linker	[363]
ADC Info	Brentuximab-Compound 79	Brentuximab	TNFRSF8	Auristatin 0101	Brentuximab-Compound 79 linker	[363]
ADC Info	Sacituzumab-Compound 79	Sacituzumab	TACSTD2	Auristatin 0101	Sacituzumab-Compound 79 linker	[363]
ADC Info	Panitumumab-Compound 79	Panitumumab	EGFR	Auristatin 0101	Panitumumab-Compound 79 linker	[363]
ADC Info	Nimotuzumab-Compound 79	Nimotuzumab	EGFR	Auristatin 0101	Nimotuzumab-Compound 79 linker	[363]
ADC Info	Gemtuzumab-Compound 79	Gemtuzumab	CD33	Auristatin 0101	Gemtuzumab-Compound 79 linker	[363]
ADC Info	Golimumab-Compound 79	Golimumab	TNF	Auristatin 0101	Golimumab-Compound 79 linker	[363]
ADC Info	Ibritumomab-Compound 79	Ibritumomab	MS4A1	Auristatin 0101	Ibritumomab-Compound 79 linker	[363]
ADC Info	Infliximab-Compound 79	Infliximab	TNF	Auristatin 0101	Infliximab-Compound 79 linker	[363]
ADC Info	Ipilimumab-Compound 79	Ipilimumab	CTLA4	Auristatin 0101	Ipilimumab-Compound 79 linker	[363]
ADC Info	Ofatumumab-Compound 79	Ofatumumab	MS4A1	Auristatin 0101	Ofatumumab-Compound 79 linker	[363]
ADC Info	Tositumomab-Compound 79	Tositumomab	MS4A1	Auristatin 0101	Tositumomab-Compound 79 linker	[363]
ADC Info	Trastuzumab-Compound 80	Trastuzumab	ERBB2	Mertansine DM4	Trastuzumab-Compound 80 linker	[363]
ADC Info	Pertuzumab-Compound 80	Pertuzumab	ERBB2	Mertansine DM4	Pertuzumab-Compound 80 linker	[363]
ADC Info	Rituximab-Compound 80	Rituximab	MS4A1	Mertansine DM4	Rituximab-Compound 80 linker	[363]
ADC Info	Alemtuzumab-Compound 80	Alemtuzumab	CD52	Mertansine DM4	Alemtuzumab-Compound 80 linker	[363]
ADC Info	Bevacizumab-Compound 80	Bevacizumab	VEGFA	Mertansine DM4	Bevacizumab-Compound 80 linker	[363]
ADC Info	Adalimumab-Compound 80	Adalimumab	TNF	Mertansine DM4	Adalimumab-Compound 80 linker	[363]
ADC Info	Cetuximab-Compound 80	Cetuximab	EGFR	Mertansine DM4	Cetuximab-Compound 80 linker	[363]
ADC Info	Amatuximab-Compound 80	Amatuximab	MSLN	Mertansine DM4	Amatuximab-Compound 80 linker	[363]
ADC Info	Blinatumomab-Compound 80	Blinatumomab	CD19; CD3D	Mertansine DM4	Blinatumomab-Compound 80 linker	[363]
ADC Info	Brentuximab-Compound 80	Brentuximab	TNFRSF8	Mertansine DM4	Brentuximab-Compound 80 linker	[363]
ADC Info	Sacituzumab-Compound 80	Sacituzumab	TACSTD2	Mertansine DM4	Sacituzumab-Compound 80 linker	[363]
ADC Info	Panitumumab-Compound 80	Panitumumab	EGFR	Mertansine DM4	Panitumumab-Compound 80 linker	[363]
ADC Info	Nimotuzumab-Compound 80	Nimotuzumab	EGFR	Mertansine DM4	Nimotuzumab-Compound 80 linker	[363]
ADC Info	Gemtuzumab-Compound 80	Gemtuzumab	CD33	Mertansine DM4	Gemtuzumab-Compound 80 linker	[363]
ADC Info	Golimumab-Compound 80	Golimumab	TNF	Mertansine DM4	Golimumab-Compound 80 linker	[363]
ADC Info	Ibritumomab-Compound 80	Ibritumomab	MS4A1	Mertansine DM4	Ibritumomab-Compound 80 linker	[363]
ADC Info	Infliximab-Compound 80	Infliximab	TNF	Mertansine DM4	Infliximab-Compound 80 linker	[363]
ADC Info	Ipilimumab-Compound 80	Ipilimumab	CTLA4	Mertansine DM4	Ipilimumab-Compound 80 linker	[363]
ADC Info	Ofatumumab-Compound 80	Ofatumumab	MS4A1	Mertansine DM4	Ofatumumab-Compound 80 linker	[363]
ADC Info	Tositumomab-Compound 80	Tositumomab	MS4A1	Mertansine DM4	Tositumomab-Compound 80 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 9	Anti-MSL1 mAb	MSL1	Mertansine DM1	Anti-MSL1 mAb-Compound 9 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 9	Anti-CD59 mAb	CD59	Mertansine DM1	Anti-CD59 mAb-Compound 9 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 9	Anti-HER2 mAb	ERBB2	Mertansine DM1	Anti-HER2 mAb-Compound 9 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 17	Anti-MSL1 mAb	MSL1	Mertansine DM4	Anti-MSL1 mAb-Compound 17 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 17	Anti-CD59 mAb	CD59	Mertansine DM4	Anti-CD59 mAb-Compound 17 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 17	Anti-HER2 mAb	ERBB2	Mertansine DM4	Anti-HER2 mAb-Compound 17 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 25	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 25 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 25	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 25 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 25	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 25 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 31	Anti-MSL1 mAb	MSL1	Auristatin 0101	Anti-MSL1 mAb-Compound 31 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 31	Anti-CD59 mAb	CD59	Auristatin 0101	Anti-CD59 mAb-Compound 31 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 31	Anti-HER2 mAb	ERBB2	Auristatin 0101	Anti-HER2 mAb-Compound 31 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 36	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 36 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 36	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 36 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 36	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 36 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 55	Anti-MSL1 mAb	MSL1	Mertansine DM1	Anti-MSL1 mAb-Compound 55 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 55	Anti-CD59 mAb	CD59	Mertansine DM1	Anti-CD59 mAb-Compound 55 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 55	Anti-HER2 mAb	ERBB2	Mertansine DM1	Anti-HER2 mAb-Compound 55 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 59	Anti-MSL1 mAb	MSL1	Mertansine DM4	Anti-MSL1 mAb-Compound 59 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 59	Anti-CD59 mAb	CD59	Mertansine DM4	Anti-CD59 mAb-Compound 59 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 59	Anti-HER2 mAb	ERBB2	Mertansine DM4	Anti-HER2 mAb-Compound 59 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 64	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 64 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 64	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 64 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 64	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 64 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 69	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 69 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 69	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 69 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 69	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 69 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 75	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 75 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 75	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 75 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 75	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 75 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 76	Anti-MSL1 mAb	MSL1	Monomethyl auristatin E	Anti-MSL1 mAb-Compound 76 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 76	Anti-CD59 mAb	CD59	Monomethyl auristatin E	Anti-CD59 mAb-Compound 76 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 76	Anti-HER2 mAb	ERBB2	Monomethyl auristatin E	Anti-HER2 mAb-Compound 76 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 77	Anti-MSL1 mAb	MSL1	Mertansine DM1	Anti-MSL1 mAb-Compound 77 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 77	Anti-CD59 mAb	CD59	Mertansine DM1	Anti-CD59 mAb-Compound 77 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 77	Anti-HER2 mAb	ERBB2	Mertansine DM1	Anti-HER2 mAb-Compound 77 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 78	Anti-MSL1 mAb	MSL1	Auristatin 0101	Anti-MSL1 mAb-Compound 78 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 78	Anti-CD59 mAb	CD59	Auristatin 0101	Anti-CD59 mAb-Compound 78 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 78	Anti-HER2 mAb	ERBB2	Auristatin 0101	Anti-HER2 mAb-Compound 78 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 79	Anti-MSL1 mAb	MSL1	Auristatin 0101	Anti-MSL1 mAb-Compound 79 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 79	Anti-CD59 mAb	CD59	Auristatin 0101	Anti-CD59 mAb-Compound 79 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 79	Anti-HER2 mAb	ERBB2	Auristatin 0101	Anti-HER2 mAb-Compound 79 linker	[363]
ADC Info	Anti-MSL1 mAb-Compound 80	Anti-MSL1 mAb	MSL1	Mertansine DM4	Anti-MSL1 mAb-Compound 80 linker	[363]
ADC Info	Anti-CD59 mAb-Compound 80	Anti-CD59 mAb	CD59	Mertansine DM4	Anti-CD59 mAb-Compound 80 linker	[363]
ADC Info	Anti-HER2 mAb-Compound 80	Anti-HER2 mAb	ERBB2	Mertansine DM4	Anti-HER2 mAb-Compound 80 linker	[363]
ADC Info	H-1-vcMMAE	Anti-HER2 mAb H-1	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[364]
ADC Info	H-3-vcMMAE	Anti-HER2 mAb H-3	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[364]
ADC Info	H-4-vcMMAE	Anti-HER2 mAb H-4	ERBB2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[364]
ADC Info	Anti-KIT 9P3?SMCC-DM1	Anti-KIT mAb 9P3	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG024?SMCC-DM1	Anti-KIT mAb NEG024	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG026?SMCC-DM1	Anti-KIT mAb NEG026	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG027?SMCC-DM1	Anti-KIT mAb NEG027	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG085?SMCC-DM1	Anti-KIT mAb NEG085	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG086?SMCC-DM1	Anti-KIT mAb NEG086	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT NEG087?SMCC-DM1	Anti-KIT mAb NEG087	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT 20376?SMCC-DM1	Anti-KIT mAb 20376	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[365]
ADC Info	Anti-KIT 9P3?SPDB-DM4	Anti-KIT mAb 9P3	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG024?SPDB-DM4	Anti-KIT mAb NEG024	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG026?SPDB-DM4	Anti-KIT mAb NEG026	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG027?SPDB-DM4	Anti-KIT mAb NEG027	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG085?SPDB-DM4	Anti-KIT mAb NEG085	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG086?SPDB-DM4	Anti-KIT mAb NEG086	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT NEG087?SPDB-DM4	Anti-KIT mAb NEG087	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT 20376?SPDB-DM4	Anti-KIT mAb 20376	KIT	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[365]
ADC Info	Anti-KIT 9P3?CX1-1-DM1	Anti-KIT mAb 9P3	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG024?CX1-1-DM1	Anti-KIT mAb NEG024	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG026?CX1-1-DM1	Anti-KIT mAb NEG026	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG027?CX1-1-DM1	Anti-KIT mAb NEG027	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG085?CX1-1-DM1	Anti-KIT mAb NEG085	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG086?CX1-1-DM1	Anti-KIT mAb NEG086	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT NEG087?CX1-1-DM1	Anti-KIT mAb NEG087	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT 20376?CX1-1-DM1	Anti-KIT mAb 20376	KIT	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[365]
ADC Info	Anti-KIT 9P3?SSNPP-DM3	Anti-KIT mAb 9P3	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG024?SSNPP-DM3	Anti-KIT mAb NEG024	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG026?SSNPP-DM3	Anti-KIT mAb NEG026	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG027?SSNPP-DM3	Anti-KIT mAb NEG027	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG085?SSNPP-DM3	Anti-KIT mAb NEG085	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG086?SSNPP-DM3	Anti-KIT mAb NEG086	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT NEG087?SSNPP-DM3	Anti-KIT mAb NEG087	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT 20376?SSNPP-DM3	Anti-KIT mAb 20376	KIT	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[365]
ADC Info	Anti-KIT 9P3?SPP-DM1	Anti-KIT mAb 9P3	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG024?SPP-DM1	Anti-KIT mAb NEG024	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG026?SPP-DM1	Anti-KIT mAb NEG026	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG027?SPP-DM1	Anti-KIT mAb NEG027	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG085?SPP-DM1	Anti-KIT mAb NEG085	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG086?SPP-DM1	Anti-KIT mAb NEG086	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT NEG087?SPP-DM1	Anti-KIT mAb NEG087	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT 20376?SPP-DM1	Anti-KIT mAb 20376	KIT	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[365]
ADC Info	Anti-KIT 9P3?SPDP-DM1	Anti-KIT mAb 9P3	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG024?SPDP-DM1	Anti-KIT mAb NEG024	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG026?SPDP-DM1	Anti-KIT mAb NEG026	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG027?SPDP-DM1	Anti-KIT mAb NEG027	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG085?SPDP-DM1	Anti-KIT mAb NEG085	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG086?SPDP-DM1	Anti-KIT mAb NEG086	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT NEG087?SPDP-DM1	Anti-KIT mAb NEG087	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT 20376?SPDP-DM1	Anti-KIT mAb 20376	KIT	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[365]
ADC Info	Anti-KIT 9P3 Sulfo-SPDB-DM4	Anti-KIT mAb 9P3	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG024 Sulfo-SPDB-DM4	Anti-KIT mAb NEG024	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG026 Sulfo-SPDB-DM4	Anti-KIT mAb NEG026	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG027 Sulfo-SPDB-DM4	Anti-KIT mAb NEG027	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG085 Sulfo-SPDB-DM4	Anti-KIT mAb NEG085	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG086 Sulfo-SPDB-DM4	Anti-KIT mAb NEG086	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT NEG087 Sulfo-SPDB-DM4	Anti-KIT mAb NEG087	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-KIT 20376 Sulfo-SPDB-DM4	Anti-KIT mAb 20376	KIT	Mertansine DM4	Sulfo-SPDB	[365]
ADC Info	Anti-FGFR2/4 mAb-12425 SMCC-DM1	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 SMCC-DM1	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 SMCC-DM1	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 SMCC-DM1	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 SMCC-DM1	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 SMCC-DM1	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-10164 SMCC-DM1	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-10220 SMCC-DM1	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-10846 SMCC-DM1	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 SMCC-DM1	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 SMCC-DM1	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 SMCC-DM1	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-11723 SMCC-DM1	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-11725 SMCC-DM1	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-12433 SMCC-DM1	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-12931 SMCC-DM1	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-12944 SMCC-DM1	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2 mAb-12947 SMCC-DM1	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 SMCC-DM1	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 SMCC-DM1	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 SMCC-DM1	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 SMCC-DM1	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 SMCC-DM1	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 SMCC-DM1	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 SPDB-DM4	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 SPDB-DM4	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 SPDB-DM4	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 SPDB-DM4	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 SPDB-DM4	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 SPDB-DM4	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-10164 SPDB-DM4	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-10220 SPDB-DM4	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-10846 SPDB-DM4	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 SPDB-DM4	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 SPDB-DM4	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 SPDB-DM4	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-11723 SPDB-DM4	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-11725 SPDB-DM4	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-12433 SPDB-DM4	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-12931 SPDB-DM4	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-12944 SPDB-DM4	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2 mAb-12947 SPDB-DM4	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 SPDB-DM4	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 SPDB-DM4	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 SPDB-DM4	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 SPDB-DM4	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 SPDB-DM4	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 SPDB-DM4	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 CX1-1-DM1	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 CX1-1-DM1	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 CX1-1-DM1	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 CX1-1-DM1	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 CX1-1-DM1	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 CX1-1-DM1	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-10164 CX1-1-DM1	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-10220 CX1-1-DM1	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-10846 CX1-1-DM1	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 CX1-1-DM1	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 CX1-1-DM1	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 CX1-1-DM1	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-11723 CX1-1-DM1	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-11725 CX1-1-DM1	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-12433 CX1-1-DM1	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-12931 CX1-1-DM1	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-12944 CX1-1-DM1	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2 mAb-12947 CX1-1-DM1	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 CX1-1-DM1	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 CX1-1-DM1	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 CX1-1-DM1	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 CX1-1-DM1	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 CX1-1-DM1	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 CX1-1-DM1	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM1	2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 SSNPP-DM3	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 SSNPP-DM3	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 SSNPP-DM3	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 SSNPP-DM3	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 SSNPP-DM3	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 SSNPP-DM3	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-10164 SSNPP-DM3	Anti-FGFR2 mAb 10164	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-10220 SSNPP-DM3	Anti-FGFR2 mAb 10220	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-10846 SSNPP-DM3	Anti-FGFR2 mAb 10846	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 SSNPP-DM3	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 SSNPP-DM3	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 SSNPP-DM3	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-11723 SSNPP-DM3	Anti-FGFR2 mAb 11723	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-11725 SSNPP-DM3	Anti-FGFR2 mAb 11725	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-12433 SSNPP-DM3	Anti-FGFR2 mAb 12433	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-12931 SSNPP-DM3	Anti-FGFR2 mAb 12931	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-12944 SSNPP-DM3	Anti-FGFR2 mAb 12944	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2 mAb-12947 SSNPP-DM3	Anti-FGFR2 mAb 12947	FGFR2	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 SSNPP-DM3	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 SSNPP-DM3	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 SSNPP-DM3	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 SSNPP-DM3	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 SSNPP-DM3	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 SSNPP-DM3	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Maytansinoid DM3	Sulfosuccinimidyl-N-succinimidyl-4-(5-nitro-2-pyridyldithio) pentanoate (SSNPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 SPP-DM1	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 SPP-DM1	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 SPP-DM1	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 SPP-DM1	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 SPP-DM1	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 SPP-DM1	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-10164 SPP-DM1	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-10220 SPP-DM1	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-10846 SPP-DM1	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 SPP-DM1	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 SPP-DM1	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 SPP-DM1	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-11723 SPP-DM1	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-11725 SPP-DM1	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-12433 SPP-DM1	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-12931 SPP-DM1	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-12944 SPP-DM1	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2 mAb-12947 SPP-DM1	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 SPP-DM1	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 SPP-DM1	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 SPP-DM1	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 SPP-DM1	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 SPP-DM1	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 SPP-DM1	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-10164 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-10220 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-10846 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-11723 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-11725 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-12433 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-12931 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-12944 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2 mAb-12947 Sulfo-SPDB-DM4	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 Sulfo-SPDB-DM4	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM4	Sulfo-SPDB	[366]
ADC Info	Anti-FGFR2/4 mAb-12425 SPDP-DM1	Anti-FGFR2/4 mAb 12425	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-14629 SPDP-DM1	Anti-FGFR2/4 mAb 14629	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20562 SPDP-DM1	Anti-FGFR2/4 mAb 20562	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-20811 SPDP-DM1	Anti-FGFR2/4 mAb 20811	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12422 SPDP-DM1	Anti-FGFR2/4 mAb 12422	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12439 SPDP-DM1	Anti-FGFR2/4 mAb 12439	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-10164 SPDP-DM1	Anti-FGFR2 mAb 10164	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-10220 SPDP-DM1	Anti-FGFR2 mAb 10220	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-10846 SPDP-DM1	Anti-FGFR2 mAb 10846	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10918 SPDP-DM1	Anti-FGFR2/4 mAb 10918	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10923 SPDP-DM1	Anti-FGFR2/4 mAb 10923	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-11722 SPDP-DM1	Anti-FGFR2/4 mAb 11722	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-11723 SPDP-DM1	Anti-FGFR2 mAb 11723	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-11725 SPDP-DM1	Anti-FGFR2 mAb 11725	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-12433 SPDP-DM1	Anti-FGFR2 mAb 12433	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-12931 SPDP-DM1	Anti-FGFR2 mAb 12931	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-12944 SPDP-DM1	Anti-FGFR2 mAb 12944	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2 mAb-12947 SPDP-DM1	Anti-FGFR2 mAb 12947	FGFR2	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10553 SPDP-DM1	Anti-FGFR2/4 mAb 10553	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10554 SPDP-DM1	Anti-FGFR2/4 mAb 10554	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10925 SPDP-DM1	Anti-FGFR2/4 mAb 10925	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-10729 SPDP-DM1	Anti-FGFR2/4 mAb 10729	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12435 SPDP-DM1	Anti-FGFR2/4 mAb 12435	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	Anti-FGFR2/4 mAb-12438 SPDP-DM1	Anti-FGFR2/4 mAb 12438	FGFR2; FGFR4	Mertansine DM1	N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)	[366]
ADC Info	AbA-vcMMAE	Anti-EGFR AbA	EGFR	Monomethyl auristatin E	Mc-Val-Cit-PABC	[367]
ADC Info	Ab1-mcMMAF	Anti-EGFR Ab1	EGFR	Monomethyl auristatin F	Maleimido-caproyl	[367]
ADC Info	Ab3-mcMMAF	Anti-EGFR Ab3	EGFR	Monomethyl auristatin F	Maleimido-caproyl	[367]
ADC Info	AbA-mcMMAE	Anti-EGFR AbA	EGFR	Monomethyl auristatin E	Maleimido-caproyl	[367]

Terminated in phase 3

Click To Hide/Show 1 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	TAA-013	Trastuzumab	ERBB2	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[368]

Terminated in phase 2

Click To Hide/Show 8 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	AGS-16C3F	Anti-ENPP3 AGS-16C3F mAb	ENPP3	Monomethyl auristatin F	Maleimido-caproyl	[369]
ADC Info	Pinatuzumab vedotin	Pinatuzumab	CD22	Monomethyl auristatin E	Mc-Val-Cit-PABC	[370]
ADC Info	Lifastuzumab vedotin	Lifastuzumab	SLC34A2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[371]
ADC Info	Cantuzumab ravtansine	Cantuzumab	SDC1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[372]
ADC Info	PSMA-ADC	Fully human IgG1 Anti-PSMA mAb	FOLH1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[373]
ADC Info	MLN2704	MLN591	FOLH1	Mertansine DM1	Thiopentanoate linker	[374]
ADC Info	SAR-566658	Anti-CA6 mAb huDS6	CA6	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[375]
ADC Info	Indusatumab vedotin	Indusatumab	GUCY2C	Monomethyl auristatin E	Mc-Val-Cit-PABC	[376]

Terminated in phase 1

Click To Hide/Show 30 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Cantuzumab mertansine	Cantuzumab	SDC1	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[377]
ADC Info	Vorsetuzumab mafodotin	Vorsetuzumab	CD70	Monomethyl auristatin F	Maleimido-caproyl	[378]
ADC Info	Sofituzumab vedotin	Anti-MUC16 Anti-ody 3A5	MUC16	Monomethyl auristatin E	Mc-Val-Cit-PABC	[379]
ADC Info	Azintuxizumab vedotin	Azintuxizumab	SLAMF7	Monomethyl auristatin E	Mc-Val-Cit-PABC	[380]
ADC Info	AVE-9633	Anti-CD33 mAb huMy9-6	CD33	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[381]
ADC Info	PCA-062	CQY684	CDH3	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[382]
ADC Info	PF-06263507	PF-06281192	TPBG	Monomethyl auristatin F	Maleimido-caproyl	[383]
ADC Info	ASG-5ME	Human IgG2 Anti-SLC44A4 mAb	SLC44A4	Monomethyl auristatin E	Mc-Val-Cit-PABC	[384]
ADC Info	LOP-628	humanized Anti-KIT mAb LMJ729	KIT	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[385]
ADC Info	Bivatuzumab mertansine	Bivatuzumab	CD44	Mertansine DM1	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)	[386]
ADC Info	HKT-288	Fully human Anti-CDH6 HKT-288 mAb	CDH6	Mertansine DM4	Sulfo-SPDB	[387]
ADC Info	Laprituximab emtansine	Laprituximab	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[388]
ADC Info	MEDI-4276	MEDI-4276	HER2 ECD2; HER2 ECD4	AZ13599185	Maleimido-caproyl based linker	[389]
ADC Info	MEDI-547	Anti-EPHA2 mAb 1C1	EPHA2	Monomethyl auristatin F	Maleimido-caproyl	[390]
ADC Info	PF-06650808	Anti-NOTCH3 mAb hu28	NOTCH3	Auristatin 0101	Mc-Val-Cit-PABC	[391]
ADC Info	PF-06664178	PF-06478924	TACSTD2	Auristatin 0101	AcLys-Val-Cit-PABC	[392]
ADC Info	RG-7598	MFRF3266A	FCRL5	Monomethyl auristatin E	Mc-Val-Cit-PABC	[393]
ADC Info	RG-7636	MEDN6000A	EDNRB	Monomethyl auristatin E	Mc-Val-Cit-PABC	[394]
ADC Info	Vandortuzumab vedotin	Vandortuzumab	STEAP1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[395]
ADC Info	SAR-428926	Undisclosed	LAMP1	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[396]
ADC Info	LY-3076226	IMC-D11	FGFR3	Mertansine DM4	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)	[397]
ADC Info	AGS-62P1	AGS62P Anti-ody with pAF residues	FLT3	AGD-0182	AGS-62P1 linker	[398]
ADC Info	BAT-8003	Undisclosed	TACSTD2	Maytansinoid derivative	Uncleavable linker	[399]
ADC Info	BAY-794620	Undisclosed	CA9	Monomethyl auristatin E	Undisclosed	[400]
ADC Info	IMGN-388	IMGN-388	ITGAV	Mertansine DM4	Undisclosed	[401]
ADC Info	MM-310	Undisclosed	EPHA2	Docetaxel	Undisclosed	[402]
ADC Info	RG-7600	Humanized IgG1 Anti-MSLN mAb h7D9.v3	MSLN	Monomethyl auristatin E	Protease-labile valine-citrulline linker	[403]
ADC Info	RG-7882	MMUC3333A	MUC16	Monomethyl auristatin E	Protease cleavable linker	[404]
ADC Info	XMT-1522	XMT-1519	ERBB2	Auristatin F hydroxypropylamide (AF-HPA)	Fleximer polymer	[405]
ADC Info	AMG-172	Anti-CD70 AMG172 mAb	CD70	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[406]

Terminated

Click To Hide/Show 12 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Alpha-CD70-Mc-MMAF	Chimeric Anti-CD70 Anti-ody	CD70	Monomethyl auristatin E	Mc-Val-Cit-PABC	[407]
ADC Info	CD30-BTG-ADC	Anti-CD30 mAb cAC10Q	TNFRSF8	Monomethyl auristatin E	PEG3-benzotriazole-PEG-Val-Cit-PABC	[408]
ADC Info	Anti-TenB2 antibody drug conjugate	Anti-TENB2 monoclonal Anti-ody (mAb)	TMEFF2	Monomethyl auristatin E	Mc-Val-Cit-PABC	[409]
ADC Info	Alpha-CD30-Val-Cit-MMAE	Anti-CD30 alphaCD30-vcMMAE mAb	TNFRSF8	Monomethyl auristatin E	Mc-Val-Cit-PABC	[410]
ADC Info	B-1453	Undisclosed	TNFSF10	Monomethyl auristatin E	Mc-Val-Cit-PABC	[411]
ADC Info	Cetuximab based antibody-drug conjugate	Cetuximab	EGFR	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[412]
ADC Info	FGFR2/FGFR4 dual targeting antibody-drug conjugate	Undisclosed	FGFR2; FGFR4	Mertansine DM1	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[413]
ADC Info	Trastuzumab-dTSPEG-MMAF	Trastuzumab	ERBB2	Monomethyl auristatin F	dTSPEG	[414]
ADC Info	B-1452	Undisclosed	MS4A1	Monomethyl auristatin E	Mc-Val-Cit-PABC	[411]
ADC Info	EGFRvIII/MMAE antibody drug conjugate	Undisclosed	EGFRvIII	Monomethyl auristatin E	Undisclosed	[415]
ADC Info	C-met monoclonal antibody-drug conjugate	STI-D0606	MET	Mertansine DM1	Undisclosed	[416]
ADC Info	Fluorescent Antibody-Drug Conjugate	Anti-CEA mAb MIC0101	PSG2	Paclitaxel	Undisclosed	[417]

References

Ref 1	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27.
Ref 2	Tisotumab Vedotin-tftv. Am J Health Syst Pharm. 2022 Jan 24;79(3):120-122. doi: 10.1093/ajhp/zxab418.
Ref 3	Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma. J Adv Pract Oncol. 2022 Jan;13(1):77-85. doi: 10.6004/jadpro.2022.13.1.7. Epub 2022 Feb 1.
Ref 4	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807.
Ref 5	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primaryanalysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765.
Ref 6	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022 Jan 25;6(2):533-543.
Ref 7	A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012 Jan 1;18(1):248-55.
Ref 8	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 Oct;10(10):e005119.
Ref 9	Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA, NCT05245071
Ref 10	First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3550-3550.
Ref 11	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Feb 10;41(5):1105-1115.
Ref 12	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Sci. 2021 Dec;112(12):5020-5033. doi: 10.1111/cas.15153. Epub 2021 Oct 30.
Ref 13	Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clin Cancer Res. 2022 Jun 29:OF1-OF10.
Ref 14	Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. Molecules. 2020 Mar 26;25(7):1515.
Ref 15	Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antib Ther. 2021 Aug 28;4(3):175-184.
Ref 16	Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evidence. 2021;1(1). doi: DOI: 10.1056/EVIDoa2100001.
Ref 17	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. Onco Targets Ther. 2022 Apr 8;15:331-343.
Ref 18	The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b. Mol Cancer Ther. 2021 May;20(5):896-905.
Ref 19	Preclinical development of BB-1701, a HER2-tageting eribulin-containing ADC with potent bystander effect and ICD activity. Cancer Res (2023) 83 (7_Supplement): 1887.
Ref 20	ADC review: basic information about Mecbotamab vedotin.
Ref 21	A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2023 41:16_suppl, TPS6107-TPS6107.
Ref 22	Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132.
Ref 23	Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. Blood Adv (2023) 7 (9): 16661670.
Ref 24	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380.
Ref 25	Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. Int J Mol Sci. 2022 Jul 6;23(14):7493. doi: 10.3390/ijms23147493.
Ref 26	Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13;28(10):2020-2029.
Ref 27	Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study. Blood (2021) 138 (Supplement 1): 526.
Ref 28	Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. doi: 10.1080/13543784.2022.2042252.
Ref 29	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. doi: 10.1002/cncr.33195. Epub 2020 Sep 11.
Ref 30	A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992.
Ref 31	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 Apr 1;125(7):1113-1123.
Ref 32	Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, NCT03953833
Ref 33	AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells. Cancer Res (2019) 79 (13_Supplement): 218. doi: 10.1158/1538-7445.AM2019-218.
Ref 34	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Jan 1;28(1):95-105.
Ref 35	Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2021 Aug 15;27(16):4521-4530.
Ref 36	First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor--Positive Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3905-3915. doi: 10.1158/1078-0432.CCR-20-4740.
Ref 37	Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. Mol Cancer Ther. 2020 Jan;19(1):168-177.
Ref 38	A Study of RC108-ADC in subjects with advanced digestive system malignant tumor.
Ref 39	GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency. Cancer Res (2023) 83 (7_Supplement): 2702. doi: 10.1158/1538-7445.AM2023-2702.
Ref 40	A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors; NCT05217693.
Ref 41	FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer; NCT05011188.
Ref 42	Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors; NCT05001516.
Ref 43	SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. Journal of Clinical Oncology 2020 38:15_suppl, 3110-3110.
Ref 44	Introduction to basic information on ADC drug RC118.
Ref 45	Preclinical safety profile of RC88-ADCa novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E. Drug Chem Toxicol. 2023 Jan;46(1):24-34. doi: 10.1080/01480545.2021.2005085. Epub 2021 Nov 28.
Ref 46	XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma. Cancer Res (2020) 80 (16_Supplement): 2894.
Ref 47	A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC. Journal of Clinical Oncology 2022 40:16_suppl, TPS8593-TPS8593.
Ref 48	REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Ref 49	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 Apr;23(4):540-552.
Ref 50	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020 Dec;38(6):1807-1814.
Ref 51	Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol Ther. 2023 Mar 22:S1525-0016(23)00140-5. doi: 10.1016/j.ymthe.2023.03.019.
Ref 52	A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology 2022 40:16_suppl, 3000-3000.
Ref 53	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021 Feb;41(2):171-182.
Ref 54	Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res (2022) 82 (12_Supplement): 6020.
Ref 55	IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models. Cancer Res (2021) 81 (13_Supplement): 1841.
Ref 56	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.
Ref 57	AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul;14(7):1650-60.
Ref 58	PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers. Mol Cancer Ther. 2020 Oct;19(10):2068-2078.
Ref 59	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Target Oncol. 2019 Oct;14(5):591-601.
Ref 60	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520.
Ref 61	A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). Blood. 2017;130(S1): 4129. doi: 10.1182/blood.V130.Suppl_1.4129.4129.
Ref 62	A Dose Escalation Phase Ia Study of Anti-CD20 Antibody Drug Conjugate, MRG001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphom. Blood. 2021 ;138():-. doi: 10.1182/blood-2021-144829.
Ref 63	OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clin Cancer Res. 2020 Jul 1;26(13):3420-3430.
Ref 64	Study of PYX-201 in Solid Tumors; NCT05720117.
Ref 65	Introduction to basic information on ADC drug RG 7841.
Ref 66	LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel). 2020 Mar 23;12(3):757.
Ref 67	GN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models. Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.854.
Ref 68	Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibodydrug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). Journal of Clinical Oncology 2022 40:16_suppl, TPS3154-TPS3154.
Ref 69	Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. Anticancer Drugs. 2023 Jul 1;34(6):763-774.
Ref 70	ADC review: basic information about sirtratumab vedotin.
Ref 71	Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers. Cancer Res (2023) 83 (7_Supplement): 6300.
Ref 72	A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress). Journal of Clinical Oncology 2021 39:15_suppl, TPS3144-TPS3144.
Ref 73	MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.
Ref 74	Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer. Cancer Res (2023) 83 (7_Supplement): 2633.
Ref 75	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021 Jan;35(1):255-258.
Ref 76	ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Mol Cancer Ther. 2021 Aug;20(8):1327-1337.
Ref 77	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020 Oct;38(5):1483-1494.
Ref 78	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica. 2020 Nov 1;105(11):2584-2591.
Ref 79	SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models. Mol Cancer Ther. 2023 Apr 3;22(4):421-434. doi: 10.1158/1535-7163.MCT-22-0401.
Ref 80	SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma. Blood. 2016 ;128(22):-. doi: 10.1182/blood.V128.22.4470.4470.
Ref 81	SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. Acta Pharmacol Sin. 2019 Jul;40(7):971-979.
Ref 82	A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. Blood 2020 Nov 5; 136(1): 41-42.
Ref 83	Conjupro biotherapeutics product pipeline
Ref 84	Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity. MAbs. 2019 Aug/Sep;11(6):1149-1161. doi: 10.1080/19420862.2019.1618674. Epub 2019 Jun 4.
Ref 85	Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antib Ther. 2022 Jan 27;5(1):18-29. doi: 10.1093/abt/tbac001.
Ref 86	Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors. Blood (2013) 122 (21): 1637.
Ref 87	Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile. Chem Sci. 2023 Jan 3;14(9):2259-2266. doi: 10.1039/d2sc05678j. eCollection 2023 Mar 1.
Ref 88	A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Mol Cancer Ther. 2022 Jan;21(1):113-124.
Ref 89	Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies. Mol Cancer Ther. 2019 Jun;18(6):1104-1114. doi: 10.1158/1535-7163.MCT-18-0854.
Ref 90	RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Mol Cancer Ther. 2016 Nov;15(11):2698-2708. doi: 10.1158/1535-7163.MCT-16-0431. Epub 2016 Aug 31.
Ref 91	RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget. 2018 Sep 11;9(71):33446-33458. doi: 10.18632/oncotarget.26002. eCollection 2018 Sep 11.
Ref 92	Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Sci Rep. 2019 Jun 10;9(1):8420. doi: 10.1038/s41598-019-44874-0.
Ref 93	Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates. Cancer Res (2018) 78 (13_Supplement): 2900.
Ref 94	Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2019 Jul;84(1):61-72. doi: 10.1007/s00280-019-03848-9. Epub 2019 Apr 29.
Ref 95	Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018 Jul 2;128(7):2927-2943. doi: 10.1172/JCI120481. Epub 2018 Jun 4.
Ref 96	Preclinical characterization of the safety and antitumor activity of IMAB027-vcMMAE, an anticlaudin 6 antibody-drug conjugate. Cancer Res (2018) 78 (13_Supplement): 1778.
Ref 97	Introduction to basic information on ADC drug Bstrongximab ADC (CureMeta).
Ref 98	Introduction to basic information on ADC drug GB-7008-01-vcMMAE.
Ref 99	Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov;116:105366.
Ref 100	Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. Oncotarget. 2018 May 1;9(33):23289-23305. doi: 10.18632/oncotarget.25289. eCollection 2018 May 1.
Ref 101	Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates. Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4.
Ref 102	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017 Sep 6;7(1):10735. doi: 10.1038/s41598-017-11255-4.
Ref 103	Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies. Mol Cancer Ther. 2015 Sep;14(9):2081-9. doi: 10.1158/1535-7163.MCT-15-0312. Epub 2015 Jul 16.
Ref 104	A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy. Cancer Res (2023) 83 (7_Supplement): 2977.
Ref 105	YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy. Cancer Res (2023) 83 (7_Supplement): 2978.
Ref 106	NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety. Cancer Res (2023) 83 (7_Supplement): 1541.
Ref 107	Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers. Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.
Ref 108	EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel). 2018 Dec 17;10(12):519. doi: 10.3390/cancers10120519.
Ref 109	A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. Adv Sci (Weinh). 2020 Nov 3;7(24):2002852. doi: 10.1002/advs.202002852.
Ref 110	A ca6 antigen-specific cytotoxic conjugate and methods of using the same; 2005-02-03
Ref 111	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget. 2019 Feb 1;10(10):1031-1044. doi: 10.18632/oncotarget.26613. eCollection 2019 Feb 1.
Ref 112	Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res. 2014 Dec 1;20(23):6045-58. doi: 10.1158/1078-0432.CCR-14-0898. Epub 2014 Oct 7.
Ref 113	Post translational modification therapeutics product pipeline
Ref 114	Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007 Nov;6(11):3009-18. doi: 10.1158/1535-7163.MCT-07-0464.
Ref 115	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. J Control Release. 2018 May 10;277:48-56. doi: 10.1016/j.jconrel.2018.03.016. Epub 2018 Mar 14.
Ref 116	MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors. Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13.
Ref 117	CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. J Hematol Oncol. 2020 Apr 7;13(1):32. doi: 10.1186/s13045-020-00865-7.
Ref 118	Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Blood. 2019 ;134():-. doi: 10.1182/blood-2019-132062.
Ref 119	Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy. Blood. 2019 ;134():-. doi: 10.1182/blood-2019-132080.
Ref 120	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. Cancers (Basel). 2020 Oct 15;12(10):2989. doi: 10.3390/cancers12102989.
Ref 121	Mediapharma product pipeline
Ref 122	Cybrexa therapeutics product pipeline
Ref 123	Spirea secures more capital to develop nextgeneration ADC cancer therapeutics; 2020
Ref 124	Old target, but new approach: Targeting cancer-associated MUC1 with ADC and Car-T. Cancer Res (2020) 80 (16_Supplement): 6530.
Ref 125	Preclinical characterization of a novel SSEA-4-targeting antibody drug conjugate, OBI-998. Cancer Res (2021) 81 (13_Supplement): 955.
Ref 126	Introduction to basic information on ADC drug IMAB362-VCMMAE.
Ref 127	Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1). Blood. 2018 ;132():-. doi: 10.1182/blood-2018-99-119447.
Ref 128	A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1. Cancer Res (2023) 83 (8_Supplement): LB214.
Ref 129	A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy. Cancer Res (2023) 83 (8_Supplement): LB215.
Ref 130	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.
Ref 131	Introduction to basic information on ADC drug ST1.
Ref 132	A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47. Cancer Res (2023) 83 (7_Supplement): 6307.
Ref 133	Antibody-Drug Conjugates Used in Breast Cancers. J Oncol. 2021 Jun 24;2021:9927433. doi: 10.1155/2021/9927433. eCollection 2021.
Ref 134	An optimized preclinical antibody-drug conjugate against cancers with cKIT overexpression or activating mutations. Cancer Res (2022) 82 (12_Supplement): 6227.
Ref 135	LCB97, an antibody drug conjugate (ADC) targeting a novel tumor antigen for the treatment of multiple solid tumors. Cancer Res (2023) 83 (7_Supplement): 5653.
Ref 136	Legochem biosciences biopharmaceutical company product pipeline
Ref 137	Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923.
Ref 138	Introduction to basic information on ADC drug DM003.
Ref 139	Anti-MSLN ADC against cancer; institute of pharmaceutics development center for biotechnology; 2020
Ref 140	Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate. Cancer Res (2023) 83 (8_Supplement): LB213.
Ref 141	A novel EGFR x MUC1 bispecific antibody-drug conjugate, BSA01, targets MUC1 transmembrane cleavage products and improves tumor selectivity. Cancer Res (2023) 83 (7_Supplement): 6325.
Ref 142	Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer. Cancer Res (2023) 83 (8_Supplement): LB216.
Ref 143	BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET. Cancer Res (2023) 83 (8_Supplement): LB212.
Ref 144	Conditionally active biologics (CAB): A novel class of molecules targeting solid tumors. Cancer Res (2020) 80 (16_Supplement): 4560.
Ref 145	A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC. Blood. 2022 ;140():11568-11569. doi: 10.1182/blood-2022-160056.
Ref 146	A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers. Cancer Res (2014) 74 (19_Supplement): 4494.
Ref 147	Anwita biosciences product pipeline
Ref 148	Bispecific HER2 ADC: Making more potent HER2 ADC by improving target internalization; Cancer Res (2019) 79 (13_Supplement): 233..
Ref 149	Antibody drug conjugate using CTAT linker technology shows superior efficacy in xenograft trial; 2015
Ref 150	Introduction to basic information on humanized anti-HER2 mab-maytansine conjugate(Anhui Anke Biotechnology/Wuxi Pharmatech).
Ref 151	MP-EV20-ADC: humanized anti-HER3 antibody drug conjugate
Ref 152	AVIPEP Therapeutics product pipeline
Ref 153	Preclinical evaluation of NC-6201, an antibody/drug-conjugated micelle incorporating novel hemiasterlin analogue E7974.
Ref 154	Utilization of the Angiopep platform to enable brain penetration of therapeutic mAbs or Antibody-Drug Conjugates for treatment of brain tumors. Cancer Res (2014) 74 (19_Supplement): 2657.
Ref 155	Aphios biotechnology company product pipeline
Ref 156	Dantari biotechnology company product pipeline
Ref 157	Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. J Immunother. 2016 Apr;39(3):117-26. doi: 10.1097/CJI.0000000000000115.
Ref 158	Xiling yuan pharmaceutical company product pipeline
Ref 159	Coare biopharmaceutical company product pipeline
Ref 160	Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development. PLoS One. 2021 Jan 27;16(1):e0246197. doi: 10.1371/journal.pone.0246197. eCollection 2021.
Ref 161	A novel molecule with profound tumor killing activity. Cancer Res (2019) 79 (13_Supplement): 353.
Ref 162	Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses. Cancer Res (2023) 83 (8_Supplement): LB221.
Ref 163	Mediapharma product pipeline
Ref 164	Novel antibody drug conjugate to inhibit mesothelioma tumor growth. Cancer Res (2019) 79 (13_Supplement): 210.
Ref 165	An overview of huPr1-vcMMAE.
Ref 166	IMGN853, a Folate Receptor- (FR)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13.
Ref 167	Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting. Mol Cancer Ther. 2018 Nov;17(11):2412-2426.
Ref 168	Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade. Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.
Ref 169	Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models. Front Oncol. 2022 May 4;12:856424.
Ref 170	High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma. Cancer Med. 2022 Oct;11(19):3700-3713.
Ref 171	Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer. Int J Mol Sci. 2022 Feb 18;23(4):2264.
Ref 172	Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Cancer Cell Int. 2022 Dec 27;22(1):417.
Ref 173	Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. 2023 Jan;35:100853.
Ref 174	Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem Biol. 2021 May 31;2(4):1206-1220.
Ref 175	An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer. Eur J Med Chem. 2022 Nov 5;241:114617.
Ref 176	Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.
Ref 177	Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 Nov 15;68(22):9280-90.
Ref 178	Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP. Front Biosci (Landmark Ed). 2022 Aug 5;27(8):234.
Ref 179	Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766.
Ref 180	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. Pharmaceutics. 2021 Nov 3;13(11):1847.
Ref 181	Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15(6):1301-10.
Ref 182	Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15(6):1301-10. doi: 10.1158/1535-7163.MCT-15-0570. Epub 2016 Mar 4.
Ref 183	A glypican-1-targeted antibody-drug conjugate exhibits potent tumorgrowth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021 Sep;23(9):939-950.
Ref 184	Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma. Mol Cancer Ther. 2021 Sep;20(9):1713-1722. doi: 10.1158/1535-7163.MCT-21-0015. Epub 2021 Jun 17.
Ref 185	Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021 Dec 9;8(1):63.
Ref 186	A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors. Mol Oncol. 2022 Mar;16(6):1290-1308.
Ref 187	Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. Cancer Discov. 2017 Sep;7(9):1030-1045.
Ref 188	Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. 2008 Oct;19(10):1960-3. doi: 10.1021/bc800289a. Epub 2008 Sep 20.
Ref 189	Protease-activated drug development. Theranostics. 2012;2(2):156-78.
Ref 190	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
Ref 191	AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. Acta Pharmacol Sin. 2023 Jun;44(6):1290-1303.
Ref 192	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018 Feb;24(2):203-212.
Ref 193	Targeting and pharmacology of an anti-IL13R2 antibody and antibody-drug conjugate in a melanoma xenograft model. MAbs. 2021 Jan-Dec;13(1):1958662.
Ref 194	A new immunochemical strategy for triple-negative breast cancer therapy. Sci Rep. 2021 Jul 21;11(1):14875.
Ref 195	Cyclopentadiene as a Multifunctional Reagent for Normal- and Inverse-Electron Demand Diels-Alder Bioconjugation. Bioconjug Chem. 2022 Sep 21;33(9):1609-1619.
Ref 196	Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1192-1200.
Ref 197	Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017 May;16(5):879-892.
Ref 198	EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing. Biol Chem. 2021 Sep 20;403(5-6):525-534.
Ref 199	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 200	An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023 Feb 1;554:216024.
Ref 201	Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjug Chem. 2022 Aug 17;33(8):1474-1484.
Ref 202	Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer. Cancer Res (2023) 83 (7_Supplement): 562.
Ref 203	NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. Cell Rep Med. 2021 May 18;2(5):100279. doi: 10.1016/j.xcrm.2021.100279. eCollection 2021 May 18.
Ref 204	FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17.
Ref 205	Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci. 2017 Jan 1;8(1):366-370. doi: 10.1039/c6sc01831a. Epub 2016 Aug 22.
Ref 206	Introduction to basic information on ADC drug IMB-101 and IMB-102.
Ref 207	Introduction to basic information on ADC drug Oberotatug ravtansine.
Ref 208	Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Mol Ther Oncolytics. 2021 Apr 29;21:329-339. doi: 10.1016/j.omto.2021.04.013. eCollection 2021 Jun 25.
Ref 209	Develop highly specific cell engager constructs with improved function and safety by understanding target-effector cell avidity.
Ref 210	Adcitmer , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol. 2022 Feb;186(2):295-306. doi: 10.1111/bjd.20770.
Ref 211	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjug Chem. 2022 Feb 16;33(2):418-426. doi: 10.1021/acs.bioconjchem.2c00015. Epub 2022 Feb 1.
Ref 212	Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability. Chem Commun (Camb). 2022 Feb 8;58(12):1962-1965. doi: 10.1039/d1cc06766d.
Ref 213	MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res. 2020 Sep 22;39(1):198. doi: 10.1186/s13046-020-01711-x.
Ref 214	Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries. Sci Rep. 2021 Jul 29;11(1):15430. doi: 10.1038/s41598-021-94902-1.
Ref 215	The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells. Mol Med. 2021 May 7;27(1):46. doi: 10.1186/s10020-021-00306-2.
Ref 216	An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells. Leuk Res. 2021 Sep;108:106626. doi: 10.1016/j.leukres.2021.106626.
Ref 217	Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J Immunother Cancer. 2019 Sep 13;7(1):250. doi: 10.1186/s40425-019-0732-8.
Ref 218	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nat Commun. 2022 Jul 5;13(1):3869. doi: 10.1038/s41467-022-31601-z.
Ref 219	Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model. Bioconjug Chem. 2021 Mar 17;32(3):595-606. doi: 10.1021/acs.bioconjchem.1c00058. Epub 2021 Feb 25.
Ref 220	Avibodie are engineered, bivalent antibody fragments, precisely loaded with imaging or cytotoxic payloads
Ref 221	Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. J Nucl Med. 2018 Mar;59(3):494-501. doi: 10.2967/jnumed.117.196279. Epub 2017 Nov 16.
Ref 222	FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17.
Ref 223	Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET. Mol Cancer Ther. 2017 Jan;16(1):134-142. doi: 10.1158/1535-7163.MCT-16-0449. Epub 2016 Oct 19.
Ref 224	A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.
Ref 225	Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen. Clin Cancer Res. 2021 Jun 1;27(11):3224-3233. doi: 10.1158/1078-0432.CCR-20-1725.
Ref 226	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. mBio. 2022 Feb 22;13(1):e0338421. doi: 10.1128/mbio.03384-21. Epub 2022 Jan 18.
Ref 227	Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. J Med Chem. 2022 May 26;65(10):7141-7153. doi: 10.1021/acs.jmedchem.1c01920. Epub 2022 May 6.
Ref 228	Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia. 2017 Sep;19(9):716-733. doi: 10.1016/j.neo.2017.07.001. Epub 2017 Aug 19.
Ref 229	Antibody-drug conjugates targeting CD248(+) myofibroblasts effectively alleviate renal fibrosis in mice. FASEB J. 2022 Feb;36(2):e22102. doi: 10.1096/fj.202101441R.
Ref 230	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.
Ref 231	Antibody-Drug Conjugate to Treat Meningiomas. Pharmaceuticals (Basel). 2021 May 2;14(5):427. doi: 10.3390/ph14050427.
Ref 232	A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer. Breast Cancer. 2022 Nov;29(6):1121-1132. doi: 10.1007/s12282-022-01393-7. Epub 2022 Aug 18.
Ref 233	Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan.
Ref 234	Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers. Vaccines (Basel). 2021 Aug 10;9(8):882. doi: 10.3390/vaccines9080882.
Ref 235	Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. Cancer Med. 2019 Apr;8(4):1793-1805. doi: 10.1002/cam4.2066. Epub 2019 Mar 7.
Ref 236	CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma. Am J Obstet Gynecol. 2021 Feb;224(2):197.e1-197.e23. doi: 10.1016/j.ajog.2020.08.028. Epub 2020 Aug 19.
Ref 237	N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability. MAbs. 2021 Jan-Dec;13(1):1914885. doi: 10.1080/19420862.2021.1914885.
Ref 238	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh). 2021 Dec;8(23):e2102414. doi: 10.1002/advs.202102414. Epub 2021 Oct 18.
Ref 239	Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. J Control Release. 2021 Aug 10;336:433-442. doi: 10.1016/j.jconrel.2021.06.041. Epub 2021 Jun 29.
Ref 240	Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14.
Ref 241	Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatr Blood Cancer. 2019 Aug;66(8):e27765. doi: 10.1002/pbc.27765. Epub 2019 Apr 23.
Ref 242	Compounds, linker-drugs and ligand-drug conjugates; 2020-06-16
Ref 243	Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjug Chem. 2015 Nov 18;26(11):2249-60. doi: 10.1021/acs.bioconjchem.5b00359.
Ref 244	Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol. 2017 Apr 20;24(4):433-442.e6. doi: 10.1016/j.chembiol.2017.02.012.
Ref 245	Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships. J Med Chem. 2023 Jan 26;66(2):1562-1573. doi: 10.1021/acs.jmedchem.2c01771.
Ref 246	Novel antibody conjugates and uses thereof; 2014-08-28.
Ref 247	Anti-huLRRC15 antibody drug conjugates and methods for their use. 2017-06-08
Ref 248	Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof; 2017-10-19.
Ref 249	Antibody molecules and conjugates; 2023-05-19.
Ref 250	CA6 antigen-specific cytotoxic conjugate and methods of using the same; 2017-11-21.
Ref 251	Anti-integrin immunoconjugates, methods and uses; 2008-01-17.
Ref 252	Immunoconjugates targeting cd138 and uses thereof; 2009-07-02.
Ref 253	Folate receptor 1 antibodies and immunoconjugates and uses thereof; 2011-09-01.
Ref 254	Compositions and methods related to anti-cd19 antibody drug conjugates; 2017-03-30.
Ref 255	Compositions and methods related to anti-egfr antibody drug conjugates; 2017-03-30.
Ref 256	Antibody-drug conjugate; 2016-08-25.
Ref 257	Tissue factor-targeted antibody-drug conjugate; 2018-03-01.
Ref 258	Anti-claudin 18.2 antibody and antibody-drug conjugate thereof; 2022-11-17.
Ref 259	Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.
Ref 260	Antibody-drug conjugate comprising antibody against human ror1, and use for the same; 2021-04-01.
Ref 261	Anti-mesothelin antibody and antibody-drug conjugate thereof; 2019-11-28.
Ref 262	Introduction to basic information on ADC drug anti-FR (clone M9346A)-SPDB-DM4.
Ref 263	Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 1;104(12):3688-96.
Ref 264	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 Jun 10;12(1):3528.
Ref 265	Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-Mediated Antibody-Drug Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1179-1191.
Ref 266	General and Robust Chemoenzymatic Method for Glycan-Mediated Site-Specific Labeling and Conjugation of Antibodies: Facile Synthesis of Homogeneous Antibody-Drug Conjugates. ACS Chem Biol. 2021 Nov 19;16(11):2502-2514.
Ref 267	Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies. Mol Pharm. 2022 May 2;19(5):1422-1433.
Ref 268	The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia. Blood. 2012 ;120(21):-. doi: 10.1182/blood.V120.21.1653.1653.
Ref 269	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020 Oct 27;4(20):5203-5214. doi: 10.1182/bloodadvances.2020002395.
Ref 270	Antibody-immunotoxin Conjugate Using FcBP-mediated Photoconjugation to Treat Cancer. Anticancer Res. 2022 Jul;42(7):3453-3461. doi: 10.21873/anticanres.15832.
Ref 271	Introduction to basic information on eribulin ADC (Jiangsu hengrui)
Ref 272	Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. Br J Cancer. 1994 Feb;69(2):279-85. doi: 10.1038/bjc.1994.52.
Ref 273	Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995 Apr 15;85(8):2139-46.
Ref 274	Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer. 2001 Feb;84(4):571-8. doi: 10.1054/bjoc.2000.1633.
Ref 275	The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer. 2022.
Ref 276	MAbs. 2023 Jan-Dec;15(1):2149057. doi: 10.1080/19420862.2022.2149057.
Ref 277	A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023 May 5;9(18):eabq7866. doi: 10.1126/sciadv.abq7866. Epub 2023 May 5.
Ref 278	Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjug Chem. 2023 Mar 15;34(3):538-548. doi: 10.1021/acs.bioconjchem.2c00611. Epub 2023 Mar 1.
Ref 279	Human antibodies targeting ENPP1 as candidate therapeutics for cancers. Front Immunol. 2023 Jan 25;14:1070492. doi: 10.3389/fimmu.2023.1070492. eCollection 2023.
Ref 280	AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer. Cancer Res (2014) 74 (19_Supplement): 666.
Ref 281	Introduction to basic information on ADC drug IGN-786
Ref 282	ADC review AVID-300
Ref 283	Click Chemistry-Generated Auristatin F-Linker-Benzylguanine for a SNAP-Tag-Based Recombinant Antibody-Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells. ACS Omega. 2023 Jan 17;8(4):4026-4037. doi: 10.1021/acsomega.2c06844. eCollection 2023 Jan 31.
Ref 284	Old Drug, New Delivery Strategy: MMAE Repackaged. Int J Mol Sci. 2023 May 10;24(10):8543. doi: 10.3390/ijms24108543.
Ref 285	Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5.
Ref 286	Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma. Mol Oncol. 2023 Aug;17(8):1460-1473. doi: 10.1002/1878-0261.13453. Epub 2023 Jun 7.
Ref 287	Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. J Control Release. 2023 Mar;355:515-527. doi: 10.1016/j.jconrel.2023.02.005. Epub 2023 Feb 14.
Ref 288	Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate. Thorac Cancer. 2023 Mar;14(7):645-653. doi: 10.1111/1759-7714.14776. Epub 2023 Jan 19.
Ref 289	Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023 Aug;137:106575. doi: 10.1016/j.bioorg.2023.106575. Epub 2023 Apr 26.
Ref 290	DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis. Front Immunol. 2023 Jan 26;14:1051506. doi: 10.3389/fimmu.2023.1051506. eCollection 2023.
Ref 291	Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma. Mol Cancer Ther. 2023 Feb 1;22(2):240-253. doi: 10.1158/1535-7163.MCT-22-0312.
Ref 292	An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer. 2023 Mar;11(3):e006274. doi: 10.1136/jitc-2022-006274.
Ref 293	Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids. Bioorg Med Chem. 2020 Dec 1;28(23):115785. doi: 10.1016/j.bmc.2020.115785. Epub 2020 Oct 11.
Ref 294	Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety. Cancers (Basel). 2020 Mar 21;12(3):744. doi: 10.3390/cancers12030744.
Ref 295	Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model. Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):37-44. doi: 10.1089/mab.2020.0001. Epub 2020 Mar 17.
Ref 296	Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020 Apr;122(9):1333-1341. doi: 10.1038/s41416-020-0781-2. Epub 2020 Mar 10.
Ref 297	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics. 2020 Jan 12;10(5):2095-2114. doi: 10.7150/thno.30736. eCollection 2020.
Ref 298	Chemical Artificial Internalizing Receptors for Primary T Cells. Adv Sci (Weinh). 2020 Jul 26;7(18):2001395. doi: 10.1002/advs.202001395. eCollection 2020 Sep.
Ref 299	Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. ACS Omega. 2019 Jul 31;4(7):12955-12968. doi: 10.1021/acsomega.9b01585. eCollection 2019 Jul 31.
Ref 300	Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Antibodies (Basel). 2019 Nov 5;8(4):54. doi: 10.3390/antib8040054.
Ref 301	Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. MAbs. 2019 Jan;11(1):153-165. doi: 10.1080/19420862.2018.1541370. Epub 2018 Nov 8.
Ref 302	Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate. Cancer Res. 2019 Apr 15;79(8):1810-1821. doi: 10.1158/0008-5472.CAN-18-3119. Epub 2019 Feb 26.
Ref 303	Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
Ref 304	APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo. Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.
Ref 305	Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker. Bioconjug Chem. 2019 Jul 17;30(7):1957-1968. doi: 10.1021/acs.bioconjchem.9b00340. Epub 2019 Jun 28.
Ref 306	Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Mol Pharm. 2018 Aug 6;15(8):3260-3271. doi: 10.1021/acs.molpharmaceut.8b00298. Epub 2018 Jun 26.
Ref 307	Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models. J Drug Target. 2018 Dec;26(10):905-912. doi: 10.1080/1061186X.2018.1450413. Epub 2018 Apr 13.
Ref 308	Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. Bioorg Med Chem. 2018 May 15;26(9):2271-2279. doi: 10.1016/j.bmc.2018.02.025. Epub 2018 Feb 21.
Ref 309	Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor?2-positive gastric cancer. Oncol Rep. 2018 Mar;39(3):1396-1404. doi: 10.3892/or.2018.6201. Epub 2018 Jan 9.
Ref 310	Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2018 Mar 1;142(5):1056-1066. doi: 10.1002/ijc.31124. Epub 2017 Oct 31.
Ref 311	Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anticancer Drugs. 2020 Jun;31(5):463-472. doi: 10.1097/CAD.0000000000000878.
Ref 312	A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. Mol Pharm. 2019 Sep 3;16(9):3926-3937. doi: 10.1021/acs.molpharmaceut.9b00529. Epub 2019 Jul 31.
Ref 313	A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol. 2019 Jul;37(7):761-765. doi: 10.1038/s41587-019-0135-x. Epub 2019 May 27.
Ref 314	A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1083-1091. doi: 10.1016/j.bbrc.2019.04.046. Epub 2019 Apr 19.
Ref 315	Introduction to basic information on ADC drug 1C1-mcMMAF
Ref 316	Beta-glucuronide-linker drug conjugates; 2007-10-25.
Ref 317	Methylene carbamate linkers for use with targeted-drug conjugates; 2015-06-25.
Ref 318	Anti-c-met antibody-drug conjugate and applications thereof; 2022-03-10.
Ref 319	Hydrophilic antibody-drug conjugates; 2015-08-20.
Ref 320	Anti-cd228 antibodies and antibody-drug conjugates; 2022-02-10.
Ref 321	A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma. Front Oncol. 2019 Apr 10;9:258. doi: 10.3389/fonc.2019.00258. eCollection 2019.
Ref 322	A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.
Ref 323	Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One. 2018 Apr 19;13(4):e0195823. doi: 10.1371/journal.pone.0195823. eCollection 2018.
Ref 324	Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers. PLoS One. 2018 Feb 8;13(2):e0192194. doi: 10.1371/journal.pone.0192194. eCollection 2018.
Ref 325	Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR(+) and Heterogeneous Tumor Models. Mol Cancer Ther. 2018 Aug;17(8):1752-1760. doi: 10.1158/1535-7163.MCT-18-0073. Epub 2018 Jun 4.
Ref 326	Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun. 2018 Jun 28;9(1):2512. doi: 10.1038/s41467-018-04982-3.
Ref 327	Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility. Antibodies (Basel). 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015.
Ref 328	Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. Sci Rep. 2019 Oct 17;9(1):14934. doi: 10.1038/s41598-019-51453-w.
Ref 329	Integrin 10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival. Cancers (Basel). 2019 Apr 25;11(4):587. doi: 10.3390/cancers11040587.
Ref 330	Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy. Cancers (Basel). 2019 Jul 8;11(7):957. doi: 10.3390/cancers11070957.
Ref 331	Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.
Ref 332	Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics. 2019 Feb 7;9(4):1154-1169. doi: 10.7150/thno.29146. eCollection 2019.
Ref 333	An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer. 2019 Oct 1;145(7):1838-1851. doi: 10.1002/ijc.32273. Epub 2019 Apr 1.
Ref 334	Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. J Immunother Cancer. 2019 Oct 29;7(1):280. doi: 10.1186/s40425-019-0765-z.
Ref 335	Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates. Org Biomol Chem. 2018 Mar 14;16(11):1882-1889. doi: 10.1039/c7ob02780j.
Ref 336	Peroxide-cleavable linkers for antibody-drug conjugates. Chem Commun (Camb). 2023 Feb 9;59(13):1841-1844. doi: 10.1039/d2cc06677g.
Ref 337	Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem. 2016 Nov 25;291(48):25106-25119. doi: 10.1074/jbc.M116.753491. Epub 2016 Sep 30.
Ref 338	ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. Cancer Res. 2020 Oct 15;80(20):4552-4564. doi: 10.1158/0008-5472.CAN-20-1418. Epub 2020 Aug 31.
Ref 339	MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.
Ref 340	Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance. Front Pharmacol. 2022 Jun 17;13:764540. doi: 10.3389/fphar.2022.764540. eCollection 2022.
Ref 341	Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother Cancer. 2022 Jun;10(6):e004646. doi: 10.1136/jitc-2022-004646.
Ref 342	A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity. Bioconjug Chem. 2022 Oct 19;33(10):1860-1866. doi: 10.1021/acs.bioconjchem.2c00314. Epub 2022 Sep 15.
Ref 343	One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Bioconjug Chem. 2021 Aug 18;32(8):1888-1897. doi: 10.1021/acs.bioconjchem.1c00314. Epub 2021 Aug 5.
Ref 344	Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022 Apr 21;139(16):2471-2482. doi: 10.1182/blood.2021015161.
Ref 345	Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766. doi: 10.1080/10717544.2022.2039807.
Ref 346	Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation. Org Lett. 2020 Nov 6;22(21):8419-8423. doi: 10.1021/acs.orglett.0c03049. Epub 2020 Oct 19.
Ref 347	Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site. Int J Mol Sci. 2020 Sep 19;21(18):6882. doi: 10.3390/ijms21186882.
Ref 348	Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models. Am J Cancer Res. 2020 Aug 1;10(8):2387-2408. eCollection 2020.
Ref 349	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer. 2020 Nov;123(10):1502-1512. doi: 10.1038/s41416-020-01046-6. Epub 2020 Sep 11.
Ref 350	Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. PLoS One. 2020 Sep 28;15(9):e0239813. doi: 10.1371/journal.pone.0239813. eCollection 2020.
Ref 351	Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Bioorg Med Chem. 2020 Dec 1;28(23):115793. doi: 10.1016/j.bmc.2020.115793. Epub 2020 Oct 6.
Ref 352	Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect. Bioeng Transl Med. 2022 Aug 21;7(3):e10388. doi: 10.1002/btm2.10388. eCollection 2022 Sep.
Ref 353	Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase. RSC Adv. 2022 Nov 22;12(52):33510-33515. doi: 10.1039/d2ra05630e. eCollection 2022 Nov 22.
Ref 354	Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates. J Med Chem. 2023 Jan 12;66(1):1011-1026. doi: 10.1021/acs.jmedchem.2c01812. Epub 2022 Dec 30.
Ref 355	AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. Acta Pharmacol Sin. 2023 Jun;44(6):1290-1303. doi: 10.1038/s41401-022-01047-6. Epub 2023 Jan 17.
Ref 356	Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate.
Ref 357	Cysteine engineered antibodies and conjugates.
Ref 358	Conjugates comprising self-immolative groups and methods related thereto.
Ref 359	Bcma monoclonal antibody-drug conjugate.
Ref 360	Site-specific antibody-drug conjugation through glycoengineering.
Ref 361	Site-specific conjugation of linker drugs to antibodies and resulting adcs.
Ref 362	Anti-cxcr4 antibodies and antibody-drug conjugates.
Ref 363	Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 364	Tridentate connexon and use thereof.
Ref 365	Antibody drug conjugates.
Ref 366	Antibody drug conjugates.
Ref 367	Anti-egfr antibodies and antibody drug conjugates.
Ref 368	TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer. Cancer Res (2021) 81 (4_Supplement): PS10-51.
Ref 369	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2021 Mar;26(3):182-e361.
Ref 370	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019 May;6(5):e254-e265.
Ref 371	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 Jan 15;26(2):364-372.
Ref 372	A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 3062-3062.
Ref 373	Antibody-drug conjugates targeting prostate-specific membrane antigen. Front Biosci (Landmark Ed). 2014 Jan 1;19(1):12-33. doi: 10.2741/4193.
Ref 374	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016 Dec;34(12):530.e15-530.e21.
Ref 375	An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
Ref 376	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017 Oct;35(5):634-641.
Ref 377	Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003 Jan 15;21(2):211-22.
Ref 378	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014 Dec;32(6):1246-57. doi: 10.1007/s10637-014-0151-0. Epub 2014 Aug 22.
Ref 379	Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. doi: 10.1093/annonc/mdw401.
Ref 380	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317.
Ref 381	Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26.
Ref 382	PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies. Mol Cancer Ther. 2021 Jul;20(7):1270-1282. doi: 10.1158/1535-7163.MCT-20-0708. Epub 2021 Apr 20.
Ref 383	First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):315-323. doi: 10.1007/s10637-016-0419-7. Epub 2017 Jan 9.
Ref 384	The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer. Mol Cancer Ther. 2016 Nov;15(11):2679-2687. doi: 10.1158/1535-7163.MCT-16-0225. Epub 2016 Aug 22.
Ref 385	Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors. Clin Cancer Res. 2018 Sep 1;24(17):4297-4308. doi: 10.1158/1078-0432.CCR-17-3795. Epub 2018 May 15.
Ref 386	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol. 2012 Mar;102(3):444-9. doi: 10.1016/j.radonc.2011.10.013. Epub 2011 Nov 17.
Ref 387	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jan;12(1):74-89.
Ref 388	Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul;70(7):841-854. doi: 10.1111/jphp.12911. Epub 2018 Mar 25.
Ref 389	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021 Aug;20(8):1442-1453.
Ref 390	Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013 Feb;31(1):77-84.
Ref 391	A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020 Feb;38(1):120-130.
Ref 392	A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 Oct;36(5):836-847.
Ref 393	Introduction to basic information on ADC drug RG 7598.
Ref 394	Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. Mar Drugs. 2017 Mar 29;15(4):99. doi: 10.3390/md15040099.
Ref 395	Introduction to basic information on ADC drug vandortuzumab vedotin.
Ref 396	ADC review SAR428926
Ref 397	A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Invest New Drugs. 2021 Dec;39(6):1613-1623. doi: 10.1007/s10637-021-01146-x. Epub 2021 Jul 15.
Ref 398	Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. Oncotarget. 2022 Dec 20;13:1359-1368.
Ref 399	Development of a potent Trop-2 antibody-drug conjugate, BAT8003, for the treatment of Trop-2 positive gastric tumors. Cancer Res (2019) 79 (13_Supplement): 4821.
Ref 400	ADC review BAY79-4620
Ref 401	A phase I dose-escalation study of IMGN388 in patients with solid tumors. Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010) 3058-3058.
Ref 402	A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors. Journal of Clinical Oncology 2018 36:15_suppl, TPS2604-TPS2604.
Ref 403	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693.
Ref 404	An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 Dec;163(3):473-480. doi: 10.1016/j.ygyno.2021.09.023. Epub 2021 Oct 6.
Ref 405	Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. Cancer Res (2017) 77 (13_Supplement): 48.
Ref 406	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62.
Ref 407	Introduction to basic information on ADC drug Alpha-CD70-Mc-MMAF
Ref 408	Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. Mol Pharm. 2015 Jun 1;12(6):1863-71. doi: 10.1021/mp500666j. Epub 2015 Feb 9.
Ref 409	Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. Oncotarget. 2019 Oct 22;10(58):6234-6244. doi: 10.18632/oncotarget.27263. eCollection 2019 Oct 22.
Ref 410	Recombinant anti-cd30 antibodies and uses thereof; 2006-02-02
Ref 411	Tasly pharma announcement; 2020
Ref 412	Introduction to basic information on ADC drug ADC-W-2589.
Ref 413	In vitro and in vivo activity of a highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug conjugate. Cancer Res (2015) 75 (15_Supplement): 1680.
Ref 414	Antibody-drug conjugates and related compounds, compositions, and methods.
Ref 415	Introduction to basic information on EGFRvIII/MMAE antibody drug conjugate(Abgenix, Inc.).
Ref 416	Introduction to basic information on ADC drug C-met monoclonal antibody-drug conjugate
Ref 417	Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. PLoS One. 2016 Jun 23;11(6):e0157762. doi: 10.1371/journal.pone.0157762. eCollection 2016.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.

Target Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)